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SUMMARY 
Due to the lack of new types of antibiotics and propagating resistance against all available 
classes, an increasing number of bacterial infections cannot be efficiently treated anymore. 
Anti-virulent compounds, which target bacterial pathogenesis without affecting cell viability 
and consequently exert less selection pressure, were recently suggested. 
Most bacteria control pathogenesis via cell-density-dependent cell-to-cell communication 
(quorum sensing, QS), which makes QS an appropriate target to pursue an anti-virulence 
strategy. Besides the widespread acyl homoserine lactone signal molecules, the opportunistic 
pathogen Pseudomonas aeruginosa applies a rather unique quinolone-based QS system. Thus, 
inhibitors of PqsD, a key enzyme in the signal molecule biosynthesis, should be developed to 
specifically combat P. aeruginosa infections. 
Using a ligand-based approach, the first class of PqsD inhibitors was identified. 
Simplification and rigidization led to a fragment with high ligand efficiency, which 
significantly inhibited signal molecule production and biofilm formation in P. aeruginosa.  
Various methods to characterize the mode of action of PqsD inhibitors were developed, which 
allowed the proposal of their binding modes. Fine-tuning of the fragment provided PqsD 
inhibitors with high potential for further improvements. Furthermore, they constitute valuable 
tools to analyze QS regulation pathways, and to evaluate PqsD as drug target for the treatment 
of P. aeruginosa. 
VI 
ZUSAMMENFASSUNG 
Die Behandlung bakterieller Infektionen wird durch die stagnierende Entwicklung neuer 
Antibiotika und vermehrter Resistenzbildung zunehmend erschwert. Anti-virulente 
Verbindungen, welche die Pathogenität der Bakterien absenken ohne deren Lebensfähigkeit 
zu beeinflussen und damit keinen Selektivitätsdruck ausüben, stellen einen neuen 
Therapieansatz dar. 
Die Pathogenität der meisten Bakterien wird durch ein zelldichteabhängiges interzelluläres 
Kommunikationssystem (Quorum Sensing, QS) gesteuert. Das opportunistische Pathogen 
Pseudomonas aeruginosa verwendet neben den üblichen Lactonen zusätzlich Chinolone als 
Signalmoleküle. Dabei ist das Enzym PqsD essentiell für deren Biosynthese und eignet sich 
daher als Wirkstoff-Target einer Anti-Virulenz Strategie für die spezifische Bekämpfung von 
P. aeruginosa. 
In einem Ligand-basierten Ansatz wurde die erste PqsD Inhibitorenklasse identifiziert. Die 
Verkleinerung und Rigidisierung führten zu einem Fragment, das eine hohe Liganden-
effizienz aufweist und die Signalmolekül- und Biofilmbildung in P. aeruginosa hemmt. 
Mehrere Methoden zur Aufklärung der Wirkungsweisen von PqsD Inhibitoren wurden 
entwickelt, so dass konkrete Bindungsposen vorgeschlagen werden konnten. Die strukturelle 
Feinabstimmung des Fragments lieferte leicht weiteroptimierbare PqsD Inhibitoren, die als 
Tools zur Analyse der QS Regulationswege genutzt werden können und ferner der 
Beurteilung von PqsD als Drug-Target zur Behandlung von P. aeruginosa dienen. 
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1 Introduction 
In 1967, the surgeon general of the United Stated, William Stewart, is supposed to have 
proclaimed, that “the time has come to close the book on infectious diseases. We have 
basically wiped out infection in the United States.”1 Whether Stewart was cited correctly or 
not, the exceeding optimism of many experts had its origin in the 1940s, when Penicillin was 
developed as the first commercial antibiotic. Besides the treatment of bacterial diseases, 
antibiotics allowed the advance of surgical methods and chemotherapy.
2
 Between the 1950s 
and 1980s, several novel classes of antibiotics were developed.  
However, since then the discovery of new antibiotic classes is extremely rare and the number 
of new antibacterial agents approved by the FDA rigorously decreased.
3,4
 Furthermore, from 
1940 to 2004 hundreds of new infections emerged. Additionally, some known infectious 
diseases rapidly increased in incidence or geographic range.
5,6
 Combined with the fact, that 
for virtually every bacterial organism and every antibiotic the development of resistance 
mechanisms can be observed, the fear of non-treatable superbugs grows. Thus, the question 
arised if we have reached the beginning of the post-antibiotic era.
7,8
 The lack of efficient 
antibiotics would have tremendous influence on modern life and society. Many surgeries 
including organ transplantations, birth of premature infants and cytotoxic therapies for cancer 
would be impossible. Slightest injuries would threaten life.
8
 Beyond increased morbidity and 
mortality, higher costs for treatment represent a serious economical burden, with barely 
foreseeable consequences for the future.
9
  
 
Thus, there is an urgent need for new treatments with diminished potential to promote 
resistance.
10
 Therefore, it is important to understand the resistance mechanisms, which render 
previously successful drugs inefficient by mutations or acquisition of resistance genes.
11,12
 
Major biochemical mechanisms, which work synergistically, are:
13
  
- Decrease of outer membrane permeability (e.g. downregulation of purin genes) 
- Target mutations decrease drug affinity while functional activity is conserved 
- Expression of efflux systems to decrease the drug concentration at the target 
- Production of enzymes inactivating the antibiotic (e. g. β-lactamases) 
- Development of by-passes turning the target non-essential 
Several common strategies to overcome bacterial resistance address the underlying 
mechanisms itself
14
 either by adaptation of the drugs according to the new requirements or by 
additional use of a second auxiliary drug blocking the acquired resistance mechanism. More 
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specifically, these strategies are the development of agents less susceptible to efflux systems, 
addition of efflux inhibitors
15
 or inhibitors of modifying enzymes (e.g. β-lactamase 
inhibitors)
16
 and development of permeabilizers
17
 enhancing the susceptibility of resistant 
bacteria. However, the success of these strategies was limited, since many infections caused 
by P. aeruginosa, for example, are rarely eradicated by conventional treatment.
18
 
Furthermore, an inherent disadvantage of these strategies is that realization necessarily lags 
behind resistance development by several years.  
A more innovative way to overcome this problem is to bypass the pathogen’s reasons to 
develop resistances. Conventional antibiotics reduce the cell viability, thus exerting selection 
pressure on bacteria. Only those can survive, which adapt to the presence of the antibiotic by 
development of at least one of the resistance mechanisms described above. Since susceptible 
bacteria are killed by the antibiotic, the small fraction of resistant cells can grow to become 
the predominant species of the population.  
However, if a drug decreases the pathogenicity of bacteria without bacteriostatic and 
bactericidal properties, there is less evolutionary pressure exerted on the bacteria. Ideally, 
inhibition of virulence factor production prevents host damage but allows non-resistant 
bacteria to survive. And even if single bacterial cells develop resistance mechanisms against 
the mode of action of the anti-virulent drug, they continue to be the minority within the 
population.
10,19
  
 
 
1.1 Pseudomonas aeruginosa 
P. aeruginosa is a ubiquitous Gram-negative bacterium, which is able to adapt to many 
natural environments.
20
 This opportunistic pathogen shows an increasing clinical relevance 
and is a frequent cause for nosocomial infections. It is responsible for 10% of all hospital-
acquired infections and the most common pathogen isolated from patients who have been 
hospitalized longer than one week.
21-23
  
Several parts of the body can be affected by P. aeruginosa infections. Examples for typical 
diseases are given in brackets.
22,24
  
- Respiratory tract (e.g., pneumonia) 
- Bloodstream (e.g., bacteremia) 
- Heart (e.g., endocarditis) 
- CNS (e.g., meningitis) 
- Ear (e.g., otitis externa) 
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- Eye (e.g., endophthalmitis, keratitis) 
- Bones and Joints (e.g., osteomyelitis) 
- GI tract (e.g., diarrhea, enteritis, enterocolitis) 
- Urinary tract  
- Skin (e.g. ecthyma gangraenosum) 
In cystic fibrosis patients, P. aeruginosa is considered as the major cause of mortality.
25
 
Furthermore, it is especially prevalent among patients with burn wounds, acute leukemia, 
organ transplants, and intravenous drug addiction.
24
  
 
Treatment of P. aeruginosa is particularly difficult, since this pathogen displays a high 
intrinsic resistance.
12
 This is due to synergistically acting multi-drug efflux pumps, 
chromosomally encoded β-lactamases and highly restricted outer-membrane permeability.8 
Furthermore, P. aeruginosa forms biofilms,
26
 which are defined as bacterial populations 
adherent to each other and/or surfaces or interfaces, embedded in a complex extracellular 
matrix.
27
 Biofilms provide protection from the immune system and are refractory to 
antimicrobial treatment.
27
 The actual mechanism behind this physiological resistance is still 
under discussion. One reason might be an additional diffusion barrier caused by the 
surrounding extracellular matrix consisting of polysaccharides, nucleic acids, and 
proteins.
28,29
 Alternatively, a less susceptible mode of growth due to altered gene expression 
leading to slow growth, activation of stress responses and accumulation of modifying 
enzymes, was described as a resistance-mediating characteristic of biofilm populating 
bacteria.
30,31
  
Additionally, the organism is able to acquire resistance to multiple classes of antimicrobial 
agents as β-lactams, fluoroquinolones, and aminoglycosides.32,33 The analysis of multidrug-
resistant P. aeruginosa isolates (as defined by resistance to three or more drug classes) from 
intensive care unit patients in the US showed an increasing prevalence from 4 to 14% in the 
period from 1993 to 2002.
34
 Much higher values are observable in individual communities 
and hospitals. This is associated with significant increases in morbidity, mortality, need for 
surgical intervention, length of hospital stay and chronic care, as well as overall cost of 
infection treatment.
33
 Furthermore, P. aeruginosa is able to develop resistances even during 
the course of attempted therapy, which doubles the length of hospitalization and overall costs 
for patient care.
35
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1.2 Inhibition of Quorum Sensing as Anti-virulence Strategy 
The inhibition of bacterial pathogenicity was introduced above as novel approach to 
overcome bacterial resistance. But which targets are appropriate for this purpose? At this 
point it might be beneficial to start with a few definitions: Bacterial pathogenicity is the 
ability of a bacterium to cause a disease. The virulence of this bacterium is a quantitative 
measure of the pathogenicity or the likelihood of causing a disease. Therefore, bacteria 
produce virulence factors, which are gene products that can damage a susceptible host and 
that are specifically expressed during the disease process.
36
 These products enable a bacterium 
to invade the host, to replicate and to disseminate within a host by subverting or eluding his 
defenses.
37
  
Consequently, if it was possible to inhibit virulence factor production, e.g. by inhibition of a 
regulatory key factor, then a pathogenic bacterium would turn in a non-pathogenic microbe, 
which is by definition not able to cause a disease associated with symptoms.  
 
Bacteria apply cell-to-cell communication to coordinate group behavior. “Quorum sensing” is 
the more specific term, which is used when regulation of gene expression responds to 
fluctuations in cell-population density.
38
 Chemical signal molecules are produced by the 
bacteria and released into the environment. The extracellular concentrations reflect the cell 
density of the population, which can in turn be detected by single cells of the colony to 
simultaneously alter gene expression. This allows a population to behave coordinately and 
synergistically as pseudo-multicellular organism. In this way, single bacterial cells can limit 
their effort regarding group-beneficial activities to cell densities that guarantee an effective 
population-wide outcome.
39
 
P. aeruginosa uses QS to regulate the coordinated production of a considerable arsenal of 
virulence factors determining the high pathogenicity. Initial colonization is mostly 
accomplished by cell-associated virulence factors as pili, lectins, alginate, and flagella. In 
chronic infections, low concentrations of extracellular virulence factors are produced. 
However, in acute infections high levels of exoproducts as proteases, exotoxin A, pyocyanin, 
siderophores, and hemolysins are required for tissue invasion and dissemination within the 
host. Thereby, the concentration-dependent coordination by QS is a perceptive strategy to 
overwhelm the host’s defense mechanisms.40 Additionally, QS plays an important role in 
biofilm formation, which is a key factor for bacterial resistance.
41
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Taken together, QS plays an important role for P. aeruginosa pathogenicity. It is the key 
regulatory network for the production of virulence factors and, thus, seems to be an attractive 
target for pursuing an anti-virulence strategy.
42
  
 
 
1.3 Quorum Sensing in P. aeruginosa 
The nature of the signal molecules employed for QS strongly depends on the bacteria. Gram-
positive bacteria primarily use modified oligopeptides, whereas N-acyl homoserine lactones 
(AHLs) are the major class of signal molecules in Gram-negative bacteria.
43
 Dependent on the 
species, AHLs with different length and substitution of their acyl side chain are produced 
(Figure 1a).
44
 Biosynthesis is accomplished by a LuxI-type synthase (named after the first 
discovered homolog, which regulated the luminescence gene lux in V. fischeri). Afterwards, 
the signal molecules diffuse between cells and can be detected by a LuxR-type transcriptional 
regulator, which changes expression of target genes after activation. Characteristically, 
activation of LuxR-type regulators increases the expression of the corresponding synthase, 
which is why the signal molecules are also called autoinducers. This positive feedback loop 
allows a rapid increase in signal molecule production after a certain threshold in cell density  
 
 
Figure 1. a) Selection of various AHLs applied as signal molecules by different bacteria. b) Structure of 
pqs signal molecules HHQ and PQS. c) Structures of known QS inhibitors.   
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has been reached. P. aeruginosa contains two AHL-based QS systems, the las and the rhl 
system. In the first one, LasI directs the synthesis of N-(3-oxododecanoyl)-L-homoserine 
lactone (3O-C12-HSL or OdDHL), which is recognized by LasR.
45,46
 The rhl system consists 
of the RhlI/R pair and uses N-butyryl-L-homoserine lactone (C4-HSL or BHL, see Figure 1a) 
as autoinducer.
47,48
 Furthermore, P. aeruginosa applies a third so-called pqs system, which is 
characteristic for particular Pseudomonas and Burkholderia species.
49
 This system utilizes the 
Pseudomonas quinolone signal (PQS) and its precursor 2-heptyl-4-hydroxyquinoline (HHQ) 
as signal molecules (Figure 1b).
50,51
 Both molecules are able to bind and activate the 
transcriptional regulator PqsR (formerly called MvfR for multiple virulence factor regulator), 
whereas PQS shows a ca. 100-fold higher affinity than HHQ.
52
 Activation of PqsR positively 
regulates the expression of the pqsABCDE operon, which is responsible for HHQ and PQS 
production, establishing a feedback circuit similar to the las and rhl systems.
50
 In addition to 
this PqsR autoinduction loop, PQS operates about at least two more distinct pathways 
(Figure 2). Firstly, pqsE is required for expression of many PQS controlled virulence factors 
and disruption leads to loss of several but not all PQS-dependent signal transductions. PqsE is 
not involved in PQS biosynthesis and its exact function remains unknown, hence it was 
designated as PQS response protein.
53,54
 Secondly, PQS, but not HHQ, is able to chelate 
iron(III), which is an essential nutrient in P. aeruginosa.
53,55
 Thereby, PQS does not act as an 
siderophore but it has been suggested that PQS acts as an iron trap at the cell surface, which 
might facilitate siderophore-mediated iron transport.
53
 Furthermore, transcriptional analysis in 
response to PQS revealed altered gene expression, e.g. the upregulation of the siderophore 
pyoverdine.
55
  
 
The QS systems present in P. aeruginosa are not strictly separated but rather closely linked 
and hierarchically organized (Figure 2). The las system is dominant over the rhl system, since 
the LasR/OdDHL complex positively regulates the expression of rhlR. Moreover, OdDHL is 
able to bind but not to activate RhlR, leading to a competition with RhlR’s autoinducer 
BHL.
56
 The expression of the PQS biosynthetic operon pqsABCDE is positively regulated by 
LasR/OdDHL and negatively regulated by RhlR/BHL.
57,58
 The pqs system in turn causes a 
major induction of rhlI and a minor one on lasR and rhlR.
59
  
However, the cross-linked network hampers the identification of direct regulation pathways. 
Only in a few cases, the specific interaction of a signal molecule/transcriptional regulator 
complex with a promoter region was demonstrated. Especially the regulation of virulence 
factor production is overly reliant on comparison of wild-type and mutant transcriptome. It  
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Figure 2. P. aeruginosa QS circuit. Genes and proteins of the las, rhl, and pqs systems are colored in 
green-grey, red, and blue, respectively. Bright green dashed arrows represent positive regulation; red 
dashed arrows represent negative regulation. Modified from Dubern and Diggle (2008).
60
  
 
was claimed, for example, that pyocyanin production is directly controlled by the rhl system
61
 
even though it has never been proven and indirect effects may well be possible.  
Indeed, several mutants of P. aeruginosa including lasR, rhlR, and pqsR (as well as the PQS 
biosynthetic genes pqsC and pqsD) are defective in the production of pyocyanin,
54
 which is a 
crucial virulence factor causing serious tissue damage and necrosis during lung infections.
62
 
Thus, inhibition of one system might lead to decreased production of various virulence 
factors, even if these are only indirectly controlled by the affected system. 
 
 
1.4 Inhibition of pqs QS in P. aeruginosa 
Disruption of the pqs system seems to be an especially attractive anti-virulence strategy. As 
mentioned above, AHLs are widely spread among Gram-negative bacteria. And even if each 
species produces a unique AHL, which interacts with the species specific LuxR-type receptor, 
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there is a high risk that small molecule inhibitors interfere with cell-to-cell communication of 
multiple bacterial species. However, this is unintentional, since even non-pathogenic or 
beneficial bacteria would be affected. This is the key advantage of targeting the pqs system. 
Modulation of pqs QS would specifically discriminate quinolone-signaling competent 
Pseudomonas and Burkholderia species. Thus, populations of non-pathogenic bacteria may 
take advantage in the competition for limited nutrients and habitat leading to the repression of 
P. aeruginosa. Additionally, it has been shown that especially PQS is closely linked to 
biofilm formation and maturation, which is a key factor for bacterial resistance.
63,64
  
There are several conceivable targets within the pqs system, which might be appropriate for 
interference by small molecules. PqsE participates in the regulation of several virulence 
factors, but is not required for 4-hydroxy-2-alkyl-4-quinolone (HAQ) biosynthesis.
54
 The 
described function as cellular response on PQS might indicate, that PqsE is located 
downstream in the QS network having a minor impact on QS gene regulation in 
P. aeruginosa. Additionally, the fact, that the function of PqsE is still not understood, 
hampers a drug discovery process.  
PqsR has been shown to drive the expression of nearly 200 genes, including genes encoding 
virulence factors as pyocyanin and hydrogen cyanide.
65-67
 However, three pathways have been 
described for PQS mediated effects (PqsR, PqsE and iron chelation) and at least the regulation 
of pyoverdine production is independent of PqsR.
53
 Furthermore, from a drug discovery point 
of view, the hydrophobic binding pocket optimized to bind HHQ and PQS might be 
challenging, since it has been proposed that (due to the outer membrane barrier) high 
hydrophilicity is beneficial or even required for activity in Gram-negative bacteria.
68
 
Nevertheless, several classes of PqsR antagonists were recently developed.
49,69-71
 The most 
promising compound (Figure 1c) showed strong inhibition of pyocyanin and significantly 
reduced the mortality of Caenorhabditis elegans and Galleria mellonella infected with 
P. aeruginosa PA14, underlining the potential of the pqs system as target. This PQS-derived 
compound might use the HAQ transport system to overcome the cellular penetration barrier, 
but drug-likeness is limited due to the high lipophilicity.  
Enzymes, which are essential for PQS biosynthesis, represent further promising targets for an 
anti-virulence strategy. Since PqsR has to be activated by PQS (or HHQ), similar effects as 
for PqsR inhibitors are expected. Furthermore, also the PqsE and Fe(III) mediated pathway 
should be inhibited. Taken together, there are several indications, that the biosynthetic 
enzymes play a central role within the pqs QS system.  
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Indeed, halogenated anthranilate analogs (Figure 1) were reported by Lesic et al. to inhibit 
PQS biosynthesis and PqsR regulated gene expression. Furthermore, these putative PqsA 
inhibitors (see Figure 3 for the role of PqsA) reduced the P. aeruginosa systemic 
dissemination and mortality in a burned mouse model. However, the compounds had to be 
used in unreasonably high concentrations and optimized derivatives were not reported until 
now.
 
 
1.5 HAQ Biosynthesis and the Role of PqsD 
In contrast to the LuxI-type biosynthetic proteins, HHQ and PQS production is more 
complicated and accomplished by several enzymes (Figure 3). Anthranilate is one of the 
precursors from which PQS is synthesized.
72
 It can be derived from tryptophan by the 
kynurenine (kyn) pathway or from chorismic acid via a unique anthranilate synthase operon 
phnAB, which is regulated by PqsR to ensure sufficient anthranilate supply when the pqs 
system is turned on.
52,73,74
  
 
Figure 3. Proposed mechanism of HHQ and PQS biosynthesis. PqsD is an essential enzyme for all 
derivatives, since it is responsible for the production of the key intermediate 2-ABA. Furthermore, it is 
sufficient for the conversion of ACoA and malonyl-CoA into DHQ as well as HHQ production in vitro. 
Modified from Dulcey et al. (2013).
76 
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The reaction cascade catalyzed by the gene products of the biosynthetic operon pqsABCD 
starts with the activation of anthranilate as thioester by the CoA ligase PqsA.
75
 This enables 
the transfer of anthranilate to Cys112, forming a covalent AA-PqsD complex,
77
 which has 
been proven unambiguously by an X-ray structure.
78
 Recently, Dulcey et al. reported that 
reaction with malonyl-CoA leads in a two step reaction over the hypothetical CoA-activated 
2-aminobenzoylacetate (2-ABA-CoA) to 2-ABA.
76
 This reactive intermediate is then 
converted to HHQ by PqsC using octanoic acid as substrate. This conversion requires the 
presence of PqsB. However, the exact mechanism of the reaction remains unknown.  
Interestingly, PqsD alone is able to synthesize HHQ in vitro directly from ACoA using 
β-ketodecanoic acid as secondary substrate,79 which was recently ruled out to happen in 
cellulo by labeling experiments.
76
 
The oxidation of HHQ to PQS is accomplished by the NADH-dependent flavin 
monooxygenase PqsH.
80
 This enzyme is not encoded by the pqsABCDE operon, but 
positively regulated by OdDHL/LasR (but not PqsR/PQS). Since O2 is essential for the 
oxidation and no PQS can be observed in an anaerobic environment, this reaction can be 
considered as trigger for aggressive group behavior when supplied with oxygen.
80
 
P. aeruginosa produces at least 55 HAQ derivatives, but only HHQ and PQS have been 
shown to participate in cell-to-cell signaling.
81
 This array of compounds was classified into 5 
distinct series (Figure 4).
50
 All series share the common 4-hydroxyquinoline structure of 
series A. Congeners of series B have a hydroxy group in 3-position, whereas derivatives of 
series C and D share an N-oxide group. Alkyl chains of series D and E are unsaturated. Many 
of these HAQs, especially HQNO, were described to be potent cytochrome inhibitors and 
antibiotics active against commensal and pathogenic bacteria, which give P. aeruginosa an 
ecological advantage in competitive environments.
50,82,83
 
 
 
Figure 4. Structures of five distinct series of HAQs isolated from P. aeruginosa PA14 culture supernatant. 
Most prominent derivatives of Series A, B, and C are HHQ, PQS, and HQNO, respectively. This indicates 
the biosynthetic enzymes preference for R = C7H15 side chains. Modified from Déziel et al. (2004).
50
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The monooxygenase PqsL has been shown to be required for synthesis of all N-oxide 
congeners (series C and E), including HQNO.
81
 2-ABA is likely the substrate of PqsL 
probably leading to a hydroxylamino derivative. Processing with PqsC and octanoic acid as 
described for HHQ and ring closure by nucleophilic attack on the carbonyl group should lead 
to HQNO production.
76
 
When 2-ABA is purified it is unstable and degrades to DHQ (predominantly produced under 
acidic conditions) and 2-aminoacetophenone (2-AA), which might happen in absence of the 
required reactants and enzymes in cellulo.
76,77
 Thus, PqsA and PqsD are sufficient for DHQ 
and 2-AA biosynthesis. The physiological role of DHQ is not fully understood, however, 
DHQ contributes to pathogenicity of P. aeruginosa by inhibition of the cell viability of mouse 
lung epithelial MLE-12 cells.
77
 The recently identified 2-AA promotes the adaptation of 
P. aeruginosa to chronic infections, whereas the production of PqsR-regulated acute virulence 
factors is reduced. Accordingly, treatment with 2-AA has been shown to reduce mortality of 
PA14-infected flies and mice.
84
  
 
Taken together, PqsA and PqsD are key players in the biosynthesis of all HAQs as well as 
DHQ and 2-AA. Thus, inhibition should have major influence on cell communication. 
Unfortunately, no structural information about PqsA exists in literature. In contrast, the X-ray 
structure of PqsD shows a deep and narrow substrate channel formed by several hydrophilic 
amino acids. Therefore, we consider PqsD as the most attractive target for an anti-virulence 
strategy to combat P. aeruginosa infections.  
 
 
 
12   
2 Aim of the Thesis 
Antibiotic resistance is a serious risk for the major achievements of modern medicine in the 
last 60 years. Untreatable bacterial infections threaten life quality and expectancy, but are also 
an economic burden. Due to the rapid global spread of drug-resistant strains, the solution of 
this problem challenges politics and scientific communities world-wide. For example, the 
excessive and often irresponsible usage of antibiotics must be restricted. But, especially the 
development of new therapeutics is crucial. Otherwise we will lose the race against time, 
since the evolution of resistances might be slowed down but can hardly be prevented.  
As a small part of the drug development community, we want to contribute to the finding of 
novel eligible treatment strategies against P. aeruginosa, one of today’s most problematic 
pathogens. Anti-virulence strategies, which combat pathogenicity but do not restrict cell 
viability, could prevent pathogens from developing drug resistances, even though the proof of 
concept is pending. Thereby, we consider the biosynthetic enzyme PqsD as promising target, 
since it plays a key role in the regulatory pqs cell-to-cell communication system of 
P. aeruginosa.  
This thesis is aimed at the development of the first PqsD inhibitors. Since no assay to evaluate 
the potency of molecules in a high-throughput fashion was available, experimental screening 
methods for the identification of hit compounds were excluded. Consequently, a ligand-based 
approach was pursued by mimicking the natural ligand ACoA and the corresponding 
transition state. The identified small molecules should ideally be capable of inhibiting signal 
molecule production in P. aeruginosa cells.  
The detailed knowledge how an inhibitor binds and inhibits an enzyme enables the rational 
and efficient optimization. For this purpose, modern biophysical and biochemical methods 
were applied to propose plausible binding poses. These poses were additionally used to assess 
whether the inhibitors bind as expected for natural substrate or transition state mimics. 
Furthermore, beneficial binding characteristics for novel inhibitor classes could be derived. 
However, since inhibitors of intracellular targets in P. aeruginosa have to overcome multiple 
barriers to reach their targets, structure-activity relationships with respect to in vitro and in 
cellulo inhibitory activity provided information about crucial molecular properties.  
The resulting optimized compounds are valuable tools to elucidate regulatory pathways of the 
QS system and virulence factor production in P. aeruginosa. No less important, they provide 
first distinct clues, whether PqsD is an appropriate target for the treatment of P. aeruginosa 
infections.
13 
3 Results 
3.1 Validation of PqsD as an Anti-biofilm Target in 
Pseudomonas aeruginosa by Development of Small-Molecule 
Inhibitors 
Michael P. Storz, Christine K. Maurer, Christina Zimmer, Nathalie Wagner, Christian 
Brengel, Johannes C. de Jong, Simon Lucas, Mathias Müsken, Susanne Häussler, 
Anke Steinbach, and Rolf W. Hartmann 
 
 Reprinted with permission from J. Am. Chem. Soc. 2012, 134, 16143-16146. 
 Copyright (2012) American Chemical Society.  
 
Publication A 
 
 
 
 
 
Contribution Report 
The author contributed significantly to the rational ligand design concept. He planned, 
synthesized and characterized all compounds. Furthermore, he conceived and wrote the 
manuscript.  
 
 
 
  
14  3.1  PUBLICATION A 
 
 
  
3  RESULTS  15 
 
 
  
16  3.1  PUBLICATION A 
 
 
  
3  RESULTS  17 
 
 
 
18  3.2  PUBLICATION B 
3.2 Biochemical and Biophysical Analysis of a Chiral PqsD 
Inhibitor Revealing Tight-Binding Behavior and 
Enantiomers with Contrary Thermodynamic Signatures 
Michael P. Storz, Christian Brengel, Elisabeth Weidel, Michael Hoffmann, Klaus 
Hollemeyer, A. Steinbach, Rolf Müller, Martin Empting, and Rolf W. Hartmann 
 
Reprinted with permission from ACS Chem. Biol. 2013, 8, 2794-2801. 
Copyright (2013) American Chemical Society.  
 
Publication B 
 
 
 
 
 
Contribution Report 
The author planned and performed the experiments regarding time-dependency and 
reversibility. He was responsible for the design of the experiment. Furthermore, the author 
significantly contributed to the interpretation of the results. He conceived and wrote the 
manuscript. 
 
 
 
 
  
3  RESULTS  19 
 
 
  
20  3.2  PUBLICATION B 
 
 
  
3  RESULTS  21 
 
 
  
22  3.2  PUBLICATION B 
 
 
  
3  RESULTS  23 
 
 
  
24  3.2  PUBLICATION B 
 
 
  
3  RESULTS  25 
 
 
  
26  3.2  PUBLICATION B 
 
 
 
3  RESULTS  27 
3.3 Combining in Silico and Biophysical Methods for the 
Development of Pseudomonas aeruginosa Quorum Sensing 
Inhibitors: An Alternative Approach for Structure-Based 
Drug Design 
J. Henning Sahner, Christian Brengel, Michael P. Storz, Matthias Groh, Alberto Plaza, 
Rolf Müller, and Rolf W. Hartmann 
 
Reprint with permission from J. Med. Chem. 2013, 56, 8656-8664. 
Copyright (2013) American Chemical Society.  
 
Publication C 
 
 
 
 
 
Contribution Report 
The author planned, performed, and interpreted the digestion/Maldi-TOF and the HPLC-MS-
ESI experiment. He contributed to the interpretation of the results.  
 
 
  
28  3.3  PUBLICATION C 
 
 
  
3  RESULTS  29 
 
 
 
30  3.3  PUBLICATION C 
 
 
  
3  RESULTS  31 
 
 
  
32  3.3  PUBLICATION C 
 
 
 
3  RESULTS  33 
 
 
 
34  3.3  PUBLICATION C 
 
 
  
3  RESULTS  35 
 
 
  
36  3.3  PUBLICATION C 
 
 
 
3  RESULTS  37 
3.4 From in vitro to in cellulo: Structure-activity relationship of 
(2-nitrophenyl)-methanol derivatives as inhibitors of PqsD in 
Pseudomonas aeruginosa 
Michael P. Storz, Giuseppe Allegretta, Benjamin Kirsch, Martin Empting, and Rolf W. 
Hartmann 
 
Org. Biomol. Chem. 2014, DOI: 10.1039/c4ob00707g – Reproduced by permission of 
The Royal Chemical Society 
 
Publication D 
 
 
 
 
 
Contribution Report 
The author planned, synthesized and characterized all new compounds. He helped to perform 
the routine in vitro assay and contributed to data interpretation. Furthermore, he wrote the 
manuscript.  
 
  
38  3.4  PUBLICATION D 
 
 
 
  
3  RESULTS  39 
 
 
  
40  3.4  PUBLICATION D 
 
 
 
  
3  RESULTS  41 
 
 
 
  
42  3.4  PUBLICATION D 
 
 
  
3  RESULTS  43 
 
 
  
44  3.4  PUBLICATION D 
 
 
  
3  RESULTS  45 
 
 
 
46  3.4  PUBLICATION D 
 
 
 
3  RESULTS  47 
 
 
  
48  3.4  PUBLICATION D 
 
 
 
 
49 
4 Final Discussion 
4.1 Hit Identification and Efficiency Guided Optimization 
The superior goal of this thesis was the development of efficient small molecule inhibitors of 
PqsD. As reported in publication A, a ligand-based design strategy was pursued (Figure 4). 
Firstly, two substrate analogues bearing a methylene ketone instead of the scissile thioester, 
which is naturally cleaved by Cys
112
 of PqsD in a transthioesterification reaction, were 
examined (Figure 4b). Besides the natural amino group, electron withdrawing groups (EWG), 
which might facilitate the nucleophilic attack on the carbonyl moiety, are promising. Since 
NO2 served as stable precursor of the nucleophilic amino function during synthesis, NO2 was 
retained as EWG. Unfortunately, none of the compounds I or II showed inhibitory activity in 
the enzymatic PqsD assay.  
In a second approach, we mimicked the transition state by introduction of a tetrahedral 
hydroxymethylene moiety instead of the carbonyl function (Figure 4c). Since we applied the 
 
 
Figure 4. Ligand-based design strategy to identify PqsD inhibitors. a) Transthioesterification reaction of 
PqsD and ACoA proceeds via a tetrahedral transition state and results in a covalent anthraniloyl-PqsD 
complex. b) Substrate analogues I and II could analogously be attacked by Cys
112
-PqsD. However, 
elimination of a CoA-type leaving group cannot occur due to the high stability of carbon-carbon bonds. c) 
Transition state mimics III and IV bearing a tetrahedral geometry. d) Structure of simplified and ridigized 
compound V. The LE value in brackets was calculated according to Eq.1 using an ITC derived Kd. LE 
values for comparison were calculated according to Eq. 2. 
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same synthetic route as for the substrate analogs, the corresponding nitro derivative was easily 
accessible. No activity was observed for the amino compound III, whereas unexpectedly, the 
nitro compound IV was identified as the first inhibitor of PqsD.  
Compared to the median affinity for current small-molecule drugs of around 20 nM,
85
 an IC50 
value of 7.9 µM reflects moderate activity. Since IC50 is not a thermodynamically derived 
metric, it strongly depends on assay conditions (especially substrate concentration for 
competitive inhibitors). In our assay, an enzyme concentration of 0.1 µM was necessary to 
obtain reasonable HHQ formation. This relativizes the IC50 value of IV, since the theoretical 
minimum IC50 is 50 nM. However, there is plenty of room for improvements.  
Furthermore, this first hit showed inadequate drug-likeness due to the potential toxicity of the 
nitrobenzene moiety
86
 (as discussed in detail in publication D) and the high flexibility of the 
alkyl side chain. A high number of rotatable bonds (nrotb ≥ 10) are reported to restrict oral 
bioavailability (here: nrotb=12)
87
 and causes a penalty in binding affinity due to a loss of 
configurational entropy.
88
 Furthermore, the complicated and time-consuming synthesis 
impedes efficient optimization.  
Thus, we reduced MW, flexibility, and complexity by simplification of the side chain as 
described in detail in publication A. The resulting compound V bears a lower MW 
(229 g/mol), only one chiral center, low flexibility (nrotb = 3) and is easily accessible by a 
one pot synthesis. Surprisingly, in vitro activity was increased from IC50 = 7.9 µM for 
compound IV to IC50 = 3.2 µM (V), which was the lowest value observed so far. This 
indicates that the side chain has a minor contribution to the overall affinity. Significant 
reduction of the molecular size while slightly enhancing the activity led to a tremendous 
increase in ligand efficiency (LE), which is an important metric in drug discovery.
89
  
Hit optimization process usually aims at increasing the affinity (ΔG, Kd) and selectivity 
regarding a target and typically involves an increase in molecular size.
90
 However, various 
values for upper limits of molecular weight have been reported in literature. Most prominent, 
MW ≤ 500 has been suggested to gain a high probability of adequate oral bioavailability,91 
while analysis of key ADMET assays even suggest a cut off of MW = 400.
92
 It is all the more 
important to start the optimization process with the molecule bearing the highest potential to 
reach sufficient affinity without crossing the MW limit. Ligand efficiency is an appropriate 
metric for this potential as it reflects the affinity of a compound normalized by molecular 
size:
89
  
  
4  FINAL DISCUSSION  51 
                                    (Eq. 1) 
 
where ΔG is the change in Gibbs energy in kcal/mol and Nnon-H the number of non-hydrogen 
atoms. At 300 K and consistent assay parameters, this formula can be simplified to give an 
estimate of LE based on measured IC50: 
 
                              (Eq. 2) 
 
From this point of view, the optimization of IV to V was highly successful, as LE 
significantly increased (Figure 4). Thereby, the thermodynamically derived LE of 0.39 
reached a range, which is generally considered to be suitable for further optimization.
93
 
 
 
4.2 Effects on P. aeruginosa 
Before spending much more effort on the optimization of compound V, the ability to inhibit 
signal molecule production in P. aeruginosa cells was examined. This cannot be taken for 
granted, since especially in P. aeruginosa access to the intracellular targets is hindered by an 
unusually restricted outer-membrane permeability and multidrug efflux systems.
8
 Thus, 
higher concentrations are necessary to achieve a comparable degree of inhibition. Fortunately, 
250 µM of compound V significantly reduced both HHQ and PQS levels produced by 
P. aeruginosa PA14.  
 
Since inhibition of QS is considered an anti-virulence strategy, no bactericidal or 
bacteriostatic effect was expected. To proof that compound V does not affect cell viability of 
the bacterial population, we measured a growth curve of P. aeruginosa PA14 in LB medium 
in the presence of 500 µM compound V, which is the highest concentration used in the assays. 
No differences in the OD600 of the treated and untreated culture could be observed (see section 
6.1.7). This indicates that signal molecule production results from QS inhibition, even if the 
modulation of a superior regulator cannot be excluded.  
 
The influence of compound V on the secondary metabolite DHQ was also examined and in 
contrast to HHQ and PQS, increased levels of DHQ were observed. At the time of these 
experiments, it was not yet clarified how P. aeruginosa accomplishes DHQ biosynthesis. 
Contrary results about the enzymes involved were reported in literature. Lépine and 
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coworkers found pqsA as the only gene within the pqsABCDE operon, which is required for 
DHQ production,
94
 whereas Zhang et al. reported, that PqsA and PqsD account for DHQ 
synthesis in P. aeruginosa PAO1.
77
 In this context, our results seemed to be in accordance to 
those of Lépine and coworkers. However, according to the mechanism recently elucidated by 
Dulcey et al. in 2013 (Figure 3),
76
 PqsD is essential for biosynthesis of all quinolones 
including DHQ. On the contrary, inhibition of PqsB or PqsC would lead to an accumulation 
of 2-ABA, which has been shown to degrade to DHQ under acidic conditions. Since PqsB 
(48%) and PqsC (42%) share some sequence homology to PqsD, this seems to be a possible 
explanation for the increased DHQ level. However, preliminary SPR measurements suggest 
much lower affinity of compound V to a PqsB/PqsC complex than for PqsD (E. Weidel, 
unpublished data).  
 
PQS has often been associated with biofilm formation. For example, increasing PQS 
concentrations strongly promoted the coverage of P. aeruginosa PAO1 on stainless steel 
coupons.
63
 Furthermore, a pqsA mutant, which is deficient in HHQ and PQS biosynthesis, 
was assigned as poor biofilm producer.
95
 Thus, we added 500 µM of compound V to a 24h 
old biofilm of P. aeruginosa PA14 and analyzed the biovolume after further 24h incubation 
period. Indeed, the biovolume was decreased by 38% (see publication A, Figure 2). 
Unfortunately, there are no quantitative data for pqsA or pqsD mutants making an assessment 
of this value difficult. However, biofilm assays are sensitive and reproducibility is often poor. 
Results generated by different groups can hardly be compared due to various incalculable 
variables:  
1) Even two P. aeruginosa PA14 strains can show tremendous differences in biofilm 
formation.  
2) It is not clear, which readout (as biovolume, surface coverage etc.) is appropriate for data 
analysis. This bears further problems: Maturation of biofilms commonly involves 
development of a mushroom-shaped structure, which does not occur in pqsA mutants.
96
 
This structure was suggested to contribute to antibiotic resistance.
97
 However, when only 
biovolume is measured, the PqsD inhibitor’s influence might remain unknown.  
3) Bacteria living in a biofilm secrete a surrounding biofilm matrix, consisting of alginate 
(an exopolysaccaride), lipids, proteins, and extracellular DNA. Biovolume is usually 
measured after staining of various biofilm components. Depending on the dye used, only 
the modulation of a specific component can be observed.  
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 Extracellular DNA is generated via an AHL- and PQS-dependent mechanism.
64,96
 
Consequently, the DNA binding stains Syto9 and propidium iodide were used in our 
assay.  
4) Different assay procedures might have major impact on results (e.g., if the biofilm is 
washed before analysis). 
Taken together, results of biofilm assays should be considered in a differentiated manner 
under a multitude of aspects. Unfortunately, we were only able to determine the biovolume, 
which provides only an incomplete picture.  
 
 
4.3 Binding Mode Analysis and Eligibility of the In Vitro Assay 
(2-Nitrophenyl)methanol derivatives as V were identified by a ligand-based approach 
(Figure 4). Surprisingly, the transition state mimic III bearing the aminophenyl moiety in 
analogy to the natural substrate was not able to inhibit PqsD in vitro, even though the amino 
group was reported to form hydrogen bonds to the γ-oxygen of Ser317 and two active site 
water molecules.
78
 A totally different interaction profile is expected for NO2. However, in 
contrast to III, the corresponding nitrophenyl derivative IV efficiently inhibited PqsD. 
Therefore, doubts arised whether compound V, which was considered as starting point for 
further optimization, binds as expected for a transition state analog. This doubt was reinforced 
by the fact, that omission of a large part of the side chain increased potency, indicating that 
only a minor part of the molecule is responsible for affinity. To find answers to this question, 
we studied the binding mode by application of several biochemical and biophysical methods, 
as described in detail in publication B. Thereby, various experiments confirmed that 
compound V binds PqsD in the active site deep in the ACoA channel:  
1) Preincubation of PqsD with ACoA (before the usual preincubation step of PqsD and 
inhibitor) results in an 8-fold increased IC50 value for V, indicating that the inhibitor’s 
access to the binding site was hindered by covalently bound anthraniloyl or ACoA itself 
(for exact values see section 6.2.4).  
2) Both enantiomers of compound V bind to PqsD but not to the AA-PqsD complex as 
shown by SPR spectroscopy. The binding site of V is blocked by the anthraniloyl moiety.  
3) Mutation of amino acids located near the active site resulted in a drop of affinity as 
measured by ITC.  
Notably, the binding site of a given compound has an influence on the biological relevance of 
the in vitro inhibition data gathered by the applied enzyme assay, as it is based on the PqsD-
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catalyzed HHQ production from ACoA and β-ketodecanoic acid. This reaction was 
considered to be responsible for HHQ production in P. aeruginosa until recently.
79
 However, 
Dulcey et al. showed, that after transfer of anthraniloyl from ACoA to PqsD, malonyl-CoA 
and octanoyl-PqsC are used as further substrates for HHQ synthesis.
76
 This is not 
problematic, since our compounds clearly interfere with the reaction of PqsD and ACoA, 
which is independent of the second substrate used.  
A further fundamental question in mode of action analysis is the nature of the molecular 
interaction. Since we observed time-dependent inhibition and apparent irreversibility (on the 
time scale of the experiment), MS techniques were applied to proof or to exclude covalent 
binding. As initial test, PqsD was incubated in presence of an excess of inhibitor V. 
Subsequent analysis by HPLC-ESI did not provide indications of a covalent adduct (see 
section 6.2.7). However, a possible covalent bond might be cleaved during ESI-MS or HPLC 
due to the non-physiological conditions (water/acetonitrile + 0.05% TFA eluent) present on 
the reversed phase column. Thus, PqsD incubated with an excess of inhibitor V was digested 
by trypsin to generate peptides suitable for MALDI-TOF MS, which is characterized by soft 
ionization and, in our case, enabled us to avoid HPLC conditions. In the mass spectra 
analysis, all relevant amino acids of PqsD were represented by at least one peptide (as 
discussed in detail in section 6.2.8), but again, no shift or disappearance of a specific peptide 
could be observed. This strongly suggests a non-covalent interaction between V and PqsD.  
 
The methods developed to disproof covalent binding of (2-nitrophenyl)methanol derivatives 
are also applicable to other classes of PqsD inhibitors. 5-Arylureidothiophene-2-carboxylic 
acids were developed recently and have been shown to bind farther outside in the substrate 
 
 
Figure 5. a) General structure 5-arylureidothiphene-2-carboxylic acid derivatives. 
b) Nucleophilic attack of Cys112 on the reactive β-chloroacetyl moiety leads to the covalent 
VI-PqsD complex VII. 
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channel (publication C). Competition experiments with (2-nitrophenyl)methanol derivatives 
of different size were applied to specify the precise position and binding poses were proposed 
by STD NMR and molecular docking. Additionally, a reactive β-chloroacetyl moiety was 
added in compound VII. If the binding pose was correct, this “electrophilic warhead”98 would 
be in immediate vicinity to the active site Cys112, which allows covalent bond formation 
(Figure 5b). VII was still able to inhibit PqsD, and indeed, incubation with VII resulted in the 
expected mass shift as measured by HPLC-ESI MS (spectra shown in 6.3.8). To show that 
Cys112 is responsible for binding, the covalent PqsD-VII complex was digested by Trypsin 
and analyzed by MALDI-TOF MS. Thereby, we observed the expected mass shift (and a 
corresponding decarboxylation product) for the peptide bearing the Cys112 residue. Since 
none of the nucleophilic amino acids on this peptide have access to the substrate channel, this 
confirms the proposed binding site. Furthermore, this compound VII served as some kind of 
positive control and demonstrates the reliability of our strategy to proof a non-covalent 
binding mode for (2-nitrophenyl)methanol derivatives.  
 
 
4.4 Structure-activity Relationships 
Compound V has high ligand efficiency and low molecular weight, which enables a fragment-
growing strategy. To this end, we fine-tuned the fragment by systematic variation of several 
structural features: substitution of the nitro group, introduction of substituents in the 
nitrophenyl moiety, and substitution of the phenyl ring by various aliphatic and 
(hetero-)aromatic groups. Over 60 derivatives were synthesized and evaluated in vitro 
(including a 10 min as well as 30 min preincubation step, since compound V showed time-
dependent behavior). The most conspicuous characteristics were the essentiality of the nitro 
group, improved inhibition by electron donating substituents in the nitrophenyl moiety, and 
high tolerance for modifications of the phenyl residue. Selected compounds were tested for 
their ability to inhibit signal molecule production in P. aeruginosa PA14 cells. Detailed 
structure-activity relationship for each assay is discussed in detail in publication D. 
Unfortunately, we observed tremendous differences when we compared in vitro and in cellulo 
data. For example, introduction of a phthalimide moiety in compound 68 resulted in at least 
equal in vitro activity, but abolished activity in P. aeruginosa. Considering the challenging 
barriers of P. aeruginosa, which an inhibitor has to overcome, this observation is not 
surprising. Differences in permeability, efflux, and metabolism depend on the molecular 
structure and possibly cause the discrepancy between enzymatic and cellular activity.  
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These observations led to the recognition that optimization only on the basis of enzymatic 
activity is unreasonable. To minimize the effort of compound evaluation in cellulo, we 
measured HHQ formation in a pqsH mutant, which is unable to convert HHQ to PQS. This 
method provided consistent results when compared to the wild-type and enables to examine 
the effect on signal molecule production efficiently by quantification of only one metabolite. 
 
Table 1. Structure and % inhibition of the most potent (2-nitrophenyl)methanol derivatives.
a
 
 
Cmpd. HHQ (pqsH
-
) HHQ (PA14)
 
PQS (PA14)
 
V (250 µM) 43 ± 6 38 ± 6 37 ± 6 
VIII (250 µM) 61 ± 2 33 ± 6 60 ± 11 
IX (250 µM) 74 ± 6 49 ± 1 68 ± 1 
a
Values were derived from section 3.4 and 6.4.6 and differ from section 3.1  
due to improvements of the assay procedure.  
 
Based on this assessment tool, systematic variation led to the structural diverse and efficient 
fragments VIII and IX (Table 1). The most potent compound IX achieved HHQ and PQS 
inhibition in P. aeruginosa wild-type of 49 and 68 %, respectively. 
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4.5 Outlook 
Compound VIII and IX are the PqsD inhibitors with the highest potency in P. aeruginosa 
cells, which were reported until now. Due to their low molecular weight and calculated logP 
values of less than 240 g/mol or 2.2, respectively, they bear a high potential in a fragment 
growing optimization process.  
We have shown in vitro, that the binding pocket is very tolerant to modifications of the right 
part of the molecule. In P. aeruginosa, introduction of substituents in the nitrophenyl moiety 
led to poor activity, even if they were favorable in the enzymatic assay. Thus, we consider the 
right part of the molecule as promising site for new substituents. Improvement of VIII might 
be complicated due to the high flexibility of the propyl chain. Furthermore, substitution of a 
hydrogen atom would mostly create a new chiral center, which increases complexicity and 
slows down compound preparation/isolation. Consequently, introduction of substituents in the 
thiophene ring of IX is a promising optimization strategy by fine-tuning electronic properties 
of the thiophene ring or the establishment of additional interactions. This should be supported 
by the binding poses proposed in publication B.  
 
By the development of PqsD inhibitors, we wanted to pursue an anti-virulence strategy. 
However, the inhibition of HHQ and PQS per se is not sufficient to reduce the pathogenicity 
of P. aeruginosa. Rather, the production of relevant virulence factors should be inhibited. In 
this regard, the optimized compounds serve as valuable tools to examine the impact on 
virulence factor production. For example, pyoverdine production is directly linked to the 
presence of PQS.
53,55
 Furthermore, PqsD mutants are defective in pyocyanin production,
54
 and 
PqsR antagonists showed significant inhibition.
99
 Similar effects on pyocyanin were expected 
for PqsD inhibitors, since PQS is needed for full activation of PqsR.
100
 However, preliminary 
data suggest no cellular effect by VIII or IX at 250 µM (unpublished data). It is unclear, 
whether PqsD is (contrary to previous reports) not crucial for pyocyanin production, or 
whether partly inhibition of HHQ and PQS is not sufficient to obtain the desired effects.  
Further metabolites, which should be affected, are DHQ (inhibits the cell viability of mouse 
lung epithelial cells
77
) and N-oxides as HQNO (series C and E in Figure 4), for which only 
antimicrobial activity has been reported until now.
50
 
Due to the influence of the pqs system on the las, and especially on the rhl system (Figure 2), 
various virulence factors, which are directly controlled by the latter systems, might be 
affected. This includes the exoproducts as elastase, the galactophilic lectin LecA, exotoxin A, 
HCN, alkaline proteases, and rhamnolipids as well as phenotypes as swarming and biofilm 
58  4.5  OUTLOOK 
formation. The examination of the effects exerted by PqsD inhibitors on these virulence 
factors and connected phenotypes should provide information, if PqsD is an appropriate drug-
target.  
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6 Supporting Information 
This section contains the relevant supporting information of the studies presented in section 3. 
It includes additional details on experimental procedures, as well as further figures and 
results.  
 
 
 
6.1 Supporting Information for Publication A 
Full supporting information is available online:  
http://pubs.acs.org/doi/suppl/10.1021/ja3072397/suppl_file/ja3072397_si_001.pdf 
 
 
6.1.1 Chemistry 
 
a) General Chemistry Methods 
 
1-Benzyl-2-nitrobenzene 21 and 1-nitro-2-(phenylsulfonyl)-benzene 22 were purchased from 
Sigma-Aldrich and used for biological assays without further purification. Starting materials were 
purchased from Aldrich, Acros, Fluka and ABCR and were used without further purification. All 
reactions were conducted under a nitrogen atmosphere unless otherwise indicated. Experimental 
procedures were not optimized. During workup drying was achieved by anhydrous sodium sulfate. 
Flash chromatography was performed using silica gel 60 (40-63 μm) and the reaction progress was 
determined by TLC analysis on ALUGRAM SIL G/UV254 (Macherey-Nagel). Visualization was 
accomplished with UV light. Purification by preparative HPLC was carried out on an Agilent 1200 
series HPLC system from Agilent Technologies, using an Agilent Prep-C18 column (30x100 mm/10 
μm) as stationary phase with acetonitrile/water as eluent. The purity of compounds used in the 
biological assays was ≥ 95 % as measured by LC/MS, monitored at 254 nm. The methods for LC/MS 
analysis and a table with data (including melting points) for all tested compounds are provided in the 
purity section. All chiral alcohols were isolated as racemates. 
1
H and 
13
C NMR spectra were recorded 
on a Bruker DRX-500 instrument at 300 K. Chemical shifts are reported in δ values (ppm) and the 
hydrogenated residues of deuterated solvents were used as internal standard (CDCl3: δ = 7.26, 77.16. 
CD3OD: δ = 3.31, 49.00. DMSO-d6: δ = 2.50, 39.52). Splitting patterns describe apparent 
multiplicities and are designated as s (singlet), d (doublet), dd (doublet of doublet), t (triplet), td 
(triplet of doublet), q (quartet), and m (multiplet). All coupling constants (J) are given in hertz (Hz). 
Mass spectra (ESI) were measured on a Finnigan Surveyor MSQ Plus instrument (ThermoFisher). 
Mass spectra (EI) were measured on a DSQII instrument (ThermoFisher). Melting points of samples 
were determined in open capillaries using a SMP3 Melting Point Apparatus of Bibby Sterilin and are 
uncorrected. 
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b) Synthesis and Spectroscopic Data of Intermediate 7
S1 
 
 
 
2-(4,4-Diethoxybutyl)isoindoline-1,3-dione (7ii). N-Carbethoxy-phthalimide (13.04 g, 59.50 
mmol) and 4-aminobutyraldehyde diethyl acetal 7i (10.28 g, 59.50 mmol) were dissolved in THF (90 
ml) and triethylamine (8.36 ml, 59.50 mmol) was added. After stirring for 20 h at room temperature 
the solvent was evaporated under reduced pressure and the remaining oil was purified by flash 
chromatography (n-hexane/ethyl acetate 8:1) to yield the title compound 7ii (15.40 g, 88 %) as a 
colorless oil. 
1
H NMR (500 MHz, CDCl3) δ 1.17 (t, J = 7.0, 6H), 1.62-1.67 (m, 2H), 1.72-1.78 (m, 
2H), 3.44-3.50 (m, 2H), 3.58-3.64 (m, 2H), 3.70 (t, J = 7.3, 2H), 4.49 (t, J = 5.5, 1H), 7.69 (dd, J = 
5.5, J = 3.0, 2H), 7.82 (dd, J = 5.5, J = 3.0, 2H). 
13
C NMR (125 MHz, CDCl3) δ 15.4, 24.1, 31.1, 37.9, 
61.4, 102.5, 123.3, 132.3, 134.0, 168.5. MS (ESI) m/z: 246 (M-OEt)
+
. 
 
4-(1,3-Dioxoindolin-2-yl)butanal (7). A mixture of 2-(4,4-diethoxybutyl)-isoindoline-1,3-dione 7ii 
(15.40 g, 52.86 mmol) and 1M aqueous HCl (101 ml) in acetone (108 ml) was heated under reflux for 
2 h. The acetone was removed in vacuo and the residue was extracted with ether (three times). The 
combined organic extracts were washed with water, dried, filtered, and concentrated in vacuo to yield 
the product 7 (11.12 mmol, 97 %) as a white solid. This was used for the next step without further 
purification. 
1
H NMR (500 MHz, CDCl3) δ 2.02 (quintet, J = 7.0, 2H), 2.53 (td, J = 7.3, J = 0.9, 2H), 
3.74 (t, J = 6.7, 2H), 7.72 (dd, J = 5.5, J = 3.0, 2H), 7.84 (dd, J = 5.5, J = 3.0, 2H), 9.77 (s, 1H). 
13
C 
NMR (125 MHz, CDCl3) δ 21.3, 37.3, 41.2, 123.4, 132.2, 134.2, 168.5, 200.9. MS (ESI) m/z: 218 
(M+H)
+
. 
 
 
 
c) General Method for the Synthesis of Compounds 8, 16-19 and 25 
 
A solution of 2-iodo-nitrobenzene 5 (1.0 eq) in THF (10 ml/g reagent) was cooled to -40°C and a 
solution of phenylmagnesium chloride (2M in THF, 1.1 eq) was added dropwise. The solution was 
stirred for 30 min at -40°C, the aldehyde (1.0 eq for 7, 19a and 25a; 0.5 eq for 16a-18a) was added 
and reaction was completed at -40°C (checked by TLC). The mixture was quenched with a saturated 
solution of NH4Cl (5 ml) and diluted with water (5 ml). The aqueous phase was extracted with ethyl 
acetate (three times) and the combined organic layers were washed with brine, dried, and concentrated 
under reduced pressure. The residue was purified by column chromatography over silica gel to give 
the desired product (8, 16-19 or 25).  
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d) General Procedure for Syntheses of the Starting Materials 16a and 17a
S2 
 
 
 
(Nitrophenyl)methanol (16ii and 17ii). Sodium borohydride (1.5 eq) was added to a solution of 
nitrobenzaldehyde 16i or 17i (1.0 eq) in ethanol (130 ml) at 0°C and stirred for 2 h at room 
temperature. Ethanol was removed in vacuo and a saturated solution of NH4Cl was carefully added. 
The mixture was extracted with DCM (three times) and the combined organic layers were washed 
with brine, dried and concentrated to dryness. The crude product was sufficiently pure for the next 
step. 2-(Nitrophenyl)methanol 16ii (91 % yield): 
1
H NMR (500 MHz, CD3OD) δ 4.94 (s, 2H), 7.48 (t, 
J = 7.6, 1H), 7.71 (t, J = 7.6, 1H), 7.85 (d, J = 7.9, 1H), 8.44 (d, J = 8.2, 1H). 
13
C NMR (125 MHz, 
CD3OD) δ 61.9, 125.5, 129.0, 129.6, 134.7, 139.0, 148.7. 3-(Nitrophenyl)methanol 17ii (95 % yield): 
1
H NMR (500 MHz, CD3OD) δ 4.72 (s, 2H), 7.57 (t, J = 7.9, 1H), 7.73 (d, J = 8.2, 1H), 8.11 (dd, J = 
8.2, J = 1.9, 1H), 8.44 (s, 1H). 
13
C NMR (125 MHz, CD3OD) δ 63.9, 122.2, 122.9, 130.5, 133.8, 
145.5, 149.7. 
 
(Aminophenyl)methanol (16iii and 17iii). Iron powder (5.5 eq) and NH4Cl (0.7 eq) were suspended 
in ethanol/water 10:1 (100 ml) and refluxed with (nitrophenyl)methanol 16ii or 17ii (1.0 eq) for 2 h. 
The solvent was evaporated and DCM was added. The mixture was washed with a saturated solution 
of sodium carbonate, dried, filtered and concentrated in vacuo. The crude product was sufficiently 
pure for the next step. 2-(Aminophenyl)methanol 16iii (88 % yield): 
1
H NMR (500 MHz, CD3OD) δ 
4.57 (s, 2H), 6.67 (td, J = 7.4, J = 1.3, 1H), 6.73 (dd, J = 7.9, J = 1.0, 1H), 7.04-7.09 (m, 2H). 
13
C 
NMR (125 MHz, CD3OD) δ 63.6, 117.2, 119.1, 127.0, 129.7, 129.8, 147.2. 3-(Aminophenyl)methanol 
17iii (68 % yield): 
1
H NMR (500 MHz, CD3OD) δ 4.85 (s, 2H), 6.63 (dd, J = 7.9, J = 2.2, 1H), 6.68 
(d, J = 7.6, 1H), 6.72-6.74 (m, 1H), 7.06 (t, J = 7.7, 1H). 
13
C NMR (125 MHz, CD3OD) δ 65.4, 115.2, 
115.6, 117.9, 130.0, 143.5, 148.7. 
 
Acetamidobenzyl acetate (16iv and 17iv). At 0°C acetyl chloride (6.0 eq) was added dropwise to a 
stirred solution of (aminophenyl)methanol 16iii or 17iii (1.0 eq) and triethylamine (3.0 eq) in DCM. 
After stirring for 16 h at room temperature, a saturated solution of sodium bicarbonate was added and 
extracted with DCM (three times). The combined organic layers were washed with 1M HCl, dried, 
filtered and evaporated in vacuo. The crude product was used for the next step without further 
purification.  
 
N-(Hydroxymethylphenyl)acetamide (16v and 17v). To a solution of acetamidobenzyl acetate 
16iv or 17iv (1.0 eq) in methanol was added NaOH (3.0 eq) and stirred for 2.5 h at room temperature. 
After evaporation of the solvent under reduced pressure, water was added and extracted with ethyl 
acetate (four times). The combined organic layers were washed with brine, dried and concentrated in 
vacuo. The crude product was sufficiently pure for the next step. N-(2-
(Hydroxymethyl)phenyl)acetamide 16v (87 % yield, 2 steps): 
1
H NMR (500 MHz, CD3OD) δ 2.16 (s, 
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3H), 4.61 (s, 2H), 7.20 (td, J = 7.6, J = 1.3, 1H), 7.28 (td, J = 7.6, J = 1.6, 1H), 7.41 (dd, J = 7.6, J = 
1.3, 1H), 7.51 (dd, J = 7.9, J = 1.3, 1H). 
13
C NMR (125 MHz, CD3OD) δ 23.4, 62.4, 125.9, 126.9, 
128.9, 129.2, 135.8, 136.6, 172.1. N-(3-(Hydroxymethyl)phenyl)acetamide 17v (86 % yield, 2 steps): 
1
H NMR (500 MHz, CD3OD) δ 2.12 (s, 3H), 4.58 (s, 2H), 7.08-7.10 (m, 1H), 7.27 (t, J = 7.9, 1H), 
7.43-7.45 (m, 1H), 7.54-7.56 (m, 1H). 
13
C NMR (125 MHz, CD3OD) δ 23.8, 65.1, 119.7, 120.1, 123.6, 
129.8, 139.9, 143.6, 171.6. 
 
N-(Formylphenyl)acetamide (16a and 17a). To a solution of N-(hydroxymethyl-phenyl)acetamide 
16v or 17v (1.0 eq) in DCM was added Dess-Martin periodinane (1.5 eq) and stirred for 20 min at 
room temperature. The mixture was washed with Na2S2O3 (4.5 eq) in a saturated solution of sodium 
carbonate and extracted with DCM (two times). The combined organic layers were dried, filtered and 
concentrated in vacuo. N-(2-Formylphenyl)acetamide 16a (56 % yield) was purified by flash 
chromatography (petroleum ether/ethyl acetate 3:1). 
1
H NMR (500 MHz, CD3OD) δ 2.22 (s, 3H), 7.29 
(t, J = 7.6, 1H), 7.62 (t, J = 8.2, 1H), 7.82 (d, J = 7.6, 1H), 8.46 (d, J = 8.5, 1H), 9.94 (s, 1H). 
13
C 
NMR (125 MHz, CD3OD) δ 24.8, 121.3, 124.7, 136.6, 136.7, 141.3, 171.9, 196.7. N-(3-
Formylphenyl)acetamide 17a (74 % yield) was purified by flash chromatography (petroleum 
ether/ethyl acetate 1:1). 
1
H NMR (500 MHz, CD3OD) δ 2.15 (s, 3H), 7.51 (t, J = 7.9, 1H), 7.63 (d, J = 
7.6, 1H), 7.82 (d, J = 7.9, 1H), 8.14 (s, 1H), 9.95 (s, 1H). 
13
C NMR (125 MHz, CD3OD) δ 23.8, 121.3, 
126.4, 126.7, 130.6, 171.9, 193.8. 
 
N-(4-Formylphenyl)acetamide (18e). The title compound was purchased from Sigma-Aldrich with 
a purity of 97 % as specified by the producer and was used for synthesis without further purification.  
 
 
 
e) Synthesis and Spectroscopic Data of Compounds 1-4, 8-20 and 23-25 
 
(R)-2,4-Dihydroxy-3,3-dimethyl-N-(3-((4-(2-nitrophenyl)-4-oxobutyl)amino)-3-oxopropyl)-
butanamide (1). To a solution of 12a (250 mg, 0.55 mmol) in DCM (4 ml) was added Dess-Martin 
periodinane (376 mg, 0.68 mmol) and the mixture was stirred for 90 min at room temperature. The 
suspension was filtered and the filtrate was concentrated to dryness. The residue was purified on silica 
gel (6 % MeOH/DCM) to give the ketal (R)-2,2,5,5-tetramethyl-N-(3-((4-(2-nitrophenyl)-4-
oxobutyl)amino)-3-oxopropyl)-1,3-dioxane-4-carbox-amide (186 mg, 75 %) as a brown oil. 
1
H NMR 
(500 MHz, CD3OD) δ 0.95 (s, 3H), 0.98 (s, 3H), 1.42 (s, 3H), 1.43 (s, 3H), 1.91-1.96 (m, 2H), 2.42 (t, 
J = 6.6, 2H), 2.91 (t, J = 7.3, 2H), 3.24 (d, J = 11.7, 1H), 3.28 (t, J = 6.9, 2H), 3.41-3.52 (m, 2H), 3.72 
(d, J = 11.7, 1H), 4.11 (s, 1H), 7.59 (dd, J = 7.6, J = 1.3, 1H), 7.67-7.71 (m, 1H), 7.80 (td, J = 7.6, J = 
1.3, 1H), 8.12 (dd, J = 8.2, J = 0.7, 1H). 
13
C NMR (125 MHz, CD3OD) δ 19.1, 19.4, 22.5, 24.8, 34.0, 
36.2, 36.4, 39.6, 40.8, 72.3, 78.4, 100.4, 125.5, 128.8, 132.1, 135.4, 138.8, 172.2, 173.8, 203.6. MS 
(ESI) m/z: 410 (M+H)
+
. To a solution of the intermediate described above (168 mg, 0.37 mmol) in 
ethyl acetate (20 ml) was added 1M aqueous HCl (3 ml) and the mixture was stirred for 16 h at room 
temperature. The water phase was extracted with ethyl acetate (two times) and the combined organic 
phases were dried, filtered and concentrated in vacuo. The residue was purified by flash 
chromatography (6 % MeOH/DCM) to give compound 1 (67 mg, 44 %) as a brown oil. 
1
H NMR (500 
MHz, CD3OD) δ 0.92 (s, 6H), 1.93 (quintet, J = 6.9, 2H), 2.45 (t, J = 6.3, 2H), 2.92 (t, J = 7.3, 2H), 
3.28 (t, J = 6.9, 2H), 3.38 (d, J = 11.3, 1H), 3.44 (d, J = 11.3, 1H), 3.52 (t, J = 6.6, 1H), 3.92 (s, 1H), 
7.60 (dd, J = 7.6, J = 1.3, 1H), 7.70 (m, 1H), 7.81 (td, J = 7.6, J = 0.9, 1H), 8.12 (dd, J = 8.2, J = 1.3, 
1H). 
13
C NMR (125 MHz, CD3OD) δ 21.2, 21.5, 24.6, 36.4, 36.5, 39.7, 40.3, 40.8, 70.2, 77.6, 125.4, 
128.8, 132.1, 135.4, 138.7, 142.5, 173.8, 176.2, 203.7. MS (ESI) m/z: 410 (M+H)
+
. 
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(4R)-N-(3-((4-(2-Aminophenyl)-4-oxobutyl)amino)-3-oxopropyl)-2,4-dihydroxy-3,3-dimethyl-
butanamide (2). Crude 12b (1.70 g) was dissolved in DCM (30 ml) and added to a solution of 
pyridinium chlorochromate (0.58 g, 2.69 mmol) in DCM and molecular sieves 4Å. The mixture was 
stirred for 18 h at room temperature. The molecular sieves were filtered off and the DCM was 
evaporated in vacuo. Ethyl acetate was added to the residue and washed with saturated Na2CO3, 
extracted with ethyl acetate (three times), washed with brine, filtered and concentrated in vacuo. The 
crude product was purified by flash chromatography (3 % MeOH/DCM + 1 ‰ TEA). The identity of 
the oxidation product (0.39 g) was proven by LC/MS, indicating a contamination by 
tetrabutylammonium. LC/MS (ESI) 96 % purity (UV), m/z: 420 (M+H)
+
, 242 (n-Bu4N)
+
. Ethyl acetate 
(20 ml) and 1M aqueous HCl were added and the mixture was stirred for 3 h at room temperature. The 
pH value was adjusted to 9-10 by addition of concentrated Na2CO3 solution and the solvent was 
removed in vacuo. Methanol was added, the mixture was filtered and the filtrate was concentrated to 
dryness. The residue obtained after flash column chromatography (8 % MeOH/DCM) was further 
purified by preparative HPLC to afford 2 (20 mg, 2 %, 3 steps) as a brown oil. 
1
H NMR (500 MHz, 
CD3OD) δ 0.91 (s, 6H), 1.85-1.91 (quintet, J = 7.0, 2H), 2.42 (t, J = 6.4, 2H), 2.99 (t, J = 7.3, 2H), 
3.26 (t, J = 7.0, 2H), 3.38 (d, J = 10.7, 1H), 3.42-3.53 (m, 3H), 3.88 (s, 1H), 6.56-6.61 (m, 1H), 6.73 
(dd, J = 8.2, J = 0.9, 1H), 7.21-7.24 (m, 1H), 7.77 (dd, J = 8.2, J = 1.2, 1H). 
13
C NMR (125 MHz, 
CD3OD) δ 20.9, 21.3, 25.6, 36.4, 36.5, 37.3, 40.1, 40.3, 70.4, 77.3, 106.2, 118.4, 118.5, 132.3, 135.3, 
152.6, 173.7, 176.0, 203.0. MS (ESI) m/z: 380 (M+H)
+
. 
 
(2R)-2,4-Dihydroxy-N-(3-((4-hydroxy-4-(2-nitrophenyl)butyl)amino)-3-oxopropyl)-3,3-
dimethylbutanamide (3). The title compound was prepared by reaction of 12a (175 mg, 0.39 mmol) 
with aqueous HCl (3 ml, 1M) in ethyl acetate (20 ml) according to the procedure described for 
compound 1. Compound 3 (73 mg, 43 %) was obtained after purification by flash chromatography (10 
% MeOH/DCM) as a red-brown solid. 
1
H NMR (500 MHz, CD3OD) δ 0.91 (s, 6H), 1.63-1.81 (m, 
4H), 2.43 (t, J = 6.6, 2H), 3.20-3.24 (m, 2H), 3.37 (d, J = 11.0, 1H), 3.45 (d, J = 11.0, 1H), 3.46-3.53 
(m, 2H), 3.90 (s, 1H), 5.16 (dd, J = 7.8, J = 3.2, 1H), 7.44-7.47 (m, 1H), 7.68 (td, J = 7.6, J = 1.3, 1H), 
7.84 (dd, J = 7.9, J = 1.3, 1H), 7.87 (dd, J = 8.2, J = 1.3, 1H). 
13
C NMR (125 MHz, CD3OD) δ 21.2, 
27.1, 36.4, 36.5, 37.2, 40.2, 40.3, 69.4, 70.3, 77.4, 125.0, 129.0, 129.1, 134.3, 142.0, 149.3, 173.7, 
176.1. MS (ESI) m/z: 412 (M+H)
+
. 
 
(2R)-N-(3-((4-(2-Aminophenyl)-4-hydroxybutyl)amino)-3-oxopropyl)-2,4-dihydroxy-3,3-
dimethylbutanamide (4). The title compound was prepared according to the procedure described for 
compound 1 by reaction of the crude product 12b (0.32 mg) with 1M aqueous HCl (2.5 ml) in ethyl 
acetate (25 ml). The crude product was purified by flash chromatography (8 % MeOH/DCM) and 
preparative HPLC to afford 4 (24 mg, 5 %, 2 steps) as a yellow oil. 
1
H NMR (500 MHz, CD3OD) δ 
0.90 (s, 6H), 1.44-1.53 (m, 1H), 1-58-1.69 (m, 1H), 1.77-1.88 (m, 2H), 2.40 (t, J = 6.7, 2H), 3.14-3.25 
(m, 2H), 3.38 (d, J = 11.0, 1H), 3.41-3.52 (m, 2H), 3.88 (s, 1H), 4.70 (t, J = 6.7, 1H), 6.67 (td, J = 7.5, 
J = 1.2, 1H), 6.71 (dd, J = 7.9, J = 0.9, 1H), 7.00 (td, J = 7.6, J = 1.5, 1H), 7.08 (d, J = 7.6, 1H). 
13
C 
NMR (125 MHz, CD3OD) δ 20.9, 21.3, 27.1, 34.1, 36.4, 36.5, 70.4, 73.2, 73.3, 77.3, 117.9, 119.1, 
128.2, 128.9, 129.8, 146.2, 173.6, 176.0. MS (ESI) m/z: 364 (M-OH)
+
, 382 (M+H)
+
. 
 
2-(4-Hydroxy-4-(2-nitrophenyl)butyl)isoindoline-1,3-dione (8). Following the general method 
described in c) using 2-iodonitrobenzene 5 (2.49 g, 10.0 mmol) and aldehyde 7 (2.61 g, 12.0 mmol), 
the crude product was purified by flash chromatography (petroleum ether/ethyl acetate 5:2) to give 8 
(2.89 g, 85 %) as a yellowish solid. 
1
H NMR (500 MHz, DMSO-d6) δ 1.56-1.61 (m, 1H), 1.63-1.72 
(m, 2H), 1.78-1.86 (m, 1H), 3.58-3.61 (m, 2H), 4.93-4.96 (m, 1H), 5.54 (d, J = 4.7, 1H), 7.46-7.49 (m, 
1H), 7.70 (td, J = 7.3, J = 1.3, 1H), 7.76 (dd, J = 7.9, J = 1.3, 1H), 7.82-7.87 (m, 5H). 
13
C NMR (125 
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MHz, DMSO-d6) δ 24.0, 35.7, 37.4, 67.3, 123.0, 123.6, 128.0, 131.6, 133.2, 134.3, 140.6, 147.5, 
167.9. MS (ESI) m/z: 341 (M+H)
+
. 
 
2-(4-((tert-Butyldimethylsilyl)oxy)-4-(2-nitrophenyl)butyl)-isoindoline-1,3-dione. To a solution 
of 8 (4.48 g, 13.16 mmol) in DMF (120 ml) were added tert-butyldimethylsilyl chloride (7.93 g, 52.61 
mmol) and imidazole (7.16 g, 105.17 mmol). The reaction mixture was stirred for 18 h at room 
temperature, washed with saturated NaHCO3 and the aqueous layer was extracted with DCM (three 
times). The combined organic layers were washed with brine, dried, and concentrated under reduced 
pressure. The residue was purified on silica gel (petroleum ether/ethyl acetate 3:1) to give the title 
compound (3.67 g, 62 %) as a yellowish solid. 
1
H NMR (500 MHz, CDCl3) δ -0.21 (s, 3H), 0.04 (s, 
3H), 0.85 (s, 9H), 1.67-1.90 (m, 4H), 3.62-3.76 (m, 2H), 5.30 (dd, J = 7.6, J = 2.5, 1H), 7.35-7.40 (m, 
1H), 7.57-7.61 (m, 1H), 7.66-7.72 (m, 2H), 7.79-7.85 (m, 3H), 7.86 (dd, J = 8.2, J = 1.3, 1H). 
13
C 
NMR (125 MHz, CDCl3) δ -5.0, -4.8, 18.2, 25.1, 25.9, 37.4, 38.1, 69.5, 123.3, 124.2, 127.9, 129.0, 
132.3, 133.3, 134.0, 141.1, 147.2, 168.5, 190.0. MS (ESI) m/z: 455 (M+H)
+
. 
 
4-((tert-Butyldimethylsilyl)oxy)-(2-nitrophenyl)butan-2-amine (9). A mixture of 2-(4-((tert-
butyldimethylsilyl)oxy)-4-(2-nitrophenyl)butyl)-isoindoline-1,3-dione (3.55 g, 7.80 mmol) and 
hydrazinium hydroxide (0.97 ml, 19.94 mmol) in ethanol (190 ml) was refluxed for 2.5 h. The reaction 
mixture was diluted with ethyl acetate and washed with saturated NaHCO3. The aqueous phase was 
extracted with ethyl acetate (three times) and the combined organic layers were washed with brine, 
dried and evaporated to afford the title compound 9 (2.49 g, 98 %) as a yellow oil. 
1
H NMR (500 
MHz, CD3OD) δ -0.19 (s, 3H), 0.05 (s, 3H), 0.89 (s, 9H), 1.54-1.63 (m, 1H), 1.66-1.83 (m, 3H), 2.63-
2.70 (m, 2H), 5.26 (dd, J = 7.9, J = 3.5, 1H), 7.45-7.49 (m, 1H), 7.68 (td, J = 7.6, J = 1.3, 1H), 7.83 
(dd, J = 7.9, J = 1.3, 1H), 7.86 (dd, J = 8.2, J = 1.3, 1H), 
13
C NMR (125 MHz, CD3OD) δ -4.9, -4.8, 
19.0, 26.3, 29.9, 38.6, 42.3, 70.9, 124.9, 129.3, 129.8, 134.2, 141.7, 149.0. MS (ESI) m/z: 366 
(M+H+CH3CN)
+
. 
 
(R)-3-(2,2,5,5-Tetramethyl-1,3-dioxane-4-carboxamido)propanoic acid (10).
S3
 Calcium 
pantothenate (22.00 g, 46.20 mmol) and anhydrous oxalic acid (4.16 g, 46.20 mmol) were suspended 
in acetone (200 ml). 2,2-Dimethoxypropane (31.2 ml, 255 mmol) and molecular sieves (4Å) were 
added and the mixture was refluxed for 20 h. The solid was removed by filtration, the filtrate was 
concentrated in vacuo, the residue was dissolved in ethyl acetate and washed with water. After drying 
and evaporation of the solvent, product 10 was obtained as a white solid (12.46 g, 52 %). 
1
H NMR 
(500 MHz, CDCl3) δ 0.97 (s, 3H), 1.03 (s, 3H), 1.42 (s, 3H), 1.45 (s, 3H), 2.61 (t, J = 6.1, 2H), 3.28 (d, 
J = 11.6, 1H), 3.45-3.52 (m, 1H), 3.56-3.63 (m, 1H), 3.68 (d, J = 11.6, 1H), 4.11 (s, 1H), 7.04 (s, 1H). 
13
C NMR (125 MHz, CDCl3) δ 18.9, 19.0, 22.2, 29.5, 33.1, 34.0, 34.2, 71.6, 99.2, 170.3, 176.6. MS 
(ESI) m/z: 260 (M+H)
+
. 
 
(4R)-N-(3-((4-((tert-Butyldimethylsilyl)oxy)-4-(2-nitrophenyl)butyl)amine)-3-oxo-propyl)-
2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamide (11a). To a solution of amine 9 (2.45 g, 7.56 mmol) 
and acid 10 (2.15 g, 8.29 mmol) in DMF (50 ml) were added N,N’-dicyclohexylcarbodiimide (1.71 g, 
8.29 mmol) and 4-hydroxy-1H-benzotriazole (1.12 g, 8.29 mmol) at 5°C. The reaction mixture was 
allowed to warm slowly to room temperature by stirring for 19 h. The solution was washed with 
saturated Na2CO3, extracted with DCM (three times) and the combined organic layers were washed 
with water and brine. After drying and evaporation the crude product was purified on silica gel 
(petroleum ether/ethyl acetate 1:2) to give product 11a (2.87 g, 67 %). 
1
H NMR (500 MHz, CDCl3) δ -
0.21 (s, 3H), 0.02 (s, 3H), 0.87 (s, 9H), 0.94 (d, J = 11.0, 3H), 1.02 (d, J = 3.8, 3H), 1.40 (s, 3H), 1.44 
(s, 3H), 1.57-1.71 (m, 3H), 1.77-1.81 (m, 1H), 2.41 (t, J = 6.3, 2H), 3.20-3.26 (m, 3H), 3.45-3.52 (m, 
1H), 3.54-3.61 (m, 1H), 3.66 (dd, J = 11.7, J = 1.9, 1H), 4.05 (s, 1H), 5.28 (dd, J = 7.3, J = 3.2, 1H), 
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5.81 (s, 1H), 7.02 (s, 1H), 7.37-7.40 (m, 1H), 7.60-7.63 (m, 1H), 7.81 (d, J = 7.9, 1H), 7.88 (dd, J = 
8.2, J = 1.3, 1H). 
13
C NMR (125 MHz, CD3OD) δ -4.9, -4.7, 18.2, 18.8, 22.3, 25.1, 25.8, 25.9, 30.0, 
34.1, 35.0, 35.0, 36.3, 36.6, 37.7, 37.4, 39.3, 39.4, 69.4, 71.6, 99.2, 124.2, 128.0, 128.8, 133.3, 141.3, 
170.3, 171.0. MS (ESI) m/z: 566 (M+H)
+
. 
 
(4R)-N-(3-((4-(2-Aminophenyl)-4-((tert-butyldimethylsilyl)oxy)-butyl)amino)-3-oxopropyl)-
2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamide (11b). Nitro compound 11a (1.00 g, 1.77 mmol) 
was dissolved in ethyl acetate (40 ml) and palladium on activated charcoal (200 mg, 10 wt. %) was 
added. The reaction mixture was stirred at room temperature under hydrogen (1 atm) for 20 h. Silica 
gel was added and the suspension was evaporated to dryness. Amine 11b (0.83 g, 87 %) was isolated 
by flash chromatography (petroleum ether/ethyl acetate 1:4). 
1
H NMR (500 MHz, CD3OD) δ -0.11 (s, 
3H), 0.08 (s, 3H), 0.89 (s, 9H), 0.94 (s, 3H), 0.98 (s, 3H), 1.41-1.42 (m, 6H), 1.56-1.65 (m, 1H), 1.69-
1.90 (m, 3H), 2.39 (t, J = 6.6, 2H), 3.10-3.25 (m, 2H), 3.25 (d, J = 11.7, 1H), 3.39-3.50 (m, 2H), 3.72 
(d, J = 11.7, 1H), 4.08 (s, 0.5H), 4.10 (s, 0.5H), 4.73 (dd, J = 7.9, J = 5.9, 1H), 6.60-6.64 (m, 1H), 6.68 
(dd, J = 8.2, J = 1.2, 1H), 6.97-7.01 (m, 2H). 
13
C NMR (125 MHz, CD3OD) δ -4.96, -4.94, 19.0, 19.1, 
19.4, 22.4, 26.4, 27.2, 29.7, 33.9, 34.7, 34.9, 36.2, 36.3, 40.1, 72.2, 76.7, 76.8, 78.3, 100.4, 117.9, 
118.7, 128.9, 129.4, 146.2, 172.1, 173.6. MS (ESI) m/z: 536 (M+H)
+
. 
 
(4R)-N-(3-((4-Hydroxy-4-(2-nitrophenyl)butyl)amino)-3-oxopropyl)-2,2,5,5-tetra-methyl-1,3-
dioxane-4-carboxamide (12a). A solution of 11a (0.82 g, 1.45 mmol) in THF (14.5 ml) and 1M 
TBAF in THF (14.5 ml, 14.5 mmol) was stirred for 4 h at 50°C. The solution was washed with water 
and the aqueous phase was extracted with ethyl acetate (two times). The organic phase was washed 
with brine, dried and concentrated to dryness. The residue was purified on silica gel to yield 12a (0.45 
g, 69 %). 
1
H NMR (500 MHz, CD3OD) δ 0.95 (d, J = 4.6, 3H), 0.98 (s, 3H), 1.42 (s, 3H), 1.43 (s, 3H), 
1.58-1.87 (m, 4H), 2.41 (t, J = 6.7, 2H), 3.19-3.26 (m, 3H), 3.40-3.52 (m, 2H), 3.73 (d, J = 11.6, 1H), 
4.10 (s, 1H), 5.16 (dd, J = 8.2, J = 3.0, 1H), 7.44-7.47 (m, 1H), 7.68 (td, J = 7.8, J = 0.9, 1H), 7.84 (d, 
J = 7.9, 1H), 7.87 (d, J = 8.0, 1H). 
13
C NMR (125 MHz, CD3OD) δ 13.9, 13.9, 19.0, 19.4, 22.4, 27.2, 
29.7, 34.0, 36.2, 36,3, 37.2, 40.2, 69.4, 72.3, 78.4, 100.4, 125.0, 129.0, 129.1, 134.3, 142.1, 149.3, 
172.1, 173.6. MS (ESI) m/z: 452 (M+H)
+
. 
 
(4R)-N-(3-((4-(2-Aminophenyl)-4-hydroxybutyl)amino)-3-oxopropyl)-2,2,5,5-tetramethyl-1,3-
dioxane-4-carboxamide (12b). To a solution of 11b (1.67 g, 3.12 mmol) in THF (31.2 ml) was added 
1M TBAF in THF (31.2 ml, 31.20 mmol) and the mixture was stirred for 80 min at room temperature. 
The solvent was evaporated under reduced pressure, the residue was redissolved in ethyl acetate and 
washed with water. The aqueous phase was extracted with ethyl acetate (three times) and the organic 
phase was washed with brine, dried and concentrated in vacuo. The crude product (2.19 g) was used 
for synthesis of compound 2 and 4 without further purification. LC/MS (ESI) 54 % purity (UV), m/z: 
404 (M-OH)
+
, 422 (M+H)
+
, 242 (n-Bu4N)
+
. 
 
N-(4-((tert-Butyldimethylsilyl)oxy)-4-(2-nitrophenyl)acetamide (13). A mixture of 9 (1.93 g, 5.95 
mol), pyridine (14 ml) and acetic anhydride (14 ml) was stirred for 17 h at room temperature. Pyridine 
was removed in vacuo, ethyl acetate was added and washed with 1M HCl. The aqueous phase was 
extracted with ethyl acetate (three times) and the organic phase was washed with brine and dried. 
After evaporation under reduced pressure, the residue was purified on silica gel (petroleum ether/ethyl 
acetate 2:1) to yield 13 (1.31 g, 60 %) as a yellowish oil. 
1
H NMR (500 MHz, CD3OD) δ -0.19 (s, 3H), 
0.05 (s, 3H), 0.88 (s, 9H), 1.53-1.62 (m, 1H), 1.65-1.73 (m, 2H), 1.75-1.83 (m, 1H), 1.91 (s, 3H), 3.17 
(td, 2H), 5.25 (dd, 1H), 7.47 (m, 1H), 7.68 (td, 1H), 7.82 (dd, 1H), 7.86 (dd, 1H). 
13
C NMR (125 MHz, 
CD3OD) δ -5.0, -4.8, 19.0, 22.5, 26.3, 27.0, 38.5, 40.3, 70.9, 124.9, 129.3, 129.8, 134.1, 141.5, 149.0, 
173.2. MS (ESI) m/z: 367 (M+H)
+
, 408 (M+H+CH3CN)
+
.  
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N-(4-Hydroxy-4-(2-nitrophenyl)butyl)acetamide (14). A solution of 1M TBAF in THF (13.6 ml, 
13.6 mmol) was added to 13 (0.50 g, 1.36 mmol) and the solution was stirred for 2 h at room 
temperature. Ethyl acetate was added and the solution was washed with water. After extraction of the 
aqueous phase with ethyl acetate (three times) the combined organic phases were washed with brine, 
dried and concentrated in vacuo. The residue was purified by flash chromatography to give 14 (207 
mg, 60 %) as a brown oil. 
1
H NMR (500 MHz, CD3OD) δ 1.61-1.71 (m, 2H), 1.72-1.84 (m, 2H), 1.92 
(s, 3H), 3.16-3.25 (m, 2H), 5.16 (dd, J = 7.9, J = 3.5, 1H), 7.44-7.47 (m, 1H), 7.68 (td, J = 7.3, J = 0.9, 
1H), 7.84 (dd, J = 7.9, J = 0.9), 1H), 7.87 (dd, J = 8.2, J = 1.2, 1H). 
13
C NMR (125 MHz, CD3OD) δ 
22.5, 27.1, 37.2, 40.2, 69.4, 125.0, 129.0, 129.1, 134.2, 142.0, 149.3, 173.3. MS (ESI) m/z: 253 
(M+H)
+
. 
 
N-(4-(2-Nitrophenyl)-4-oxobutyl)acetamide (15). To a solution of 14 (120 mg, 0.48 mmol) in 
DCM (4 ml) was added Dess-Martin periodinane (81 mg, 0.19 mmol) and the mixture was stirred for 
4 h at room temperature. The solid was filtered off and the filtrate was washed with water. The 
aqueous phase was extracted with DCM (three times) and the organic phase was washed with brine, 
dried and concentrated under reduced pressure. The residue was purified by flash chromatography (5 
% MeOH/DCM) and preparative HPLC to afford 15 (85 mg, 71 %) as a brown powder. 
1
H NMR (500 
MHz, CD3OD) δ 1.92 (quintet, J = 7.3, 2H), 1.94 (s, 3H), 2.90 (t, J = 7.3, 2H), 3.26 (t, J = 7.3, 2H), 
7.58 (d, J = 7.6, 1H), 7.69 (t, J = 7.9, 1H), 7.80 (t, J = 7.6, 1H), 8.12 (d, J = 7.9, 1H). 
13
C NMR (125 
MHz, CD3OD) δ 22.6, 24.7, 39.6, 40.8, 125.4, 128.8, 132.0, 135.4, 138.7, 173.4, 203.7. MS (ESI) m/z: 
251 (M+H)
+
, 292 (M+H+CH3CN)
+
. 
 
N-(2-(Hydroxy(2-nitrophenyl)methyl)phenyl)acetamide (16). Following the general method 
described in c) using 2-iodonitrobenzene 5 (1.00 g, 4.01 mmol) and N-(2-formylphenyl)acetamide 16a 
(180 mg, 2.01 mmol), the crude product was purified by flash chromatography (petroleum ether/ethyl 
acetate 3:2) to give 16 (210 mg, 18 %) as a yellow-brown powder. 
1
H NMR (500 MHz, CD3OD) δ 
2.03 (s, 3H), 6.53 (s, 1H), 7.18-7.25 (m, 2H), 7.31 (td, J = 7.3, J = 1.6, 1H), 7.43 (dd, J = 7.9, J = 0.9, 
1H), 7.44 (m, 1H), 7.60-7.65 (m, 2H), 7.88 (dd, J = 8.2, J = 0.9, 1H). 
13
C NMR (125 MHz, CD3OD) δ 
23.2, 69.0, 125.4, 127.2, 128.9, 129.4, 129.6, 130.2, 133.9, 136.7, 137.7, 138.6, 150.2, 172.3. MS 
(ESI) m/z: 310 (M+Na)
+
. 
 
N-(3-(Hydroxy(2-nitrophenyl)methyl)phenyl)acetamide (17). Following the general method 
described in c) using 2-iodonitrobenzene 5 (1.00 g, 4.01 mmol) and N-(3-formylphenyl)acetamide 17a 
(180 mg, 2.01 mmol), the crude product was purified by flash chromatography (petroleum ether/ ethyl 
acetate 2:3) and recrystallized from water to give 17 (287 mg, 25 %) as a yellow-brown solid. 
1
H 
NMR (500 MHz, CD3OD) δ 2.08 (s, 3H), 6.37 (s, 1H), 7.02-7.04 (m, 1H), 7.24 (t, J = 7.9, 1H), 7.46-
7.47 (m, 1H), 7.48-7.51 (m, 2H), 7.67-7.70 (m, 1H), 7.85-7.87 (m, 1H), 7.87 (dd, J = 7.9, J = 1.3, 1H). 
13
C NMR (125 MHz, CD3OD) δ 23.8, 73.5, 120.1, 120.4, 124.1, 125.2, 129.3, 129.7, 130.0, 134.1, 
140.0, 140.0, 144.8, 149.8, 171.7. MS (ESI) m/z: 269 (M-OH)
+
. 
 
N-(4-(Hydroxy(2-nitrophenyl)methyl)phenyl)acetamide (18). Following the general method 
described in c) using 2-iodonitrobenzene 5 (1.00 g, 4.01 mmol) and N-(4-formylphenyl)acetamide 18a 
(180 mg, 2.01 mmol), the crude product was purified by flash chromatography (petroleum ether/ethyl 
acetate 1:1) to give 18 (416 mg, 66 %) as a yellow-brown solid. 
1
H NMR (500 MHz, CD3OD) δ 2.10 
(s, 3H), 6.35 (s, 1H), 7.20-7.23 (m, 2H), 7.46-7.50 (m, 3H), 7.69 (t, J = 7.6, 1H), 7.88 (t, J = 8.5, 2H). 
13
C NMR (125 MHz, CD3OD) δ 23.8, 71.3, 121.0, 125.2, 128.8, 129.3, 129.7, 134.1, 139.2, 139.7, 
140.2, 149.8, 171.7. MS (ESI) m/z: 227 (M-OH-Ac)
+
, 269 (M-OH)
+
. 
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(2-Nitrophenyl)(phenyl)-methanol (19). Following the general method described in c) using 2-
iodonitrobenzene 5 (1.00 g, 4.01 mmol) and benzaldehyde 19a (0.41 ml, 4.02 mmol), the crude 
product was purified by flash chromatography (petroleum ether/ethyl acetate 6:1) to give 19 (681 mg, 
70 %) as a brown solid (mp. 55°C). 
1
H NMR (500 MHz, CDCl3): δ 6.44 (s, 1H), 7.27-7.32 (m, 1H), 
7.33-7.34 (m, 4H), 7.44-7.47 (m, 1H), 7.62-7.65 (m, 1H), 7.73-7.75 (m, 1H), 7.93 (dd, J = 8.2, J = 1.3, 
1H). 
13
C NMR (125 MHz, CDCl3): δ 71.7, 124.9, 127.1, 128.2, 128.7, 128.7, 129.6, 133.6, 138.6, 
141.7. MS (ESI) m/z: 221.1 (M-OH)
+
. 
 
(2-Nitrophenyl)(phenyl)methanone (20). Alcohol 19 (107 mg, 0.47 mmol) was dissolved in DCM 
(3 ml), Dess-Martin periodinane (317 mg, 0.75 mmol) was added and the mixture was stirred for 5 h at 
room temperature and filtered. The filtrate was washed with water and the aqueous layer was extracted 
with DCM (three times). The combined organic layers were washed with brine, dried and purified by 
flash chromatography (petroleum ether/ethyl acetate 10:1) to yield ketone 20 (38 mg, 36 %) as a 
brownish solid. 
1
H NMR (500 MHz, CDCl3) δ 7.43-7.47 (m, 2H), 7.49 (dd, J = 7.6, J = 1.6, 1H), 7.57-
7.61 (m, 1H), 7.66-7.70 (m, 1H), 7.74-7.76 (m, 2H), 7.78 (td, J = 7.3, J = 1.3, 1H), 8.24 (dd, J = 8.2, J 
= 1.3, 1H). 
13
C NMR (125 MHz, CDCl3) δ 124.6, 128.9, 129.1, 129.4, 130.6, 133.9, 134.3, 136.1, 
136.4, 146.9, 193.6. 
 
1-(Methoxy(phenyl)methyl)-2-nitrobenzene (23). A 60 % dispersion of sodium hydride (21 mg, 
0.87 mmol) in mineral oil was washed with petroleum ether and DMF (2 ml) was added. The mixture 
was cooled to 0°C and alcohol 19 (200 mg, 0.87 mmol) dissolved in DMF (2 ml) was added. After 10 
min iodomethane (0.05 ml) was added and the mixture was stirred for 1 h at 0°C and quenched with 
water. After extraction with diethyl ether (four times), the combined organic layers were washed with 
brine, dried, filtered and concentrated in vacuo. The residue was purified by flash chromatography to 
give 23 (88 mg, 42 %) as a brown oil. 
1
H NMR (500 MHz, CD3OD) δ 3.32 (s, 3H), 5.90 (s, 1H), 7.26-
7.35 (m, 5H), 7.47-7.50 (m, 1H), 7.60-7.66 (m, 1H), 7.86 (dd, J = 8.2, J = 1.3, 1H). 
13
C NMR (125 
MHz, CDCl3) δ 57.6, 81.4, 125.2, 128.8, 129.1, 129.5, 129.7, 133.9, 137.6, 141.1. 
 
1-(2-Nitrophenyl)-1-phenylethanol (24). Mixture 1: CeCl3 (989 mg, 4.02 mmol) was added to 
THF (4 ml) at 0°C and stirred for 1 h at room temperature. Acetophenone (0.47 ml, 4.02 mmol) was 
added at 0°C and the mixture was stirred at room temperature for 1 h. Mixture 2: 2-Iodo-nitrobenzene 
5 (1.00 g, 4.02 mmol) was dissolved in THF (10 ml), a solution of phenylmagnsium chloride (2.21 ml, 
2 M in THF, 4.02 mmol) was added dropwise at -40°C and the mixture was stirred for 90 min. 
Mixture 1 was added slowly to mixture 2 and stirred for 4 h at -40°C. The reaction was quenched with 
saturated NH4Cl solution and the aqueous layer was extracted with ethyl acetate (three times). The 
combined organic layers were dried, filtered and concentrated in vacuo. The residue was purified by 
flash chromatography (petroleum ether/ethyl acetate 15:1) to yield 24 (269 mg, 27 %) as a brown 
solid. 
1
H NMR (500 MHz, CD3OD) δ 1.97 (s, 3H), 7.21-7.23 (m, 1H), 7.25-7.29 (m, 1H), 7.32-7.35 
(m, 1H), 7.40-7.44 (m, 2H), 7.52-7.55 (m, 1H), 7.65-7.67 (m, 1H). 
13
C NMR (125 MHz, CD3OD) δ 
31.2, 76.6, 125.0, 127.0, 128.0, 128.9, 129.2, 130.1, 131.7, 141.8, 148.2.  
 
2,2,2-Trifluoro-1-(2-nitrophenyl)-1-phenylethanol (25). Following the general method described 
in c) using 2-iodonitrobenzene 5 (1.00 g, 4.01 mmol) and 2,2,2-trifluoro-acetophenone 25a (180 mg, 
2.01 mmol), the crude product was purified by flash chromatography (petroleum ether/ethyl acetate 
9:1) to give 25 (596 mg, 50 %) as a brownish solid. 
1
H NMR (500 MHz, CD3OD) δ 7.32-7.35 (m, 
3H), 7.39-7.42 (m, 2H), 7.50 (dd, J = 7.9, J = 1.6, 1H), 7.55 (td, J = 7.9, J = 1.6, 1H), 7.60 (td, J = 7.6, 
J = 1.6, 1H), 7.70-7.73 (m, 1H). 
13
C NMR (125 MHz, CD3OD) δ 80.4 (q, JCF = 28.4), 125.3, 126.5 (q, 
JCF = 287.2), 127.6, 128.2, 128.3, 129.0, 129.5, 130.0 (q, JCF = 3.7), 130.9, 131.2, 132.5, 139.9, 152.1. 
MS (EI) m/z: 228 (M-CF3
•
)
+
, 251 (M-NO2
•
)
+
. 
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6.1.2 Purity (LC/MS Determination) 
 
The purity of all compounds tested in the biological assays was determined using LC/MS as follows 
and are indicated in Table 1: 
 
Table 1. Purity 
Cmpd Rt (min) 
HPLC purity  
(≥ %) 
MS (ESI) m/z mp (°C) 
1 7.23 97 410.1 (M+H)
+ 
66-72 
2 6.97 97 380.2 (M+H)
+ 
- 
3 7.39 98 412.2 (M+H)
+
 88-95 
4 4.81 98 382.2 (M+H)
+
 - 
14 7.42 98 253.2 (M+H)
+
 - 
15 7.20 99 251.2 (M+H)
+
 81-85 
16 7.93 99 309.7 (M+Na)
+
 162-164 
17 8.14 96 268.8 (M-OH)
+
 166-167 
18 7.96 95 268.9 (M-OH)
+
 92-96 
19 10.52 99 212.1 (M-OH)
+
 54-55 
20 10.66 97 - 92-93 
21 11.22 99 * 228.3 (M-CF3
•
)
+
 97-98 
22 10.89 98 - 92-94 
23 13.32 99 - - 
24 13.21 93 - - 
25 10.85 99 - 146 
  * MS (EI) m/z 
 
A SpectraSystems
®
 LC system consisting of a pump, an autosampler, and a PDA detector was 
employed. Mass spectrometry was performed on an MSQ
®
 electro spray mass spectrometer 
(ThermoFisher, Dreieich, Germany) unless indicated otherwise. m/z values determined by DSQII 
electron ionization analyzer (ThermoFisher, Dreieich, Germany) are marked by an asterisk (*). The 
system was operated by the standard software Xcalibur
®
. An RP-C18 NUCLEODUR
®
 100-5 (125x3 
mm) column (Macherey-Nagel GmbH, Düren, Germany) was used as stationary phase. All solvents 
were HPLC grade. 
In a gradient run the percentage of acetonitrile (containing 0.1 % trifluoroacetic acid) in 0.1 % 
trifluoroacetic acid was increased from an initial concentration of 0 % at 0 min to 100 % at 15 min and 
kept at 100 % for 5 min. The injection volume was 15 µL and flow rate was set to 800 µL/min. MS 
analysis was carried out at a spray voltage of 3800 V, a capillary temperature of 350°C, and a source 
CID of 10 V. Spectra were acquired in positive mode from 100 to 1000 m/z at 254 nm for the UV 
trace.  
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6.1.3 ITC Characterization of (2-Nitrophenyl)(phenyl)methanol (19) 
 
 
 
Figure S1. ITC titration of 19 (3500 µM) against PqsD (328 µM). The recorded change in heat is 
shown in units of µcal/sec as a function of time for successive injections of the ligand (upper panel). 
Integrated heats (black squares) plotted against the molar ratio of the binding reaction. The continuous 
line represents the results of the non-linear least squares fitting of the data to a binding model (lower 
panel). Kd (19) = 13 µM is a mean value of three experiments and standard deviation is less than 25 %. 
 
 
 
6.1.4 Biological Methods 
 
Expression and purification of recombinant PqsD in E. coli. His6-tagged PqsD (H6-PqsD) was 
expressed in E. coli and purified using a single affinity chromatography step. Briefly, E. coli BL21 
(λDE3) cells containing the pET28b(+)/pqsD (kindly provided by Prof. Rolf Müller) were grown in 
LB medium containing 50 µg ml
-1
 kanamycin at 37°C to an OD600 of approximately 0.8 units and 
induced with 0.2 mM IPTG for 16 h at 16°C. The cells were harvested by centrifugation (5000 rpm, 
10 min, 4°C) and the cell pellet was resuspended in 100 ml binding buffer (25 mM Tris pH 7.8, 150 
mM NaCl, 20 mM imidazole, 1 mM β-mercaptoethanol) and lysed by sonication for a total process 
time of 2.5 min. Cell debris were removed by centrifugation (18500 rpm, 40 min, 4°C) and the 
supernatant was filtered through a syringe filter (0.20 μm). The clarified lysate was immediately 
applied to a Ni-NTA column, washed with binding buffer and eluted with 500 mM imidazole. The 
protein containing fractions were buffer-exchanged into 50 mM Tris pH 8.0, 150 mM NaCl, 10 % 
glycerol (v/v), 1 mM β-mercaptoethanol using a PD10 column and judged pure by SDS-PAGE 
analysis. Subsequently, the His6-tag was removed by thrombin cleavage using 1 unit thrombin per mg 
protein in presence of 2.5 mM CaCl2 for 16 h at 16°C. The protein was separated from any uncleaved 
or His6-tag containing protein by running the mixture through a second Ni-NTA column under the 
same conditions. The cleaved protein was buffer-exchanged into 50 mM Tris pH 8.0, 150 mM NaCl, 
10 % glycerol (v/v), 1 mM β-mercaptoethanol using a PD10 column and stored in aliquots at -80°C.  
 
Synthesis of anthraniloyl-S-CoA thioester.
S4
 Anthraniloyl-CoA (ACoA) was synthesized from 
isatoic anhydride and coenzyme A (CoA) using a previously described method. ACoA was purified by 
HPLC (Agilent 1200 series consisting of a quaternary pump, a fraction collector and an MWD; 
Agilent Technologies, USA) after freeze drying of the aqueous reaction mixture (25 ml) and 
resuspending of the dried residue in 3 ml of a mixture of 50 % methanol and water. A 10 µm RP C18 
150-30 column (30 x 100 mm, Agilent) was used along with a mobile phase consisting of water 
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containing 1‰ TFA (A) and acetonitrile containing 1‰ TFA (B) with a flow rate of 5 ml/min. The 
following gradient was used: 0-35 min, linear gradient 10 % - 100 % B; 35-42 min, 100 % B; 42-43 
min, 10 % B (initial conditions). ACoA containing fractions were pooled and freeze dried. 
 
Synthesis of β-ketodecanoic acid.S5 Ethyl 3-oxodecanoate (300 mg, 1.4 mmol, 1.0 eq) was stirred 
with NaOH (56 mg, 1.4 mmol, 1.0 eq) in water (2 ml) overnight. Any remaining ester was removed by 
washing with Et2O (10 ml). The aqueous layer was cooled and acidified with 32 % HC1 to pH = 6. 
After filtration the 3-oxodecanoic acid was dried in vacuo and obtained as white solid (100 mg, 0.54 
mmol, 38 %). 
1
H-NMR (500 MHz, CDCl3) δ 0.86 (t, J = 7.0 Hz, 3H), 1.25-1.29 (m, 8H), 1.58 (quintet, 
J = 7.0 Hz, 2H), 2.54 (t, J = 7.5 Hz, 2H), 3.49 (s, 2H). LC/MS (ESI) no ionization, 99 % (UV). 
 
Synthesis of ethyl 3-oxodecanoate.
S6
 To a THF solution of 2M LDA (20 ml, 40 mmol 2.4 eq) was 
added ethyl acetoacetate (2.16 g, 16.6 mmol, 1.0 eq) at 0°C. The deep yellow clear solution was stirred 
at 0°C for 1 h. To this solution the 1-iodohexane was added (4.20 g, 19.81 mmol, 1.2 eq) at -78°C. The 
temperature was allowed to reach an ambient temperature over 14 h and the solution was stirred at 
room temperature for 2 h. To the solution was added 10 % HCl (200 ml) and the mixture was 
extracted with Et2O (4 × 250 ml). The combined organic layers were dried over Na2SO4, filtered, and 
the filtrate was concentrated in vacuo. The residue was purified by column chromatography (n-
hexane/ethyl acetate, 30/1) to give ethyl 3-oxodecanoate as a yellow oil (1.98 g, 9.24 mmol, 55 %). 
1
H-NMR (500 MHz, CDCl3) δ 0.84 (t, J = 7.0 Hz, 3H), 1.23-1.28 (m, 11H), 1.54 (quintet, J = 7.0 Hz, 
2H), 2.49 (t, J = 7.0 Hz, 2H), 3.39 (s, 2H), 4.16 (m, 2H).  
 
Screening assay procedure for in vitro PqsD inhibition. The assay was performed monitoring 
enzyme activity by measuring HHQ formed by condensation of anthraniloyl-CoA and β-ketodecanoic 
acid. The reaction mixture contained MOPS buffer (0.05 M, pH 7.0) with 0.005 % (w/v) Triton X-100, 
0.1 µM of the purified enzyme and inhibitor. The test compounds were dissolved in DMSO and 
diluted with buffer. The final DMSO concentration was 0.5 %. Control reactions without inhibitor 
containing identical amounts of DMSO were performed in parallel. After 10 min preincubation at 
37°C, the reaction was started by the addition of 5 µM anthraniloyl-CoA and 70 µM β-ketodecanoic 
acid. Reactions were stopped by addition of methanol containing 1 µM amitriptyline as internal 
standard for LC/MS-MS analysis. All reactions were performed in triplicates. 
HHQ was quantified using a HPLC-MS/MS mass spectrometer (ThermoFisher, Dreieich, Germany) 
in ESI mode. Ionization of HHQ and the internal standard amitriptyline was optimized in each case. 
The solvent system consisted of 10 mM ammonium acetate (A) and acetonitrile (B), both containing 
0.1 % trifluoroacetic acid. The initial concentration of B in A was 45 %, increasing the percentage of 
B to 100 % in 2.8 min and keeping it at 98 % for 0.7 min with a flow of 500 µl/min. The column used 
was a NUCLEODUR-C18, 100-3/125-3 (Macherey&Nagel, Duehren, Germany).  
Absolute concentration values for HHQ were calculated by comparison of peak area ratios (HHQ 
versus internal standard) to a calibration curve in which the peak area ratios of the calibrators had been 
plotted against their nominal concentration. Without inhibitor approximately 12 % of ACoA were 
converted into HHQ and these HHQ concentrations were set to 100 %. Percentage of inhibition is a 
mean value of at least two independent experiments and standard deviations were less than 25 %. IC50 
values were calculated from at least three experiments with standard deviations less than 25 %. 
 
Cultivation and Determination of Extracellular PQS, HHQ and DHQ Levels. Extra-cellular 
levels of PQS, HHQ and DHQ produced by P. aeruginosa PA14 were determined using the method of 
Lépine et al.
S7
 with some modifications: Cultures were inoculated with a starting OD600 = 0.02 in 24 
well plates (Greiner, Cellstar) containing 1.5 ml LB medium per well. DMSO as a control or DMSO 
solutions of inhibitors were added to the cultures to a final DMSO concentration of 1 %. Plates were 
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incubated at 37°C, 200 rpm and a humidity of 75 % for 14 h. For PQS, HHQ and DHQ analysis, 1 ml 
of methanol containing 750 nM of the internal standard was mixed with 500 µl of each culture by 
vigorously pipetting. After centrifugation (4500 rpm, 20 min), 200 µL of the supernatant were 
transferred to glass vials for UHPLC-MS/MS analysis. For each sample, cultivation and extraction 
were performed in triplicates. 
 
UHPLC-MS/MS analysis of extracellular PQS, HHQ and DHQ levels. The analyses were 
performed using a TSQ Quantum Access Max mass spectrometer equipped with an HESI-II source 
and a triple quadrupole mass detector (Thermo Scientific, Dreieich, Germany). For MS detection, the 
spray voltage, the nitrogen sheath gas pressure, the auxiliary gas pressure and the capillary 
temperature were optimized. Observed ions were (mother ion [m/z], product ion [m/z], scan time [s], 
scan width [m/z], collision energy [V], tube lens offset [V]): PQS: 260.098, 175.028, 0.1, 0.010, 28, 
107; HHQ: 244.130, 159.050, 0.5, 0.010, 33, 88; DHQ: 162.130, 89.138, 0.3, 0.010, 33, 52; internal 
standard (amitriptyline): 278.100, 233.100, 0.1, 0.010, 15, 58. Xcalibur software was used for data 
acquisition and quantification with the use of a calibration curve relative to the area of the internal 
standard. All samples were injected by autosampler (Accela
®
, Thermo Scientific, Dreieich, Germany) 
with a volume of 10 l. An Accucore RP-MS® 2.6 µm (150  2.1 mm) column (Thermo Scientific, 
Dreieich, Germany) was used as stationary phase along with a mobile phase consisting of 10 mM 
ammonium acetate buffer containing 1 ‰ TFA (v/v; A) and acetonitrile containing 1 ‰ TFA (v/v; B) 
and a flow rate of 0.8 ml/min (PQS, HHQ) or 0.7 ml/min (DHQ). 
For PQS and HHQ analysis, the following chromatographic conditions were used: 0.00-1.70 min, 
isocratic 40 % A, 1.71-3.00 min, 95 % A, 3.01-4.50, initial conditions 40 % A. The column oven 
temperature was 45°C. The chromatographic conditions used for DHQ determination were: 0.00-2.00 
min, linear gradient 20 % - 98 % A, 2.00-3.30 min, 98 % A, 3.32-4.50 min, initial conditions 20 % A. 
 
Biofilm growth assay. Static biofilms at the bottom of 96 well microtiter plates were grown with 
small modifications as previously described.
S8
 In brief, overnight P. aeruginosa LB cultures of PA14 
were adjusted to an OD600 of 0.002 with fresh medium and transferred into a half-area 96 well μClear 
plate (Greiner Bio-One, 100 μl/well). The plate was covered with an air-permeable foil and incubated 
at 37°C in a chamber with humid atmosphere. After 24 h, a staining solution including Syto9 and 
propidium iodide (LIVE/DEAD BacLight Bacterial Viability kit, Molecular Probes/Invitrogen) and 
the test compound solved in DMSO was added to the biofilms (final concentration 500 µM, 1 % 
DMSO (v/v)) and biofilms were further incubated for 24 h at 37°C. After in total 48 h, biofilm stacks 
were acquired in the center of each well (step size: 2 μm) using a confocal microscope (Fluoview 
1000, Olympus) equipped with an x60/1.20 water objective. The acquired image stacks were 
processed and analyzed as previously described
S9
 to determine the parameter total biovolume 
estimating the µm
3
 covered by biofilm.
S10
 3D-projections of the biofilms are visualized with the 
software IMARIS (version 5.7.2, Bitplane). 
 
Determination of the Growth Curves of P. aeruginosa PA14. Cultures of P. aeruginosa PA14 
were inoculated with an overnight culture to obtain a starting OD600 = 0.05 and grown in three 
replicates in 100 ml Erlenmeyer flasks containing 10 ml LB medium at 37°C, 200 rpm and a humidity 
of 75 %. DMSO solutions of compound 19 were added to the cultures to a final concentration of 500 
µM inhibitor and 1 % DMSO. Bacterial growth was measured as a function of OD600 using FLUOstar 
Omega (BMG LABTECH, Ortenberg, Germany). P. aeruginosa PA14 cultures containing 1 % DMSO 
were used as a control.  
In vitro cytotoxicity test. THP-1 cells (DSMZ, Braunschweig) were routinely cultured in RPMI 
1640 (Pan Biotech, Aidenbach) supplemented with 10 % FCS (CCPro, Oberdola) and 1 % Pen/Strep 
(Pan Biotech). Prior to seeding, viability of cells was determined by trypan blue staining. Cells in 
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exponential growth phase were plated in 96-well flat bottom plates at 2.5x10E4 cells / mL, 100 µL / 
well. Cells were differentiated into macrophages for 24 h with 100 nM Phorbol-12-myristate-13-
acetate (Sigma Aldrich). Dilutions of 19 were added at 100 µL / well. Plates were incubated for 48 hrs 
at 37
0
C and 5% CO2 in a humidified atmosphere. For proliferation measurement, resazurin (Sigma 
Aldrich) was added at 45µM (final) and plates were incubated for an additional 3.5 hrs. Plates were 
measured in a Victor3 (Perkin Elmar) fluorescent plate reader at 544/590nM (Ex/Em). Relative 
proliferation was calculated as % of untreated control. 
 
 
 
6.1.5 Separation into the Enantiomers of 19 and their PqsD Inhibitory Activity 
 
The separation was performed using an Agilent 1200 HPLC system equipped with an MWD 
triggering an automated fraction collector (Agilent Technologies, Inc. Headquarters, Santa Clara, CA, 
USA) in “time based” mode. ChemStation® software was used for control and report. The sample was 
manually injected. A Nucleocel Delta S® 5µm (250 / 8 mm) column (Macherey-Nagel GmbH, 
Duehren, Germany) was used as stationary phase. The solvent system consisted of n-hexane (A) and 
iso-propanol (B). HPLC-Method: Flow rate 2 mL/min. Isocratic run of 2 % of B in A.  
Determination of enantiomeric excess was performed using a Nucleocel Alpha S® 5µm (250 / 4,6 
mm) column (Macherey-Nagel GmbH, Duehren, Germany) as stationary phase. HPLC-Method: Flow 
rate 0.5 mL/min. Isocratic run of 2 % of B in A, using the above mentioned solvents. The % ee of (R)-
19 was determined using the relative peak areas in the MWD trace. 
 
 
Table S1. Comparison of the PqsD Inhibition by rac-19 and the (R)-19. 
 
 
a
Absolute configuration was derived from measurement of the optical rotation and comparison to 
literature.
S11
 
  
Compd.
a direction 
of rotation 
% ee
 
% inhibition IC50 [µM] 
rac-19  0 99 3.2 
(R)-19 (+) 65.8 99 3.5 
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6.1.6 Biovolume and Representative Biofilm Slices of PA14 Biofilms 
 
Figure S2. Biovolume of PA14 biofilms. The total biovolume was decreased by compound 19. Bars 
represent mean values of n = 4, ±SD. * P < 0.003. 
 
 
 
 
Figure S3. Representative slices of the (a) green and (b) red stained biofilm proportion as well as 
the (c) overlay of the DMSO control at the approx. height of 20 µm. 48 h old biofilms were stained 
with Syto9 (green) and propidium iodide (red) representing live and dead bacteria, respectively. 
 
 
 
 
Figure S4. Representative slices of the (a) green and (b) red stained biofilm proportion as well as 
the (c) overlay of the 19 treated biofilm at the approx. height of 20 µm. 48 h old biofilms were stained 
with Syto9 (green) and propidium iodide (red) representing live and dead bacteria, respectively. 
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6.1.7 Growth Curves of P. aeruginosa PA14 
 
Figure S5. Growth Curves of P. aeruginosa PA14. Strains were grown in the absence () / 
presence of 500 μM of compound 9 () in LB. Samples were taken at 0h, 4h, 5 h, 6.5h, 8 h and 9.5 h 
to measure OD600. Mean value of one experiment with n = 3, standard deviation less than 7 %. 
 
 
 
6.1.8 Results of the in vitro Cytotoxicity against Human THP-1 Macrophages  
 
Figure S6. Proliferation of human THP-1 macrophages in presence of compound 19 compared to 
untreated control. Points represent mean values of n = 6, ±SD. IC50 > 500 µM; 45 % inhibition at 
500 µM.  
 
 
 
6.1.9 Structures of PqsD Inhibitors A and B, Derived from Known FabH Inhibitors.
S12 
 
  
c) 
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6.2.1 Primer Sequence of Mutations 
 
Mutant 
Primer 
forward 5’  3’ reverse 3’ 5’  
S317F 
GCTGGTCCTGACCTACGGTTTTGGC
GCGACCTGGGGCG 
CGCCCCAGGTCGCGCCAAAACCGTA
GGTCAGGACCAGC 
C112A 
GCTGGATATCCGGGCACAGGCGAG
CGGGTTGCTGTACG 
CGTACAGCAACCCGCTCGCCTGTGC
CCGGATATCCAGC 
H257F 
CGACCATGTGATCTGCTTTCAACC
GAACCTGC 
GCAGGTTCGGTTGAAAGCAGATCAC
ATGGTCG 
C112S 
GCTGGATATCCGGGCACAGAGCAG
CGGGTTGCTGTACG’ 
CGTACAGCAACCCGCTGCTCTGTGC
CCGGATATCCAGC 
S317A 
GCTGGTCCTGACCTACGGTGCGGG
CGCGACCTGGGGCG 
CGCCCCAGGTCGCGCCCGCACCGTA
GGTCAGGACCAGC 
N287A CGTCTGGGCGCGATGGCTTCGGCC GGCCGAAGCCATCGCGCCCAGACG 
 
 
 
6.2.2 Table S1: Catalytic Activity of PqsD Wild-type and Mutants
a 
 
 wild-type S317F C112A H257F
 
C112S
 
S317A
 
N287A 
Formed HHQ [nM] 2154 15 1 18 171 2182 7 
a
Reactions were performed according to the screening assay procedure described in the Methods 
Section using 1.0 µM of P. aeruginosa PqsD. 
 
 
 
6.2.3 Synthesis of Substrates Used in the Enzymatic Inhibition Assays 
 
Synthesis of anthraniloyl-S-CoA thioester.
S1
 Anthraniloyl-CoA (ACoA) was synthesized from 
isatoic anhydride and coenzyme A (CoA) using a previously described method. ACoA was purified by 
HPLC (Agilent 1200 series consisting of a quaternary pump, a fraction collector and an MWD; 
Agilent Technologies) after freeze drying of the aqueous reaction mixture (25 ml) and resuspending of 
the dried residue in 3 ml of a mixture of 50% methanol and water (v/v). A 10 µm RP C18 150-30 
column (30 x 100 mm, Agilent) was used along with a mobile phase consisting of water containing 
1‰ TFA (A) and acetonitrile containing 1‰ TFA (B) with a flow rate of 5 ml min–1. The following 
gradient was used: 0–35 min, linear gradient 10% – 100% B (v/v); 35–42 min, 100% B; 42–43 min, 
10% B (v/v) (initial conditions). ACoA containing fractions were pooled and freeze dried. 
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Synthesis of β-ketodecanoic acid.S2 Ethyl 3-oxodecanoate (300 mg, 1.4 mmol) was stirred with 
NaOH (56 mg, 1.4 mmol) in 2 ml of water overnight. Any remaining ester was removed by washing 
with Et2O (10 ml). The aqueous layer was cooled and acidified with 32% HCl (w/v) to pH = 6. After 
filtration the 3-oxodecanoic acid was dried in vacuo and obtained as white solid (100 mg, 38%). 
1
H-
NMR (500 MHz, CDCl3) δ 0.86 (t, J = 7.0, 3H), 1.25–1.29 (m, 8H), 1.58 (m, 2H), 2.54 (t, J = 7.5, 
2H), 3.49 (s, 2H). LC/MS (ESI) m/z 242.0, 99% (UV). 
 
Synthesis of ethyl 3-oxodecanoate.
S3
 To a THF solution of 2 M LDA (20 ml, 40 mmol) was added 
ethyl acetoacetate (2.16 g, 16.6 mmol) at 0°C. The deep yellow clear solution was stirred at 0°C for 1 
h. To this solution the 1-iodohexane was added (4.20 g, 19.81 mmol) at -78°C. The temperature was 
allowed to reach an ambient temperature over 14 h and the solution was stirred at room temperature 
for 2 h. To the solution was added 200 ml of 10% HCl (v/v) and the mixture was extracted with Et2O 
(4 × 250 ml). The combined organic layers were dried over Na2SO4, filtered, and the filtrate was 
concentrated in vacuo. The residue was purified by column chromatography (n-hexane/ethyl acetate, 
30/1) to give ethyl 3-oxodecanoate as a yellow oil (1.98 g, 55%). 
1
H-NMR (500 MHz, CDCl3) δ 0.84 
(t, J = 7.0, 3H), 1.23–1.28 (m, 11H), 1.54 (m, 2H), 2.49 (t, J = 7.0, 2H), 3.39 (s, 2H), 4.16 (m, 2H). 
LC/MS (ESI) m/z 458.0, 87% (UV). 
 
 
 
6.2.4 Table S2: Comparison of IC50 Values Determined by Different Assay Procedures 
 
 
Cmpd. IC50 [µM]
ab
 IC50,mod [µM]
ac 
IC50,ext [µM]
ad 
1 1.2 ± 0.1 1.1 ± 0.2 1.8 ± 0.4 
2 3.0 ± 0.7 4.2 ± 0.3 7.6 ± 1.5 
3 3.2 ± 0.1 24.6 ± 6.2 1.0 ± 0.4 
4 4.3 ± 1.0 19.7 ± 8.9 2.6 ± 0.5 
5 14.8 ± 2.9 >50 9.7 ± 1.4 
6 n.i. n.d. n.d. 
7 7.9 ± 0.7 n.d. n.d. 
a
n.i. no inhibition (<10% at 50 µM); n.d. not determined. 
b
PqsD and inhibitor were preincubated for 
10 min prior to addition of the substrates. 
c
Modified procedure including additional 30 min 
preincubation of enzyme and ACoA. 
d
Preincubation time of PqsD/inhibitors was extended to 30 min.   
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6.2.5 Percentages of Inhibition and Uncertainty of the Time Dependency Experiment 
 
Table S3. HHQ formation in presence of compounds 2 and 3 relative to untreated control. 
time control [%] 
Cmpd. 2,  
3 µM [%] 
uncertainty [%] 
3 min 100 60.37 2.95 
6 min 100 59.36 8.27 
9 min 100 60.21 8.09 
12 min 100 58.95 8.34 
15 min 100 61.99 8.16 
20 min 100 72.15 5.19 
25 min 100 63.28 7.17 
30 min 100 64.18 10.05 
 
time control [%] 
Cmpd. 3,  
6 µM [%] 
uncertainty [%] 
3 min 100 71.17 4.33 
6 min 100 46.38 2.91 
9 min 100 41.85 4.49 
12 min 100 36.40 4.36 
15 min 100 31.98 4.58 
20 min 100 25.39 2.41 
25 min 100 27.01 3.60 
30 min 100 26.07 4.82 
 
 
 
6.2.6 Figure S1: Dose-response Curve of PqsD Inhibition by Compound 3 
 
 
 
Figure S1. Inhibition of PqsD by compound 3 is plotted against the concentration (log scale). Data 
were generated using the screening assay procedure for in vitro PqsD inhibition as described above. 
Compounds 4 and 5 show similar curve shapes (data not shown). 
 
  
6  SUPPORTING INFORMATION  85 
 
6.2.7 Further HPLC-ESI MS Experiments 
 
 
 
Figure S2. (A-D) PqsD containing a His6-tag was incubated in absence (A) or in presence (B) of 
compound 3. Thereby, no anti-oxidative reagent was present. Samples were subjected to HPLC-ESI 
MS analysis, whereas no relevant amounts of oxidation products were observed. Subsequent addition 
of an excess of maleimid resulted in a shift of +582 (corresponding to a 6-fold addition of the labeling 
agent regardless of the presence of compound 3 (C: PqsD; D: PqsD pretreated with compound 3). 
Maleimid labels all available cystein residues present in PqsD, indicating that no cystein was oxidized 
previously. (E-H) C112S mutant containing a His6-tag was treated in absence (E) or in presence (F) of 
compound 3 using the same procedure as described above. Subsequent addition of an excess of 
maleimid resulted in a shift of +485 (corresponding to a 5-fold addition of the labeling agent 
regardless of the presence of compound 3 (G: PqsD; H: PqsD pretreated with compound 3). In all 
spectra, signals with a shift of +178 Da were observed. This is probably due to spontaneous α-N-6-
Phosphogluconoylation of the His6-tag in E. coli (S4). 
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6.2.8 Maldi-TOF Analysis 
 
Figure S3. Maldi-TOF spectra of native PqsD after tryptic digestion. Blue labeled fragments bear 
one missed cleavage (MC). Fragments generated by complete digestion (MC=0) were labeled in black. 
 
Figure S4. Sequence of the PqsD. 334 of 340 amino acids are visible in at least one peptide 
observed by Maldi-TOF, when native PqsD has been digested. Amino acids not observed in the 
experiment are Thr41, Gly42, Val43, Arg44, Gly156 and Arg157. (Numbering refers to the sequence 
of PqsD used in the experiment; in the X-ray structure denoted as Thr37, Gly38, Val39, Arg40, 
Gly152, Arg153 (A. K. Bera et al. Biochemistry 2009, 48, 8644).   
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Figure S5. Molecular surface of the PqsD binding channel and side chains of the uncaptured amino 
acids Thr41, Gly42, Val43, Arg44, Gly156 and Arg157. The alkyl residues of Gly42, Val43 and 
Gly156 are unable to form covalent bonds. Thr41, Arg44 and Arg157 are located at the tunnel 
entrance, too far away from the binding site of compound 3, which is located deep in the active site 
near the catalytically active Cys116 (in the construct used for X-ray analysis denoted as Cys112). 
 
 
 
Table S4. Comparison of peptide masses (calculated and observed by Maldi-TOF analysis) formed by 
tryptic digestion of untreated PqsD and PqsD treated with compound 3. 
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All fragments without missed cleavages (MC=0) with m/z >800 are listed. Fragments with MC=1 
contributing to coverage of the amino acid sequence were added.  
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Figure S6. Maldi-TOF spectra of PqsD/compound 3 after tryptic digestion. Blue labeled fragments 
bear one missed cleavage (MC). Fragments generated by complete digestion (MC=0) were labeled in 
black. Compared to untreated PqsD the only difference is the disappearance of the peptide m/z of 
1071.  
 
Figure S7. Amino acids observed after preincubation of PqsD with compound 3. Compared to 
untreated PqsD the red labeled peptide at the C-terminus disappeared, maybe because of an oxidation 
of the terminal Cys340.  
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6.2.9 Separation of 3 into the Enantiomers (R)-3 and (S)-3 by Chiral-HPLC 
 
The separation was performed using an Agilent 1200 HPLC system equipped with an MWD 
triggering an automated fraction collector (Agilent Technologies) in “time based” mode. 
ChemStation® software was used for control and report. The sample was manually injected. A 
Chiralpak IE® 5µm (250 / 10 mm) column (DAICEL Corporation) was used as stationary phase. The 
solvent system consisted of n-hexane (A) and iso-propanol (B). HPLC-Method: Flow rate 2.4 ml 
min
-1
. Isocratic run of 7% of B in A (v/v).  
 
Determination of enantiomeric excess was performed using a Chiralpak IE® 5µm (250 / 4.6 mm) 
column (DAICEL Corporation) as stationary phase. The solvent system consisted of n-heptane (A) 
and iso-propanol (B). HPLC-Method: Flow rate 1 ml min
–1
. Isocratic run of 7% of B in A (v/v). The 
% ee of (R)-9 and (S)-9 was determined using the relative peak areas in the MWD trace. 
 
 
 
 
 
 
Figure S8. HPLC analysis of enantiomeric purity. (A) Racemic mixture 9, (B) S-enantiomer (–) of 9 
(>99.9% ee) and (C) R-enantiomer (+) of 9 (87.2% ee). Absolute configurations were derived from 
measurement of the optical rotation and comparison to literature.
S6
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6.2.10 Figure S9: Binding Site analysis of (R)-3 and (S)-3 by SPR 
 
 
Figure S9. Binding site analysis of (R)-3 and (S)-3 by SPR. Addition of 250 and 125 µM (R)-3 
(blue) or (S)-3 (orange), respectively, to native PqsD resulted in response curves (A) and (B). When 
added to PqsD pretreated with ACoA, no response was observed in (C) and (D). When (R)-3 was 
added until saturation, subsequent addition of (S)-3 did not affect the observed response (E). The 
results indicate that the binding sites of both enantiomers are blocked by anthranilate. 
 
 
 
6.2.11 Figure S10: Reversibility of PqsD Inhibition by the Enantiomers (R)-3 and (S)-3 
 
 
 
Figure S10. PqsD was preincubated with enantiomers (R)-3 and (S)-3 and the remaining HHQ 
formation was quantified with and without removal of unbound inhibitor by diafiltration. Centrifugal 
filter devices with a molecular weight limit of 10k were used to remove at least 95% inhibitor by three 
diafiltration steps as controlled by HPLC analysis, while PqsD was retained. 
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6.2.12 Representative ITC Curves 
 
 
Figure S11. Representative ITC titrations of R-enantiomer against PqsD wild-type and mutants. 
3500 µM of compound against: a) PqsD wild-type (347µM), b) S317A (351µM), c) N287A (347µM), 
d) C112A (350µM), e) C112S (354µM), f) H257F (352µM), g) S317F (345µM). The recorded change 
in heat is shown in units of μcal sec–1 as a function of time for successive injections of the ligand 
(upper panel). Integrated heats (black squares) plotted against the molar ratio of the binding reaction. 
The continuous line represents the results of the non-linear least squares fitting of the data to a binding 
model (lower panel). 
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Figure S12. Representative ITC titrations of S-enantiomer against PqsD wild-type and mutants. 
3500 µM of compound against: a) PqsD wild-type (347µM), b) S317A (351µM), c) N287A (347µM), 
d) C112A (350µM), e) C112S (354µM), f) H257F (352µM), g) S317F (345µM). The recorded change 
in heat is shown in units of μcal sec–1 as a function of time for successive injections of the ligand 
(upper panel). Integrated heats (black squares) plotted against the molar ratio of the binding reaction. 
The continuous line represents the results of the non-linear least squares fitting of the data to a binding 
model (lower panel). 
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6.3.1 Chemistry 
 
Methyl 3-amino-5-(4’-methoxyphenyl)thiophene-2-carboxylate (IIa). The title compound was 
prepared from 4’-methoxyacetophenone according to general procedure A and used directly in the 
next step without further purification. 
1
H NMR (500 MHz, DMSO-d6) δ 7.56 (d, J = 8.8 Hz, 2H), 7.00 
(d, J = 8.8 Hz, 2H), 6.86 (s, 1H), 6.56 (s, 2H), 3.79 (s, 3H), 3.72 (s, 3H). 
13
C NMR (125 MHz, DMSO-
d6) δ 163.9, 160.0, 155.7, 147.7, 127.0, 125.3, 114.9, 114.6, 95.7, 55.3, 50.8. 
 
Methyl 3-amino-5-(4’-phenoxyphenyl)thiophene-2-carboxylate (IIb). The title compound was 
prepared from 4’-phenoxyacetophenone according to general procedure A and used directly in the 
next step without further purification. 
1
H NMR (500 MHz, DMSO-d6) δ 7.64 (d, J = 8.8 Hz, 2H), 
7.46−7.40 (m, 2H), 7.22−7.17 (m, 1H), 7.11−7.06 (m, 2H), 7.04 (d, J = 8.8 Hz, 2H), 6.91 (s, 1H), 6.59 
(s, 2H), 3.72 (s, 3H).
 13
C NMR (125 MHz, DMSO-d6) δ 163.9, 157.7, 155.9, 147.0, 130.2, 127.8, 
127.4, 124.1, 119.3, 118.7, 115.7, 96.2, 50.9. 
 
Methyl 3-amino-5-(4’-bromophenyl)thiophene-2-carboxylate (IIc). The title compound was 
prepared from 4’-bromoacetophenone according to general procedure A. 1H NMR (300 MHz, CDCl3) 
δ 7.51 (d, J = 8.0 Hz, 2H), 7.43 (d, J = 8.0 Hz, 2H), 6.75 (s, 1H), 5.49 (s, 2H), 3.85 (s, 3H). 13C NMR 
(75 MHz, CDCl3) δ 164.8, 154.2, 147.6, 132.3, 132.1, 127.3, 123.0, 115.8, 100.7, 51.3. 
 
3-Amino-5-(4’-methoxyphenyl)thiophene-2-carboxylic acid (IIIa). The title compound was 
prepared from IIa according to general procedure B. 
1
H NMR (300 MHz, DMSO-d6) δ 7.55 (d, J = 8.8 
Hz, 2H), 6.99 (d, J = 8.8 Hz, 2H), 6.84 (s, 1H), 3.79 (s, 3H). 
13
C NMR (75 MHz, DMSO-d6) δ 165.3, 
159.9, 155.3, 147.0, 127.0, 125.6, 115.0, 114.6, 97.1, 55.3. 
 
3-Amino-5-(4’-phenoxyphenyl)thiophene-2-carboxylate (IIIb). The title compound was prepared 
from IIb according to general procedure B. 
1
H NMR (500 MHz, DMSO-d6) δ 7.63 (d, J = 8.8 Hz, 2H), 
7.47−7.38 (m, 2H), 7.23−7.16 (m, 1H), 7.08 (d, J = 8.8 Hz, 2H), 7.06−6.99 (m, 2H), 6.90 (s, 1H). 
13
C NMR (125 MHz, DMSO-d6) δ 165.2, 157.5, 155.9, 146.3, 130.2, 128.1, 127.3, 124.0, 119.2, 
118.7, 115.8, 97.7. 
 
3-Amino-5-(4’-bromophenyl)thiophene-2-carboxylic acid (IIIc). The title compound was 
prepared from IIc according to general procedure B. 
1
H NMR (500 MHz, DMSO-d6) δ 7.63 (d, J = 8.8 
Hz, 2H), 7.57 (d, J = 8.8 Hz, 2H), 6.98 (s, 1H). 
13
C NMR (125 MHz, DMSO-d6) δ 165.2, 155.1, 145.3, 
132.2, 132.1, 127.5, 122.0, 116.8, 98.5. 
 
6-(4’-Methoxyphenyl)-2,4-dihydro-1H-thieno[3,2-d][1,3]oxazine-2,4-dione (IVa). The title 
compound was prepared from IIIa according to general procedure C. 
1
H NMR (300 MHz, DMSO-d6) 
δ 12.28 (s, 1H), 7.74 (d, J = 8.9 Hz, 2H), 7.12 (s, 1H), 7.04 (d, J = 8.9 Hz, 2H), 3.82 (s, 3H). 13C NMR 
(75 MHz, DMSO-d6) δ 161.1, 155.5, 155.0, 149.6, 148.6, 127.9, 124.1, 114.8, 111.2, 103.1, 55.4. 
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6-(4’-Phenoxyphenyl)-2,4-dihydro-1H-thieno[3,2-d][1,3]oxazine-2,4-dione (IVb). The title 
compound was prepared from IIIb according to general procedure C. 
1
H NMR (500 MHz, DMSO-d6) 
δ 12.33 (s, 1H), 7.83 (d, J = 8.8 Hz, 2H), 7.48−7.43 (m, 2H), 7.23 (t, J = 7.4 Hz, 1H), 7.18 (s, 1H), 
7.13−7.10 (m, 2H), 7.08 (d, J = 8.8 Hz, 2H). 13C NMR (125 MHz, DMSO-d6) δ 158.9, 155.4, 155.0, 
154.8, 149.6, 148.5, 130.3, 128.4, 126.4, 124.4, 119.6, 118.6, 112.1, 103.8. 
 
6-(4’-Bromophenyl)-2,4-dihydro-1H-thieno[3,2-d][1,3]oxazine-2,4-dione (IVc). The title 
compound was prepared from IIIc according to general procedure C. 
1
H NMR (500 MHz, DMSO-d6) 
δ 12.39 (s, 1H), 7.77 (d, J = 8.8 Hz, 2H), 7.70 (d, J = 8.8 Hz, 2H), 7.29 (s, 1H). 13C NMR (125 MHz, 
DMSO-d6) δ 155.1, 153.5, 149.7, 148.6, 132.4, 130.8, 128.3, 123.8, 113.4, 104.7. 
 
3-(3’’-Benzyl-3’’-ethylureido)-5-(4’-methoxyphenyl)thiophene-2-carboxylic acid (1). The title 
compound was prepared from IVa according to general procedure D. 
1
H NMR (300 MHz, DMSO-d6) 
δ 13.21 (s, 1H), 10.10 (s, 1H), 8.17 (s, 1H), 7.63 (d, J = 8.9 Hz, 2H), 7.38–7.29 (m, 5H), 7.02 (d, J = 
8.9 Hz, 2H), 3.80 (s, 3 H), 3.39 (q, J = 7.1 Hz, 2H), 1.16 (t, J = 7.1 Hz, 3H). 
13
C NMR (75 MHz, 
DMSO-d6) δ 165.8, 160.2, 153.1, 147.9, 147.0, 138.1, 128.5, 127.2, 127.1, 127.1, 125.3, 116.1, 114.7, 
105.6, 55.3, 49.3, 41.8, 13.1. 
 
5-(4’-Methoxyphenyl)-3-ureidothiophene-2-carboxylic acid (2). The title compound was 
prepared from IVa according to general procedure D. 
1
H NMR (300 MHz, DMSO-d6) δ 12.92 (s, 1H), 
9.30 (s, 1H), 8.15 (s, 1H), 7.60 (d, J = 8.8 Hz, 2H), 7.01 (d, J = 8.8 Hz, 2H), 6.81 (s, 2H), 3.76 (s, 3H). 
13
C NMR (75 MHz, DMSO-d6) δ 164.8, 160.0, 154.7, 147.1, 146.6, 127.1, 125.4, 116.7, 114.7, 105.4, 
55.3. 
 
5-(4’-Phenoxyphenyl)-3-ureidothiophene-2-carboxylic acid (3). The title compound was prepared 
from IVb according to general procedure D. 
1
H NMR (300 MHz, DMSO-d6) δ 12.99 (s, 1H), 9.30 (s, 
1H), 8.21 (s, 1H), 7.68 (d, J = 8.8 Hz, 2H), 7.49−7.38 (m, 2H), 7.25−7.14 (m, 1H), 7.13−7.02 (m, 4H), 
6.90−6.60 (m, 2H). 13C NMR (75 MHz, DMSO-d6) δ 164.7, 157.7, 155.9, 154.6, 146.5, 146.4, 130.2, 
127.9, 127.5, 124.1, 119.3, 118.8, 117.5, 106.1. 
 
3-(3’’-(Carboxymethyl)ureido)-5-(4’-methoxyphenyl)thiophene-2-carboxylic acid (4). The title 
compound was prepared from IVa according to general procedure D. 
1
H NMR (300 MHz, DMSO-d6) 
δ 12.79 (s, 2H, COOH), 9.47 (s, 1H), 8.13 (s, 1H), 8.08 (t, J = 5.6 Hz, 1H), 7.61 (d, J = 8.8 Hz, 2H), 
7.01 (d, J = 8.8 Hz, 2H), 3.83−3.77 (m, 2H) 3.80 (s, 3H, OCH3). 
13
C NMR (75 MHz, DMSO-d6) δ 
171.9, 164.7, 160.1, 154.1, 147.2, 146.1, 127.1, 125.4, 116.7, 114.7, 105.7, 55.3, 41.3. 
 
3-(3’’-(2-Carboxyethyl)ureido)-5-(4’-methoxyphenyl)thiophene-2-carboxylic acid (5). The title 
compound was prepared from IVa according to general procedure D. 
1
H NMR (300 MHz, DMSO-d6) 
δ 12.58 (s, 2H, COOH), 9.34 (s, 1H), 8.16 (s, 1H), 7.90− 7.72 (m, 1H), 7.60 (d, J = 8.4 Hz, 2H), 7.01 
(d, J = 8.4 Hz, 2H), 3.80 (s, 3H, OCH3), 3.33−3.24 (m, 2H), 2.44 (t, J = 6.2 Hz, 2H). 
13
C NMR (75 
MHz, DMSO-d6) δ 173.0, 164.7, 160.1, 153.8, 147.1, 146.3, 127.1, 125.4, 116.7, 114.7, 105.4, 55.3, 
35.6, 34.3. 
 
(S)-3-(3’’-(1-Carboxyethyl)ureido)-5-(4’-methoxyphenyl)thiophene-2-carboxylic acid (6). The 
title compound was prepared from IVa according to general procedure D. 
1
H NMR (300 MHz, 
DMSO-d6) δ 12.76 (s, 2H, COOH), 9.43 (s, 1H), 8.14 (s, 1H), 8.09 (d, J = 7.1 Hz, 1H), 7.61 (d, J = 8.8 
Hz, 2H), 7.03 (d, J = 8.8 Hz, 2H), 4.22−4.08 (m, 1H), 3.81 (s, 3H, OCH3), 1.32 (d, J = 7.30 Hz, 3H, 
CH3). 
13
C NMR (75 MHz, DMSO-d6) δ 174.7, 164.7, 160.1, 153.5, 147.2, 146.1, 127.1, 125.4, 116.6, 
114.7, 105.6, 55.3, 48.3, 17.4. 
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(S)-3-(3’’-(1-Carboxy-2-phenylethyl)ureido)-5-(4’-methoxyphenyl)thiophene-2-carboxylic acid 
(7). The title compound was prepared from IVa according to general procedure D. 
1
H NMR (300 
MHz, DMSO-d6) δ 12.84 (s, 2H, COOH), 9.42 (s, 1H), 8.15 (d, J = 7.9 Hz, 1H), 8.09 (s, 1H), 
7.69−7.51 (m, J = 8.8 Hz, 2H), 7.37−7.25 (m, 4H), 7.25−7.17 (m, 1H), 7.03−6.97 (m, J = 8.8 Hz, 2H), 
4.56−4.28 (m, 1H), 3.79 (s, 3H, OCH3), 3.11 (dd, J = 13.9, 4.6 Hz, 1H), 2.88 (dd, J = 13.9, 9.8 Hz, 
1H). 
13
C NMR (75 MHz, DMSO-d6) δ 173.6, 164.6, 160.1, 153.7, 147.1, 145.9, 137.7, 129.0, 128.2, 
127.1, 126.4, 125.4, 116.7, 114.7, 105.8, 55.3, 54.4, 36.9. 
 
5-(4’-Methoxyphenyl)-3-(3’’-phenethylureido)thiophene-2-carboxylic acid (8). The title 
compound was prepared from IVa according to general procedure D. 
1
H NMR (300 MHz, DMSO-d6) 
δ 12.96 (s, 1H, CCOH), 9.33 (s, 1H), 8.18 (s, 1H), 7.84−7.70 (m, 1H), 7.61 (d, J = 8.3 Hz, 2H), 
7.39−7.13 (m, 5H), 7.02 (d, J = 8.3 Hz, 2H), 3.80 (s, 3H, OCH3), 3.42−3.26 (m, 2H), 2.90−2.67 (m, 
2H). 
13
C NMR (75 MHz, DMSO-d6) δ 164.8, 160.0, 153.8, 147.2, 146.5, 139.5, 128.6, 128.3, 127.1, 
126.1, 125.4, 116.7, 114.7, 105.2, 55.3, 41.0, 35.5. 
 
(R)-3-(3’’-(1-Carboxyethyl)ureido)-5-(4’-methoxyphenyl)thiophene-2-carboxylic acid (9). The 
title compound was prepared from IVa according to general procedure D. 
1
H NMR (300 MHz, 
DMSO-d6) δ 12.76 (s, 2H, CCO), 9.43 (s, 1H), 8.14 (s, 1H), 8.09 (d, J = 7.1 Hz, 1H), 7.61 (d, J = 8.9 
Hz, 2H), 7.01 (d, J = 8.9 Hz, 2H), 4.22−4.08 (m, 1H), 3.80 (s, 3H, OCH3), 1.31 (d, J = 7.4 Hz, 3H, 
CH3). 
13
C NMR (75 MHz, DMSO-d6) δ 174.7, 164.7, 160.1, 153.5, 147.2, 146.1, 127.1, 125.4, 116.6, 
114.7, 105.6, 55.3, 48.3, 17.4. 
 
(R)-3-(3’’-(1-Carboxy-2-phenylethyl)ureido)-5-(4’-methoxyphenyl)thiophene-2-carboxylic acid 
(10). The title compound was prepared from IVa according to general procedure D. 
1
H NMR (300 
MHz, DMSO-d6) δ 12.84 (s, 2H, CCOH), 9.42 (s, 1H), 8.15 (d, J = 7.9 Hz, 1H), 8.09 (s, 1H), 7.59 (d, 
J = 8.8 Hz, 2H), 7.37−7.25 (m, 4H), 7.25−7.17 (m, 1H), 7.00 (d, J = 8.8 Hz, 2H), 4.56−4.28 (m, 1H), 
3.79 (s, 3H, OCH3), 3.11 (dd, J = 13.9, 4.6 Hz, 1H), 2.88 (dd, J = 13.9, 9.8 Hz, 1H). 
13
C NMR (75 
MHz, DMSO-d6) δ 173.6, 164.6, 160.1, 153.7, 147.1, 145.9, 137.7, 129.0, 128.2, 127.1, 126.4, 125.4, 
116.7, 114.7, 105.8, 55.3, 54.4, 36.9. 
 
3-(3’’-(2-Carboxypropan-2-yl)ureido)-5-(4’-methoxyphenyl)thiophene-2-carboxylic acid (11). 
The title compound was prepared from IVa according to general procedure D. 
1
H NMR (300 MHz, 
DMSO-d6) δ 12.59 (s, 2H, CCOH), 9.37 (s, 1H), 8.13 (s, 1H), 8.01 (s, 1H), 7.61 (d, J = 8.8 Hz, 2H), 
7.00 (d, J = 8.8 Hz, 2H), 3.80 (s, 3H, OCH3), 1.40 (s, 6H, (CH3)2). 
13
C NMR (75 MHz, DMSO-d6) δ 
176.0, 164.7, 160.0, 153.0, 147.2, 146.1, 127.1, 125.4, 116.5, 114.7, 105.4, 55.3, 54.9, 25.3. 
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Scheme S2: Synthesis of compound 12. 
 
 
 
(S)-3-(3’’-(1-Carboxy-2-phenylethyl)ureido)-5-(4’-bromophenyl)thiophene-2-carboxylic acid 
(12a) was prepared from IVc according to general procedure D. 
1
H NMR (300 MHz, DMSO-d6) δ 
12.93 (s, 2H, CCOH), 9.42 (s, 1H), 8.23 (s, 1H), 8.17 (d, J = 7.9 Hz, 1H), 7.70−7.54 (m, 4H), 7.38− 
7.14 (m, 5H), 4.47−4.30 (m, 1H), 3.11 (dd, J = 13.9, 4.8 Hz, 1H), 2.88 (dd, J = 13.9, 9.7 Hz, 1H). 13C 
NMR (75 MHz, DMSO-d6) δ 173.5, 164.5, 153.7, 145.7, 145.4, 137.7, 132.2, 132.0, 129.0, 128.2, 
127.6, 126.4, 122.3, 118.5, 107.3, 54.4, 37.0. 
 
(S)-3-(3’’-(1-Carboxy-2-phenylethyl)ureido)-5-(4’-aminophenyl)thiophene-2-carboxylic acid 
(12b) was prepared from 12a according to the following procedure: CuI (10 mg, 5.30 µmol), 12a (127 
mg, 0.26 mmol), Na3PO4∙12 H2O (100 mg, 0.26 mmol), 25−28% aqueous ammonia (0.5 mL) and 
PEG-400 (1 mL) were added to a sealed tube. The reaction was stirred at 100 °C for 24 h, cooled to 
0 °C and cautiously acidified with 1 M HCl to pH 4−5. The resulting mixture was extracted with 
EtOAc (3 x 50 mL). The combined organic layers were washed with water (50 mL) and brine (50 mL), 
dried over MgSO4 and concentrated to afford the title compound. The crude product was used in the 
next step without further purification. 
 
(S)-3-(3’’-(1-Carboxy-2-phenylethyl)ureido)-5-(4’-(2-chloroacetamido)phenyl)-thiophene-2-
carboxylic acid (12) was prepared from 12b according to the following procedure: A solution of 12b 
(142 mg, 1.10 mmol) and triethylamine (142 mg, 1.10 mmol) in CH2Cl2 (6 mL) was stirred at −78 °C 
under stream of nitrogen. 2-Chloroacetyl chloride in CH2Cl2 (4 mL) was added slowly and stirring was 
continued for 1 h at −78 °C, 1 h at 0 °C and 1 h at room temperature. The solution was diluted with ice 
water (30 mL) and acidified with a saturated solution of KHSO4. The resulting mixture was extracted 
with EtOAc (3 x 50 mL). The combined organic layers were then washed with water (50 mL) and 
brine (50 mL), dried over MgSO4 and concentrated in vacuo. The crude material was purified via 
preparative HPLC (RP18, acetonitrile/H2O 50% → 95%) to yield the title compound as a light green 
solid (Purity: 90%). 
1
H NMR (300 MHz, DMSO-d6) δ 12.89 (s, 2H, CCOH), 10.48 (s, 1H), 9.41 (s, 
1H), 8.16 (d, J = 7.8 Hz, 1H), 8.15 (s, 1H), 7.73−7.62 (m, 4H), 7.33−7.20 (m, 5H), 4.43−4.34 (m, 1H), 
4.27 (s, 2H, CH2Cl), 3.14−3.07 (m, 1H), 2.92−2.84 (m, 1H). 
13
C NMR (125 MHz, DMSO-d6) δ 173.7, 
164.9, 164.7, 153.8, 146.8, 145.9, 139.4, 137.8, 129.1, 128.3, 128.2, 126.5, 126.4, 119.8, 117.3, 106.3, 
54.5, 43.6, 36.9. 
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6.3.2 SPR - studies with R223A mutant of PqsD 
 
Preparation of PqsD mutant: 
R223A PqsD mutant was generated using the QuikChange Site-Directed Mutagenesis Kit (Stratagene, 
La Jolla, CA) according to the manufacturer’s instructions using the pET28b(+)/pqsD plasmid as a 
template. Briefly, pqsD gene was amplified through 16 cycles of PCR. After treatment with DpnI, the 
PCR product was transformed into E. coli strain XL1-Blue. Plasmid DNA was purified using the 
GenEluteTM HP Plasmid Miniprep Kit (Sigma-Aldrich, St. Louis, MO) and sequenced to confirm the 
site-directed mutations. The primer sequence of the mutations: 
 
Primer-design: 
Arg223Ala-Mutante: 
Wild:  5‘ GCGAGTTCCTCATGCGCGGCCGGCCGATGTTCGAGC 3´ 
Mut:   5‘ GCGAGTTCCTCATGCGCGGCGCGCCGATGTTCGAGC 3´ 
 
Sequence of the Primer: 
R223A_PqsD_Forward: 5' GCGAGTTCCTCATGCGCGGCGCGCCGATGTTCGAGC 3' 
R223A_PqsD_Reverse: 5' GCTCGAACATCGGCGCGCCGCGCATGAGGAACTCGC 3' 
 
 
 
6.3.3 Selectivity data for hit compounds: PqsD vs. RNAP inhibition 
 
Table S1. Inhibitory activities of several virtual hit compounds against PqsD and RNAP and the 
derived selectivity factors. 
 
 
 
 
 
Compound IC50 PqsD [µM] IC50 RNAP [µM]
 
Selectivity factor
a 
4-OCH3 6 241 40.2 
3,4-di-Cl 4 22 5.5 
3-CF3, 4-Cl 3 21 7.0 
2,5-di-Cl 9 35 4.0 
4-NO2 10 73 7.3 
4-CF3 8 51 6.4 
4-OCF3 9 45 5.0 
H 50 292 6.0 
a
Selectivity factor was calculated as IC50(RNAP) IC50(PqsD)
−1
. 
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6.3.4 Results of the competition experiments for identification of the binding mode  
 
 
Figure S1. SPR-competition experiments with model compounds 1–3 and competitor compounds A 
(black) and B (red) from the 2-nitrophenyl methanol class. Reference without competition is shown in 
blue. A reduced response in competition with A can be observed exclusively for compound 3. The 
reference signal is shown in grey. 
 
 
Figure S2. Visualization of the SPR-competition results shown in Figure S1. Competitor A 
(yellow), competitor B (magenta) a) A does not affect the binding of 1 (green). b) B leads to sterical 
clash with methoxy group of 1 (green). c) A does not affect the binding of 2 (blue). d) B leads to 
sterical clash with methoxy group of 2 (blue). e) A leads to sterical clash with phenoxy group of 3 
(turquoise). f) B leads to sterical clash with phenoxy group of 3 (turquoise). 
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Figure S3. SPR-competition experiments with compounds 7 and competitor compounds A (black) 
and B (red) from the 2-nitrophenyl methanol class. Reference without competition is shown in blue. 
The reference signal is shown in grey. 
 
 
 
6.3.5 Experiment with R223A mutant and compound 2 
 
 
Figure S4. SPR-experiment using a R223A mutant and compound 2. Different responses were 
observed when compound 2 was added to PqsD wild-type (blue) and the R223A mutant (green). 
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6.3.6 STD-NMR spectrum of 7 
 
 
Figure S5. Reference (black) and STD NMR difference (red) spectra of compound 7 in complex 
with PqsD. Samples comprising 100:1 7/PqsD were prepared in 20 mM Na3PO4, 50 mM NaCl, and 5 
mM MgCl2, pH 7.0, and spectra were recorded at 298 K. Overlaid spectra were normalized to the 
signals for 2H-21, which gave the strongest enhancement. 
 
 
 
6.3.7 MALDI-TOF MS Spectra 
 
 
Figure S6. MALDI-TOF-MS analysis of tryptic digested PqsD. For the sake of clarity, only signals 
>15% intensity are labeled. 
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Figure S7. MALDI-ToF-MS analysis of tryptic digested PqsD after preincubation with 12. For the 
sake of clarity, only signals >15% intensity are labeled. 
 
 
 
6.3.8 LC-ESI-MS Data 
 
 
Figure S8. LC-ESI-MS data. Top panel (red): Reference sample containing only PqsD. Bottom 
panel (blue): PqsD after 30 minutes preincubation with compound 12. Mass shift of 465 Da indicates 
covalent binding of 12. 
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6.4 Supporting Information for Publication D 
Full supporting information is available online:  
http://www.rsc.org/suppdata/ob/c4/c4ob00707g/c4ob00707g1.pdf 
 
 
6.4.1 Synthesis and analytical data of all tested compounds 
 
(2-Nitrophenyl)(phenyl)methanol (3)
S1
 The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and benzaldehyde according to general method A. 
Purification via flash chromatography (petroleum ether/ethyl acetate 1:1) gave 3 (681 mg, 70 %) as a 
brown solid. 
1
H NMR (500 MHz, CDCl3) δ 6.44 (s, 1H), 7.27-7.32 (m, 1H), 7.33-7.34 (m, 4H), 7.44-
7.47 (m, 1H), 7.62-7.65 (m, 1H), 7.73-7.75 (m, 1H), 7.93 (dd, J = 8.2, J = 1.3, 1H). 
13
C NMR (125 
MHz, CDCl3) δ 71.7, 124.9, 127.1, 128.2, 128.7, 128.7, 129.6, 133.6, 138.6, 141.7. Rt = 9.75 min; 
purity ≥ 97 % (UV). HRMS (ESI) m/z: (M-OH)+ calculated 212.07060, found 212.07037. Mp: 54-
55°C (Lit. 59-60°C).
S2
  
 
tert-Butyl phenylcarbamate (5)
S3
 To a solution of aniline (3.42 ml, 37.50 mmol) in 35 ml THF was 
added di-tert-butyl dicarbonate (9.48 ml, 41.25 mmol) and the mixture was refluxed for 3 h. The 
solvent was removed in vacuo and 75 ml ethyl acetate were added. The solution was washed with 1 M 
citric acid and brine, dried and concentrated under reduced pressure. Crystallization from hexane 
yielded 5 (5.013 g, 69 %) as a white solid. 
1
H NMR (500 MHz, acetone-d6) δ 1.48 (s, 9H), 6.98 (t, J = 
7.4, 1H), 7.24-7.29 (m, 2H), 7.55 (d, J = 7.9, 2H). 
13
C NMR (125 MHz, acetone-d6) δ 28.5, 79.9, 
119.0, 123.0, 123.0, 129.5. Mp: 135°C (Lit. 137°C).
S2
 
 
tert-Butyl (2-(hydroxy(phenyl)methyl)phenyl)-carbamate (6)
S3
 A solution of tert-butyl 
phenylcarbamate 5 (1.200 g, 6.20 mmol) in 10 ml THF was cooled to -60°C and 8.76 ml of a tert-
butyllithium solution (1.7 M in pentane, 14.89 mmol) were added slowly. The solution was stirred at -
60°C for 15 min followed by 2 h at -20°C. A solution of benzaldehyde (0.63 ml, 6.20 mmol) in 5 ml 
THF was added and the mixture was stirred for 2 h at -20°C. The reaction was quenched with a 
saturated solution of NH4Cl (10 ml) and the aqueous phase was extracted with ethyl acetate (three 
times). The combined organic layers were washed with brine, dried, and concentrated under reduced 
pressure. The residue was purified by column chromatography (petroleum ether/ethyl acetate 8:1) to 
yield 6 (653 mg, 35 %) as a white solid. 
1
H NMR (500 MHz, MeOH-d4) δ 1.41 (s, 9H), 5.88 (s, 1H), 
7.07 (td, J = 7.6, J = 1.3, 1H), 7.19-7.34 (m, 7H), 7.60 (d, J = 7.6, 1H). 
13
C NMR (125 MHz, MeOH-
d4) δ 28.6, 75.4, 81.0, 124.8, 127.3, 128.1, 129.1, 129.1, 129.4, 137.9, 144.2, 155.3. MS (ESI) m/z: 
267.2 (M-O
t
Bu)
+
. Mp: 135-137°C (Lit. 141-142°C).
S2
 
 
4-Phenyl-1H-benzo[d][1,3]oxazin-2(4H)-one (7) To a solution of 6 (200 mg, 0.67 mmol) in 4 ml 
of dry dichloromethane at 0°C were added 0.8 ml TFA and the mixture was stirred at room 
temperature for 1 h. The solvent and TFA were removed in vacuo, DCM was added and the pH was 
adjusted to 7 using a saturated solution of sodium bicarbonate. The solution was extracted three times 
with ethyl acetate and the combined organic phase was dried, filtered and concentrated in vacuo. The 
crude product was purified by flash chromatography (petroleum ether/ethyl acetate 3:1) to give 7 (117 
mg, 78 %) as a brownish solid. 
1
H NMR (500 MHz, CDCl3) δ 6.39 (s, 1H), 6.86 (d, J = 7.6, 1H), 6.92 
(dd, J = 7.9, J = 0.6, 1H), 7.02 (td, J = 7.6, J = 0.9, 1H), 7.26-7.30 (m, 1H), 7.35-7.42 (m, 5H). 
13
C 
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NMR (125 MHz, MeOH-d4) δ 81.4, 114.5, 121.1, 123.5, 126.0, 127.9, 128.9, 129.3, 129.6, 135.5, 
153.1. Rt = 9.46 min; purity ≥ 99 % (UV). HRMS (ESI) m/z: (M+H)
+
 calculated 226.08626, found 
226.08576. Mp: 57-60°C.  
 
(2-Aminophenyl)(phenyl)methanol (8) To a solution of 7 (200 mg, 0.89 mmol) in 5 ml methanol a 
solution of potassium hydroxide (2.00 g) in 5 ml H2O was added. The mixture was refluxed for 18 h, 
methanol was removed under reduced pressure and the phases were separated. The aqueous phase was 
extracted twice with ethyl acetate and the combined organic phase was dried, filtered and concentrated 
in vacuo. The crude product was purifed by flash chromatography (petroleum ether/ethyl acetate 4:1) 
to give 8 (30 mg, 17 %) as a yellowish solid. 
1
H NMR (500 MHz, MeOH-d4) δ 5.82 (s, 1H), 6.66 (t, J 
= 7.3, 1H), 6.72 (d, J = 7.9, 1H), 6.99 (d, J = 7.6, 1H), 7.04 (td, J = 7.6, J = 1.3, 1H), 7.25 (t, J = 7.3, 
1H), 7.32 (t, J = 7.6, 2H), 7.38 (d, J = 7.6, 2H). 
13
C NMR (125 MHz, MeOH-d4) δ 74.6, 117.8, 118.9, 
127.9, 128.2, 129.1, 129.2, 129.3, 129.7, 144.3, 146.6. Rt = 6.16 min; purity ≥ 97 % (UV). HRMS 
(ESI) m/z: (M+H)
+
 calculated 200.10699, found 200.10644. Mp: 118-120°C (Lit. 115-116°C).
S4 
 
3-Phenylisobenzofuran-1(3H)-one (10) The title compound was prepared according to the general 
method B using methyl 2-iodobenzoate (2.00 g, 7.63 mmol) and purified by column chromatography 
(petroleum ether/ethyl acetate 6:1) to yield 10 (1.007 g, 63 %) as a white solid. 
1
H NMR (500 MHz, 
DMSO-d6) δ 6.73 (s, 1H), 7.30-7.34 (m, 2H), 7.37-7.43 (m, 3H), 7.45 (d, J = 7.6, 1H), 7.63 (t, J = 7.6, 
1H), 7.76 (t, J = 7.6, 1H), 7.93 (d, J = 7.3, 1H). 
13
C NMR (125 MHz, DMSO-d6) δ 81.8, 123.2, 124.6, 
125.0, 126.8, 128.9, 129.0, 129.5, 134.7, 136.9, 149.9, 169.9. Rt = 10.70 min; purity ≥ 95 % (UV). 
HRMS (ESI) m/z: (M+H)
+
 calculated 226.07536, found 211.07491. Mp: 116-117°C (Lit. 115-
117°C).
S5
 
 
Sodium 2-(hydroxy(phenyl)methyl)benzoate (11) To a solution of 10 (400 mg, 1.90 mmol) in 20 
ml MeOH an aqueous solution of sodium hydroxide (20 ml, 1M) was added. The mixture was stirred 
for 2 h at room temperature followed by 2 h at 50°C. The solvent was evaporated and 11 was isolated 
by preparative HPLC to afford 199 mg (39 %) as a white solid. 
1
H NMR (500 MHz, MeOH-d4) δ 6.10 
(s, 1H), 7.16-7.21 (m, 2H), 7.23-7.30 (m, 4H), 7.36 (d, J = 7.9, 2H), 7.66 (d, J = 7.3, 1H). 
13
C NMR 
(125 MHz, MeOH-d4) δ 75.7, 127.6, 127.6 128.1, 128.8, 129.4, 129.9, 130.6. 140.8, 143.4, 145.2, 
177.5. Rt = 8.80 min; purity ≥ 98 % (UV). HRMS (ESI) m/z: (M-OH)
+
 calculated 211.07536, found 
211.07512. IR (ATR) νmax 3288, 3061, 3028, 1557 (νas COO
-) , 1385 (νs COO
-
), 1015, 739, 699 cm
-1
. 
Mp: 67-71°C. 
 
Phenyl(2-(trifluoromethyl)phenyl)methanol (14) The title compound was prepared according to 
the general method B using 2-iodobenzotrifluorid (1.00 g, 3.68 mmol) and purified by column 
chromatography (petroleum ether/ethyl acetate 10:1) to yield 14 (665 mg, 71 %) as a colorless oil. 
1
H 
NMR (500 MHz, MeOH-d4) δ 6.21 (s, 1H), 7.22 (t, J = 7.6, 1H), 7.27-7.32 (m, 4H), 7.41 (t, J = 7.6, 
1H), 7.58 (t, J = 7.6, 1H), 7.68 (d, J = 7.9, 1H), 7.70 (d, J = 7.9, 1H). 
13
C NMR (125 MHz, MeOH-d4) 
δ 71.5, 126.0 (q, J = 273), 126.3 (q, J = 6), 127.7, 128.3, 128.5 (q, J = 30), 128.7, 129.2, 130.8, 133.4, 
144.4, 145.0. Rt = 11.74 min; purity ≥ 99 % (UV). HRMS (ESI) m/z: (M-OH)
+
 calculated 235.07291, 
found 235.07263.  
 
2-(Hydroxy(phenyl)methyl)benzonitrile (15) The title compound was prepared according to the 
general method B using 2-iodobenzonitril (1.00 g, 4.36 mmol) and purified by column 
chromatography (petroleum ether/ethyl acetate 1:1) to yield 15 (426 mg, 47 %) as a yellowish solid. 
1
H NMR (500 MHz, MeOH-d4) δ 6.52 (s, 1H), 7.26-7.30 (m, 3H), 7.33-7.39 (m, 3H), 7.52-7.56 (m, 
1H), 7.59 (td, J = 7.6, J = 1.3, 1H), 7.95-7.97 (m, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 86.5, 123.9, 
106  6.4  SUPPORTING INFORMATION FOR PUBLICATION D 
124.7, 126.6, 127.9, 129.4, 129.9, 130.1, 130.2, 134.0, 139.5, 149.1. Rt = 6.58 min; purity ≥ 96 % 
(UV). HRMS (ESI) m/z: (M+H)
+
 calculated 210.09143, found 210.09094. Mp: 86-91°C. 
 
(2-Chlorophenyl)(phenyl)methanol (21) The title compound was prepared according to the 
general method C using 2-chlorobenzaldehyde (0.40 ml, 3.56 mmol) and purified by column 
chromatography (petroleum ether/ethyl acetate 10:1) to yield 21 (450 mg, 58 %) as a grey solid. 
1
H 
NMR (500 MHz, MeOH-d4) δ 6.16 (s, 1H), 7.20-7.25 (m, 2H), 7.27-7.31 (m, 2H), 7.31-7.36 (m, 4H), 
7.65-7.67 (m, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 73.1, 128.1, 128.2, 128.4, 129.2, 129.6, 130.3, 
133.5, 143.2, 144.3. Rt = 11.07 min; purity ≥ 99 % (UV). HRMS (ESI) m/z: (M-OH)
+
 calculated 
201.04655, found 201.04627. Mp: 64-66°C (Lit. 64-66°C).
S6
 
 
(2-Bromophenyl)(phenyl)methanol (22) The title compound was prepared according to the 
general method C using 2-bromobenzaldehyde (0.63 ml, 5.41 mmol) and purified by column 
chromatography (petroleum ether/ethyl acetate 10:1) to yield 22 (516 mg, 36 %) as a yellowish solid. 
1
H NMR (500 MHz, MeOH-d4) δ 6.12 (s, 1H), 7.17 (td, J = 7.7, J = 1.9, 1H), 7.22 (tt, J = 8.2, J = 1.4, 
1H), 7.27-7.31 (m, 2H), 7.34-7.398 (m, 3H), 7.54 (dd, J = 8.2, J = 1.3, 1H), 7.64 (dd, J = 7.9, J = 1.6, 
1H). 
13
C NMR (125 MHz, MeOH-d4) δ 75.3, 128.3, 128.4, 129.2, 129.6, 130.0, 133.7, 144.3, 144.7. Rt 
= 11.13 min; purity ≥ 96 % (UV). HRMS (ESI) m/z: (M-OH)+ calculated 244.99604, found 
244.99585. Mp: 56-58°C (Lit. 56°C).
S7
 
 
Phenyl(o-tolyl)methanol (23) The title compound was prepared according to the general method C 
using 2-methylbenzaldehyde (0.42 ml, 3.67 mmol) and purified by column chromatography 
(petroleum ether/ethyl acetate 8:1) to yield 23 (700 mg, 92 %) as a white solid. 
1
H NMR (500 MHz, 
MeOH-d4) δ 2.22 (s, 3H), 5.96 (s, 1H), 7.10-7.25 (m, 4H), 7.27-7.31 (m, 4H), 7.47 (d, J = 7.6, 1H). 
13
C 
NMR (125 MHz, MeOH-d4) δ 19.5, 73.9, 126.8, 127.5, 128.2, 128.4, 129.2, 131.3, 136.5, 143.3, 
144.8. Rt = 10.90 min; purity ≥ 95 % (UV). HRMS (ESI) m/z: (M-OH)
+
 calculated 181.10118, found 
181.10078. Mp: 90-91°C (Lit. 90-91°C).
S8
 
 
2-Methoxyphenyl)(phenyl)methanol (24) To a solution of 14.20 ml 2-methoxy-magnesium 
bromide (1M in TFH, 14.3 mmol) in 35 ml THF at -40°C was slowly added benzaldehyde (1.73 ml, 
17.03 mmol). After 3 h at -40°C the reaction was quenched with a saturated solution of NH4Cl (10 ml) 
and diluted with water (10 ml). The workup was carried out as described in method A. The crude 
product was purified by column chromatography (petroleum ether/ethyl acetate 8:1) to give the 
desired product (2.098 g, 69 %). 
1
H NMR (500 MHz, MeOH-d4) δ 3.76 (s, 3H), 6.12 (s, 1H), 6.91-
6.96 (m, 2H), 7.18 (tt, J = 7.3, J = 1.3, 1H) 7.20-7.23 (m, 1H), 7.24-7.27 (m, 2H), 7.32-7.35 (m, 2H), 
7.44 (dd, J = 7,6, J = 1.9, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 55.8, 70.8, 111.6, 121.5, 127.8, 
127.9, 129.0, 129.4, 134.0, 145.7, 157.7. Rt = 10.48 min; purity ≥ 99 % (UV). HRMS (ESI) m/z: (M-
OH)
+
 calculated 197.09609, found 197.09576. Mp: 37-38°C (Lit. 38-39°C).
S9
 
 
2-(Hydroxy(phenyl)methyl)phenol (25) The title compound was prepared according to the general 
method C using 2-hydroxybenzaldehyde (0.87 ml, 8.19 mmol) and 2.5 eq phenylmegnesium chloride 
(10.23 ml, 20.47 mmol). The crude product was purified by column chromatography (petroleum 
ether/ethyl acetate 6:1) to yield 25 (1.160 g, 70 %) as a white solid. 
1
H NMR (500 MHz, MeOH-d4) δ 
6.11 (s, 1H), 6.76 (dd, J = 8.2, J = 0.9, 1H), 6.80 (tt, J = 7.6, J = 1.3, 1H), 7.05-7.09 (m, 1H), 7.19 (tt, J 
= 6.6, J = 1.9, 1H), 7.23 (dd, J = 7.6, J = 1.8, 1H), 7.25-7.29 (m, 2H), 7.37-7.40 (m, 2H). 
13
C NMR 
(125 MHz, MeOH-d4) δ 72.3, 120.4, 127.7, 127.9, 128.4, 129.0, 129.2, 131.5, 145.6, 155.8. Rt = 9.00 
min; purity ≥ 99 % (UV). HRMS (ESI) m/z: (M-OH)+ calculated 183.08044, found 183.08003. Mp: 
136-137°C (Lit. 84-86°C).
S10 
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(3-Nitrophenyl)(phenyl)methanol (28) The title compound was prepared according to the general 
method D using meta-nitrobenzaldehyde 26 to yield 28 (102 mg, 7 %) as a brown oil. 
1
H NMR (500 
MHz, MeOH-d4) δ 5.88 (s, 1H), 7.26 (tt, J = 7.3, J = 1.3, 1H), 7.32-7.35 (m, 2H), 7.37-7.40 (m, 2H), 
7.54 (t, J = 7.9, 1H), 7.73-7.76 (m, 1H), 8.08-8.11 (m, 1H), 8.27-8.28 (m, 1H). 
13
C NMR (125 MHz, 
MeOH-d4) δ 75.8, 122.1, 122.9, 127.8, 128.7, 129.6, 130.5, 133.9, 148.7. Rt = 10.26 min; purity ≥ 99 
% (UV). HRMS (ESI) m/z: (M-OH)
+
 calculated 212.07060, found 212.07028. 
 
(4-Nitrophenyl)(phenyl)methanol (29) The title compound was prepared according to the general 
method D using para-nitrobenzaldehyde 27 to yield 29 (176 mg, 12 %) as a green-brown solid. 
1
H 
NMR (500 MHz, MeOH-d4) δ 5.87 (s, 1H), 7.25 (t, J = 7.6, 2H), 7.36-7.39 (m, 2H), 7.62 (d, J = 8.8, 
2H), 8.16-8.19 (m, 2H), 7.73-7.76 (m, 1H), 8.08-8.11 (m, 1H), 8.27-8.28 (m, 1H). 
13
C NMR (125 
MHz, MeOH-d4) δ 76.1, 124.4, 127.8, 128.4, 128.7, 129.6, 145.0, 148.4, 153.7. Rt = 10.25 min; purity 
≥ 99 % (UV). HRMS (ESI) m/z: (M+H)+ calculated 230.08117, found 230.08099. Mp: 58-59°C (Lit. 
52-53°C).
S11
 
 
(4-Chloro-2-nitrophenyl)(phenyl)methanol (33) The title compound was prepared from 
phenylmagnesium chloride (0.67 ml, 2M in THF, 1.35 mmol) and 4-chloro-2-nitrobenzaldehyde (259 
mg, 1.35 mmol) using the procedure described in the general method D. Pure 33 (174 mg, 49 %) was 
obtained as brown oil by flash chromatography (petroleum ether/ethyl acetate 8:1). 
1
H NMR (500 
MHz, MeOH-d4) δ 6.34 (s, 1H), 7.25-7.32 (m, 5H), 7.71 (dd, J = 8.5, J = 2.2, 1H), 7.86 (d, J = 8.5, 
1H), 7.92 (d, J = 2.2, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 71.3 125.1, 128.3, 128.8, 129.4, 131.5, 
134.0, 134.7, 139.1, 143.6. Rt = 12.14 min; purity ≥ 96 % (UV). HRMS (ESI) m/z: (M-OH)
+
 
calculated 246.03163, found 246.03135. 
 
(5-Chloro-2-nitrophenyl)(phenyl)methanol (34) The title compound was prepared from 
phenylmagnesium chloride (2.69 ml, 2M in THF, 5.39 mmol) and 5-chloro-2-nitrobenzaldehyde (1.00 
g, 5.39 mmol) using the procedure described in the general method D. Pure 34 (0.792 mg, 56 %) was 
obtained as brown oil by flash chromatography (petroleum ether/ethyl acetate 12:1). 
1
H NMR (500 
MHz, MeOH-d4) δ 6.40 (s, 1H), 7.23-7.27 (m, 3H), 7.29-7.32 (m, 2H), 7.50 (dd, J = 8.8, J = 2.2, 1H), 
7.89-7.92 (m, 2H). 
13
C NMR (125 MHz, MeOH-d4) δ 71.5, 127.3, 128.4, 128.9, 129.3, 129.5, 129.7, 
140.4, 142.8, 143.3. Rt = 11.29 min; purity ≥ 95 % (UV). HRMS (ESI) m/z: (M-OH)
+
 calculated 
246.03163, found 246.03134.  
 
(2,4-Dinitrophenyl)(phenyl)methanol (35) The title compound was prepared from 
phenylmagnesium chloride (1.27 ml, 2M in THF, 2.55 mmol) and 2,4-dinitrobenzaldehyde (0.50 g, 
5.39 mmol) using the procedure described in the general method D. Pure 35 (141 mg, 20 %) was 
obtained as brown oil by flash chromatography (petroleum ether/ethyl acetate 6:1). 
1
H NMR (500 
MHz, MeOH-d4) δ 6.44 (s, 1H), 7.24-7.32 (m, 5H), 8.21 (dd, J = 8.8, 1H), 8.53 (dd, J = 8.8, J = 2.2, 
1H), 8.69 (d, J = 2.2, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 71.7, 120.8, 128.1, 128.5, 129.1, 129.6, 
131.4, 143.0, 147.0, 148.4, 149.5. Rt = 10.82 min; purity ≥ 95 % (UV). HRMS (ESI) m/z: (M-OH)
+
 
calculated 257.05568, found 257.05544.  
 
(4-Methyl-2-nitrophenyl)(phenyl)methanol (39) The title compound was synthesized from 4-
iodo-3-nitro-toluene 37 (2.00 g, 7.60 mmol) and benzaldehyde according to general method A. 
Purification by flash chromatography (petroleum ether/ethyl acetate 8:1) gave 39 (765 mg, 41 %) as a 
brown oil. 
1
H NMR (500 MHz, MeOH-d4) δ 2.41 (s, 3H), 6.34 (s, 1H), 7.21-7.30 (m, 5H), 7.45-7.51 
(m, 1H), 7.68-7.71 (m, 2H). 
13
C NMR (125 MHz, MeOH-d4) δ 20.6, 71.5, 125.4, 128.3, 128.6, 129.3, 
129.8, 134.7, 137.2, 140.1, 144.2, 149.7. Rt = 11.20 min; purity ≥ 95 % (UV). HRMS (ESI) m/z: (M-
OH)
+
 calculated 226.08626, found 226.08597.  
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(5-Methyl-2-nitrophenyl)(phenyl)methanol (40) The title compound was synthesized from 3-
iodo-4-nitro-toluene 38 (1.00 g, 3.80 mmol) and benzaldehyde according to general method A. 
Purification by flash chromatography (petroleum ether/ethyl acetate 8:1) gave 40 (383 mg, 42 %) as a 
yellow-brown oil. 
1
H NMR (500 MHz, MeOH-d4) δ 2.45 (s, 3H), 6.42 (s, 1H), 7.21-7.30 (m, 6H), 
7.70-7.71 (m, 1H), 7.81 (d, J = 8.2, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 21.6, 71.6, 125.5, 128.4, 
128.6, 129.3, 129.7, 130.2, 140.4, 144.1, 145.6, 147.5. Rt = 11.09 min; purity ≥ 96 % (UV). HRMS 
(ESI) m/z: (M-OH)
+
 calculated 226.08626, found 226.08598. 
 
(4-Methoxy-2-nitrophenyl)(phenyl)methanol (43) A solution of 4-iodo-3-nitroanisol 41 (1.00 g, 
3.59 mmol) in 25 ml THF was cooled to -40°C and a solution of 4-methoxyphenylmagnesium chloride 
(3.94 ml, 1M in THF, 3.94 mmol) was added drop-wise. The solution was stirred for 1 h at -20°C. 
Then, benzaldehyde (0.39 ml, 3.59 mmol) was added at -40°C and the mixture was stirred for further 
90 min at constant temperature. The workup was carried out as described in method A. The crude 
product was purified by column chromatography (petroleum ether/ethyl acetate 8:1) to give the 
desired product (192 mg, 21 %).
1
H NMR (500 MHz, MeOH-d4) δ 3.86 (s, 3H), 6.30 (s, 1H), 7.21-7.31 
(m, 6H), 7.40 (d, J = 2.5, 1H), 7.69 (d, J = 8.8, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 56.4, 71.3, 
110.1, 112.0, 128.2, 128.5, 129.3, 131.1, 132.0, 144.3, 160.6. Rt = 10.57 min; purity ≥ 98 % (UV). 
HRMS (ESI) m/z: (M-OH)
+
 calculated 226.08117, found 226.08092. 
 
(5-Methoxy-2-nitrophenyl)(phenyl)methanol (44) A solution of 3-iodo-4-nitroanisol 42 (1.00 g, 
3.59 mmol) in 25 ml THF was cooled to -40°C and a solution of 4-methoxyphenylmagnesium chloride 
(3.94 ml, 1M in THF, 3.94 mmol) was added drop-wise. The solution was stirred for 1 h at -20°C. 
Then, benzaldehyde (0.39 ml, 3.59 mmol) was added at -40°C and the mixture was stirred for further 
90 min at constant temperature. The workup was carried out as described in method A. The crude 
product was purified by column chromatography (petroleum ether/ethyl acetate 6:1) to give the 
desired product (298 mg, 68 %). 
1
H NMR (500 MHz, MeOH-d4) δ 3.91 (s, 3H), 6.53 (s, 1H), 6.98 (dd, 
J = 9.1, J = 2.8, 1H), 7.21-7.30 (m, 5H), 7.48 (d, J = 2.8, 1H), 8.01 (d, J = 8.8, 1H). 
13
C NMR (125 
MHz, MeOH-d4) δ 56.5 72.0, 113.8, 114.7, 128.5, 128.7, 129.3, 143.9, 165.0. Rt = 10.32 min; purity 
≥ 95 % (UV). HRMS (ESI) m/z: (M-OH)+ calculated 242.08117, found 226.08099. 
 
1-(2-Nitrophenyl)ethanol (47)
S13
 To a solution of 1-(2-nitrophenyl)ethanone 46 (400 mg, 2.42 
mmol) in methanol (6 ml) sodium borohydride (366 mg, 9,69 mmol) was slowly added at 5°C. The 
reaction mixture was stirred for 16 h at room temperature, the solvent was evaporated and water was 
added. The solution was extracted three times with ethyl acetate and the combined organic phase was 
dried, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography 
(petroleum ether/ethyl acetate 4:1) to give 47 (252 mg, 62 %) as a brownish oil. 
1
H NMR (500 MHz, 
MeOH-d4) δ 1.49 (d, J = 6.3, 3H), 5.31 (q, J = 6.3, 1H), 7.45 (td, J = 7.7, J = 1.3, 1H), 7.69 (td, J = 
7.7, J = 1.3, 1H), 7.84-7.87 (m, 2H). 
13
C NMR (125 MHz, MeOH-d4) δ 25.1, 66.0, 124.8, 128.6, 
129.0, 134.3, 142.8, 149.3. Rt = 8.21 min; purity ≥ 96 % (UV). HRMS (ESI) m/z: (M-OH)
+
 calculated 
168.06552, found 168.06508. Mp: 26-28°C (Lit. 40-41°C).
S12
 
 
1-(2-Nitrophenyl)propan-1-ol (48) The title compound was synthesized from 2-iodonitrobenzene 
36 (1.00 g, 4.02 mmol) and propionaldehyde according to general method A. Purification by flash 
chromatography (petroleum ether/ethyl acetate 6:1) gave 48 (398 mg, 55 %) as a brown oil. 
1
H NMR 
(500 MHz, DMSO-d6) δ 1.01 (t, J = 7.3, 3H), 1.62-1.71 (m, 1H), 1.76-1.84 (m, 1H), 5.07 (dd, J = 8.2, 
J = 3.8, 1H), 7.43-7.46 (m, 1H), 7.70 (d, J = 7.6, J = 1.3, 1H), 7.81 (dd, J = 7.9, J = 1.3, 1H), 7.85 (dd, 
J = 8.2, J = 1.3, 1H). 
13
C NMR (125 MHz, DMSO-d6) δ 10.8, 32.8, 71.0, 124.9, 129.0, 129.1, 134.1, 
141.8, 149.5. Rt = 9.45 min; purity ≥ 98 % (UV). HRMS (ESI) m/z: (M-OH)
+
 calculated 164.09609, 
found 164.07060. 
6  SUPPORTING INFORMATION  109 
 
1-(2-nitrophenyl)butan-1-ol (49) The title compound was synthesized from 2-iodonitrobenzene 36 
(498 mg, 2.00 mmol) and butyraldehyde according to general method A. Purification by flash 
chromatography (petroleum ether/ethyl acetate 8:1) gave 49 (398 mg, 55 %) as a brown oil. 
1
H NMR 
(500 MHz, DMSO-d6) δ 0.97 (t, J = 7.6, 3H), 1.41-1.50 (m, 1H), 1.52-1.62 (m, 1H), 1.70-1.82 (m, 
2H), 5.25 (dd, J = 7.9, J = 4.1, 1H), 7.39-7.42 (m, 1H), 7.61-7.64 (m, 1H), 7.80 (dd, J = 7.9, J = 1.3, 
1H), 7.89 (dd, J = 8.2, J = 1.3, 1H). 
13
C NMR (125 MHz, CDCl3) δ 13.7, 19.3, 40.2, 69.2, 124.3, 
128.0, 128.1, 133.4, 140.24, 148.0. Rt = 10.36 min; purity ≥ 98 % (UV). MS (EI) m/z: 152.0* (M-
C3H7
•
)
+
, 135.0* (M-C3H8O
•
)
+
. 
 
1-(2-nitrophenyl)pentan-1-ol (50) The title compound was synthesized from 2-iodonitrobenzene 
36 (1.00 g, 4.02 mmol) and pentanal according to general method A. Purification by flash 
chromatography (petroleum ether/ethyl acetate 9:1) gave 50 (312 mg, 37 %) as a brownish solid. 
1
H 
NMR (500 MHz, MeOH-d4) δ 0.92 (t, J = 6.9, 3H), 1.33-1.45 (m, 3H), 1.45-1.56 (m, 1H), 1.61-1.68 
(m, 1H), 1.71-1.78 (m, 1H), 5.14 (dd, J = 8.5, J = 3.8, 1H), 7.44 (t, J = 7.9, 1H), 7.67 (t, J = 7.6, 1H), 
7.82 (d, J = 7.9, 1H), 7.85 (d, J = 8.2, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 14.4, 23.5, 29.4, 39.7, 
69.6, 124.8, 128.9, 129.0, 134.1, 142.2, 149.4. Rt = 10.95 min; purity ≥ 99 % (UV). HRMS (ESI) m/z: 
(M+H)
+
 calculated 210.11247, found 210.11189. Mp: 28-32°C. 
 
1-(2-nitrophenyl)hexan-1-ol (51) The title compound was synthesized from 2-iodonitrobenzene 36 
(1.00 g, 4.02 mmol) and hexanal according to general method A. Purification by flash chromatography 
(petroleum ether/ethyl acetate 9:1) gave 51 (349 mg, 39 %) as a brownish solid. 
1
H NMR (500 MHz, 
MeOH-d4) δ 0.91 (t, J = 6.9, 3H), 1.28-1.38 (m, 4H), 1.39-1.47 (m, 1H), 1.50-1.59 (m, 1H), 1.60-1.67 
(m, 1H), 1.70-1.77 (m, 1H), 5.14 (dd, J = 8.5, J = 3.8, 1H), 7.42-7.46 (m, 1H), 7.70 (td, J = 7.3, J = 
1.3, 1H), 7.81 (dd, J = 7.9, J = 1.3, 1H), 7.85 (dd, J = 8.2, J = 1.3, 1H). 
13
C NMR (125 MHz, MeOH-
d4) δ 14.4, 23.6, 26.8, 32.7, 39.9, 69.9, 124.8, 128.9, 129.9, 134.1, 142.2, 149.4. Rt = 12.07 min; purity 
≥ 99 % (UV). HRMS (ESI) m/z: (M-OH)+ calculated 206.11756, found 206.11725. Mp: 26-29°C. 
 
3-Methyl-1-(2-nitrophenyl)butan-1-ol (52) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and 3-methylbutanal according to general method A. 
Purification by flash chromatography (petroleum ether/ethyl acetate 8:1) gave 52 (417 mg, 50 %) as a 
brown oil. 
1
H NMR (500 MHz, MeOH-d4) δ 0.95 (d, J = 6.6, 3H), 1.01 (d, J = 6.6, 3H), 1.42-1.48 (m, 
1H), 1.57-1.63 (m, 1H), 1.90-1.98 (m, 1H), 5.25 (dd, J = 9.8, J = 2.8, 1H), 7.43 (td, J = 7.7, J = 1.3, 
1H), 7.67 (td, J = 7.6, J = 0.9, 1H), 7.84 (td, J = 8.2, J = 1.3, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 
21.6, 24.1, 26.1, 67.8, 124.8, 128.8, 129.0, 134.2, 143.0, 149.2. Rt = 11.05 min; purity ≥ 99 % (UV). 
HRMS (ESI) m/z: (M-OH)
+
 calculated 192.10191, found 192.10154. 
 
3,3-Dimethyl-1-(2-nitrophenyl)butan-1-ol (53) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and 3,3-dimethylbutanal according to general method A. 
Purification by flash chromatography (petroleum ether/ethyl acetate 12:1) gave 53 (447 mg, 50 %) as a 
brown oil. 
1
H NMR (500 MHz, MeOH-d4) δ 1.04 (s, 9H), 1.51-1.64 (m, 2H), 5.34 (dd, J = 9.5, J = 2.2, 
1H), 7.41-7.44 (m, 1H), 7.64-7.68 (m, 1H), 7.81 (dd, J = 8.2, J = 1.3, 1H), 7.83 (dd, J = 7.9, J = 1.3, 
1H). 
13
C NMR (125 MHz, MeOH-d4) δ 30.7, 31.7, 53.1, 67.6, 124.7, 128.7, 129.3, 134.1, 143.4, 
149.0. Rt = 11.91 min; purity ≥ 97 % (UV). HRMS (ESI) m/z: (M-OH)
+
 calculated 206.11756, found 
206.11724. 
 
Cyclopentyl(2-nitrophenyl)methanol (54) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and cyclopentanecarbaldehyde according to general method 
A. Purification by flash chromatography (petroleum ether/ethyl acetate 7:1) gave 54 (574 mg, 51 %) 
as a brown solid. 
1
H NMR (500 MHz, MeOH-d4) δ 1.25-1.32 (m, 1H), 1.40-1.74 (m, 7H), 2.21-2.29 
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(m, 1H), 5.02 (d, J = 8.2, 1H), 7.41-7.45 (m, 1H), 7.63-7.66 (m, 1H), 7.77- 7.80 (m, 2H). 
13
C NMR 
(125 MHz, MeOH-d4) δ 26.4, 26.4, 29.5, 30.1, 72.3, 124.6, 129.0, 129.8, 133.7, 140.8, 150.3. Rt = 
11.23 min; purity ≥ 99 % (UV). HRMS (ESI) m/z: (M-OH)+ calculated 204.10191, found 206.10162.  
 
Cyclohexyl(2-nitrophenyl)methanol (55) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and cyclohexanecarbaldehyde according to general method 
A. Purification by flash chromatography (petroleum ether/ethyl acetate 8:1) gave 55 (279 mg, 29 %) 
as a yellow-brown solid. 
1
H NMR (500 MHz, MeOH-d4) δ 1.09-1.23 (m, 5H), 1.35-1.37 (m, 1H), 
1.57-1.65 (m, 1H), 1.74-1.77 (m, 1H), 1.81-1.85 (m, 1H), 4.95 (d, J = 6.3, 1H), 7.42-7.46 (m, 1H), 
7.63-7.67 (m, 1H), 7.75 (dd, J = 7.9, J = 1.6, 1H), 7.80 (dd, J = 8.2, J = 1.3, 1H). 
13
C NMR (125 MHz, 
MeOH-d4) δ 27.2, 27.4, 27.5, 30.9, 46.2, 73.5, 124.7, 128.9, 129.9, 133.5, 140.3, 150.3. Rt = 12.10 
min; purity ≥ 99 % (UV). MS (EI) m/z: 152.1* (M-C6H11
•
)
+
. Mp: 64-65°C. 
 
Adamantan-1-yl(2-nitrophenyl)methanol (56) The title compound was synthesized from 2-
iodonitrobenzene 36 (0.61 g, 2.44 mmol) and 1-adamantylcarboxaldehyde according to general 
method A. Purification by flash chromatography (petroleum ether/ethyl acetate 10:1) gave 56 (290 
mg, 42 %) as a brown oil. 
1
H NMR (500 MHz, MeOH-d4) δ 1.42 (d, J = 12.0, 3H), 1.57 (t, J = 12.0, 
6H), 1.68 (d, J = 12.0, 3H), 1.91 (s, 3H), 5.03 (s, 1H), 7.42-7.45 (m, 1H), 7.60-7.63 (m, 1H), 7.71-7.74 
(m, 2H). 
13
C NMR (125 MHz, MeOH-d4) δ 29.8, 38.9, 39.3, 75.6, 124.4, 128.9, 131.4, 132.4, 136.9, 
151.4. Rt = 13.74 min; purity ≥ 95 % (UV). MS HRMS (ESI) m/z: (M-OH)
+
 calculated 270.14886, 
found 270.14863. 
 
1-(2-Nitrophenyl)-2-phenylethanol (57) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and phenylacetaldehyde according to general method A. 
Purification by flash chromatography (petroleum ether/ethyl acetate 6:1) gave 57 (331 mg, 32 %) as a 
brown solid. 
1
H NMR (500 MHz, MeOH-d4) δ 2.84-2.89 (m, 1H), 3.07-3.10 (m, 1H), 5.42 (dd, J = 
8.5, J = 3.8, 1H), 7.17-7.19 (m. 1H), 7.22-7.26 (m, 4H), 7.43-7.47 (m, 1H), 7.64-7.68 (m, 1H), 7.83 
(dd, J = 7.9, J = 1.6, 1H), 7.87 (dd, J = 8.2, J = 1.3, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 46.2, 71.1, 
124.9, 127.3, 129.1, 129.1, 129.4, 130.6, 134.2, 139.8, 141.6. Rt = 11.10 min; purity ≥ 97 % (UV). 
HRMS (ESI) m/z: (M+H)
+
 calculated 244.09682, found 244.09712. 
 
1-(2-Nitrophenyl)-3-phenylpropan-1-ol (58) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and 3-phenylpropanal according to general method A. 
Purification by flash chromatography (petroleum ether/ethyl acetate 6:1) gave 58 (331 mg, 32 %) as a 
brown solid. 
1
H NMR (500 MHz, MeOH-d4) δ 1.88-1.96 (m, 1H), 2.01-2.08 (m, 1H), 2.70-2.76 (m, 
1H), 2.84-2.90 (m, 1H), 5.16 (dd, J = 8.8, J = 3.5, 1H), 7.12-7.16 (m, 1H), 7.18-7.20 (m, 2H), 7.22-
7.26 (m, 2H), 7.42-7.46 (m, 1H), 7.66-7.69, 7.84-7.87 (m, 2H) 
13
C NMR (125 MHz, MeOH-d4) δ 33.6, 
41.8, 69.3, 124.9, 126.8, 129.0, 129.1, 129.4, 129.4, 134.2, 141.9, 143.0. Rt = 11.55 min; purity ≥ 95 
% (UV). HRMS (ESI) m/z: (M-OH)
+
 calculated 240.10191, found 240.11247. 
 
Naphthalen-1-yl(2-nitrophenyl)methanol (59) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and 1-naphthaldehyde according to general method A. 
Purification by flash chromatography (petroleum ether/ethyl acetate 6:1) gave 59 (302 mg, 27 %) as a 
brown solid. 
1
H NMR (500 MHz, MeOH-d4) δ 7.19 (d, J = 6.9, 1H), 7.23 (s, 1H), 7.35-7.38 (m, 1H), 
7.47-7.53 (m, 3H), 7.62-7.65 (m, 1H), 7.69-7.71 (m, 1H), 7.81 (d, J = 8.2, 1H), 7.87-7.89 (m, 1H), 
7.96 (dd, J = 8.2, J = 1.3, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 68.8, 124.8, 125.4, 125.6, 126.1, 
127.3, 129.6, 129.6, 129.7, 130.5, 132.7, 134.0, 135.4, 139.4, 139.8, 150.1. Rt = 11.39 min; purity ≥ 97 
% (UV). HRMS (ESI) m/z: (M-OH)
+
 calculated 262.08626, found 262.08606. Mp: 74-75°C (Lit. 68-
70°C).
S14 
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Naphthalen-2-yl(2-nitrophenyl)methanol (60) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and 2-naphthaldehyde according to general method A. 
Purification by flash chromatography (petroleum ether/ethyl acetate 6:1) gave 60 (969 mg, 86 %) as a 
brown oil. 
1
H NMR (500 MHz, MeOH-d4) δ 6.56 (s, 1H), 7.42 (dd, J = 8.5, J = 1.6, 1H), 7.43-7.45 (m, 
2H), 7.47-7.50 (m, 1H), 7.68-7.71 (m, 1H), 7.73-7.74 (m, 1H), 7.77-7.81 (m, 1H), 7.88 (dd, J = 8.2, J 
= 1.0, 1H), 7.90 (dd, J = 8.2, J = 1.6, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 71.7, 125.2, 126.5, 126.9, 
127.1, 127.2, 128.6, 129.1, 129.1, 129.4, 130.0, 134.1, 134.3, 134.6, 140.0, 141.4, 150.0. Rt = 11.58 
min; purity ≥ 95 % (UV). HRMS (ESI) m/z: (M-OH)+ calculated 262.08626, found 262.08591. 
 
(2-Nitrophenyl)(thiophen-2-yl)methanol (61) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and thiophen-2-carboxaldehyde according to general method 
A. Purification by flash chromatography (petroleum ether/ethyl acetate 5:1) gave 61 (514 mg, 54 %) 
as a brown oil. 
1
H NMR (500 MHz, MeOH-d4) δ 6.64 (s, 1H), 6.83-6.91 (m, 2H), 7.30 (d, J = 4.1, 
1H), 7.50 (t, J = 7.3, 1H), 7.71 (t, J = 7.3, 1H), 7.91 (d, J = 7.9, 1H), 7.97 (d, J = 7.9, 1H). 
13
C NMR 
(125 MHz, MeOH-d4) δ 67.5, 125.2, 126.2, 126.3, 127.4, 129.4, 129.6, 134.3, 140.2, 148.2, 149.3. Rt 
= 9.74 min; purity ≥ 99 % (UV). HRMS (ESI) m/z: (M-OH)+ calculated 218.02703, found 218.02672. 
 
(2-Nitrophenyl)(thiophen-3-yl)methanol (62) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and thiophene-3-carboxaldehyde according to general 
method A. Purification by flash chromatography (petroleum ether/ethyl acetate 5:1) gave 62 (584 mg, 
62 %) as a green-brown solid. 
1
H NMR (500 MHz, MeOH-d4) δ 6.45 (s, 1H), 7.01 (dd, J = 5.0, J = 
1.3, 1H), 7.14-7.15 (m, 1H), 7.32 (dd, J = 5.0, J = 2.8, 1H), 7.48 (t, J = 7.8, 1H), 7.69 (t, J = 7.6, 1H), 
7.87-7.90 (m, 2H). 
13
C NMR (125 MHz, MeOH-d4) δ 67.9, 123.2, 125.1, 126.8, 127.8, 129.4, 129.6, 
134.2, 140.3, 145.4, 149.6. Rt = 9.79 min; purity ≥ 95 % (UV). HRMS (ESI) m/z: (M-OH)
+
 calculated 
218.02703, found 218.02670. Mp: 62-64°C. 
 
Furan-2-yl(2-nitrophenyl)methanol (63) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and furan-2-carboxaldehyde according to general method A. 
Purification by flash chromatography (petroleum ether/ethyl acetate 5:1) gave 63 (391 mg, 44 %) as a 
red-brown solid. 
1
H NMR (500 MHz, MeOH-d4) δ 6.01 (dt, J = 3.2, J = 0.6, 1H), 6.31 (dd, J = 3.2, J = 
1.9, 1H), 6.44 (s, 1H), 7.42 (dd, J = 1.9, J = 0.7, 1H), 7.53 (td, J = 7.7, J = 1.6, 1H), 7.73 (td, J = 7.6, J 
= 1.3, 1H), 7.93-7.97 (m, 2H). 
13
C NMR (125 MHz, MeOH-d4) δ 65.7, 108.3, 111.2, 125.3, 129.7, 
129.8, 134.2, 137.9, 143.7, 149.4, 156.5. Rt = 8.97 min; purity ≥ 98 % (UV). HRMS (ESI) m/z: (M-
OH)
+
 calculated 202.04955, found 202.04987. Mp: 52-53°C. 
 
Furan-3-yl(2-nitrophenyl)methanol (64) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and furan-3-carboxaldehyde according to general method A. 
Purification by flash chromatography (petroleum ether/ethyl acetate 7:1) gave 64 (412 mg, 47 %) as a 
brown solid. 
1
H NMR (500 MHz, MeOH-d4) δ 6.34 (s, 1H), 6.34-6.35 (m, 1H), 7.29-7.30 (m, 1H), 
7.40 (t, J = 1.6, 1H), 7.47-7.05 (m, 1H), 7.70 (t, J = 7.6, 1H), 7.89 (dd, J = 8.2, J = 0.9, 1H), 7.93 (dd, 
J = 7.9, J = 0.9, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 64.8, 110.4, 125.1, 129.3, 129.4, 129.4, 134.2, 
140.1, 141.2, 144.4. Rt = 8.90 min; purity ≥ 98 % (UV). HRMS (ESI) m/z: (M-OH)
+
 calculated 
202.04987, found 202.04947. Mp: 35-36°C. 
 
(2-Nitrophenyl)(pyridin-2-yl)methanol (65) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and pyridine-2-carboxaldehyde according to general method 
A. Purification by flash chromatography (petroleum ether/ethyl acetate 3:1; TEA 0,1 %) gave 65 (410 
mg, 44 %) as a brown solid. 
1
H NMR (500 MHz, MeOH-d4) δ 6.47 (s, 1H), 7.27-7.29 (m, 1H), 7.48-
7.51 (m, 2H), 7.67 (td, J = 7.9, J = 1.3, 1H), 7.76 (dd, J = 7.9, J = 1.6, 1H), 7.80 (td, J = 7.6, J = 1.6, 
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1H), 7.92 (dd, J = 8.2, J = 1.3, 1H), 8.42-8.43 (m, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 72.5, 123.0, 
124.0, 125.3, 129.6, 130.4, 134.1, 138.6, 139.0, 149.6, 150.1, 162.6. Rt = 4.92 min; purity ≥ 99 % 
(UV). HRMS (ESI) m/z: (M+H)
+
 calculated 231.07642, found 231.07510. Mp: 71°C. 
 
(2-Nitrophenyl)(pyridin-3-yl)methanol (66) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and pyridine-3-carboxaldehyde according to general method 
A. Purification by flash chromatography (petroleum ether/ethyl acetate 3:1; TEA 0.1 %) gave 66 (602 
mg, 65 %) as a orange-brown solid. 
1
H NMR (500 MHz, MeOH-d4) δ 6.42 (s, 1H), 7.38 (dd, J = 7.9, J 
= 4.7, 1H), 7.52-7.56 (m, 1H), 7.73-7.78 (m, 2H), 7.94-7.98 (m, 2H), 8.42 (dd, J = 4.7, J = 1.6, 1H), 
8.50 (d, J = 1.9, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 69.7, 125.1, 125.5, 129.8, 129.9, 134.6, 137.0, 
139.4, 140.7, 149.0, 149.2, 149.5. Rt = 4.86 min; purity ≥ 99 % (UV). ). HRMS (ESI) m/z: (M+H)
+
 
calculated 231.07642, found 231.07549. Mp: 78°C (Lit. 105-106).
S15 
 
(2-Nitrophenyl)(pyridin-4-yl)methanol (67) The title compound was synthesized from 2-
iodonitrobenzene 36 (1.00 g, 4.02 mmol) and pyridine-4-carboxaldehyde according to general method 
A. Purification by flash chromatography (petroleum ether/ethyl acetate 1:1; TEA 0.1 %) gave 67 (553 
mg, 60 %) as a brownish powder. 
1
H NMR (500 MHz, MeOH-d4) δ 6.37 (s, 1H), 7.40-7.41 (m, 1H), 
7.41-7.42 (m, 1H), 7.52-7.56 (m, 1H), 7.71-7.74 (m, 1H), 7.81-7.83 (m, 1H), 7.95 (dd, J = 8.2, J = 1.3, 
1H), 8.46-8.48 (m, 2H). 
13
C NMR (125 MHz, MeOH-d4) δ 70.3, 123.6, 125.4, 130.0, 130.0, 134.6, 
139.0, 149.8, 150.1, 154.5. Rt = 4.79 min; purity ≥ 99 % (UV). ). HRMS (ESI) m/z: (M+H)
+
 calculated 
231.07642, found 231.07542. Mp: 158-160°C (Lit. 169-170°C).
S15
 
 
2-(3-Hydroxy-3-(2-nitrophenyl)propyl)isoindoline-1,3-dione (68) The title compound was 
synthesized from 2-iodonitrobenzene 36 (4.00 g, 16.06 mmol) and aldehyde 68i according to general 
method A. Purification by flash chromatography (petroleum ether/ethyl acetate 2:1) gave 68 (2.25 g, 
43 %) as a yellowish solid. 
1
H NMR (500 MHz, DMSO-d6) δ 1.82-1.89 (m, 1H), 1.96-2.02 (m, 1H), 
3.72-3.78 (m, 1H), 3.81-3.86 (m, 1H), 5.01-5.04 (m, 1H), 5.66 (dd, J = 4.4, J = 1.1, 1H), 7.45-7.50 (m, 
1H), 7.71-7.74 (m, 1H), 7.82-7.89 (m, 6H). 
13
C NMR (125 MHz, DMSO-d6) δ 35.0, 36.8, 65.8, 122.9, 
123.9, 128.0, 128.1, 131.7, 133.5, 134.3, 140.7, 147.0, 167.9. Rt = 10.45 min; purity ≥ 98 % (UV). 
HRMS (ESI) m/z: (M+H)
+
 calculated 327.09755, found 327.09695. Mp: 154-155°C. 
 
2-(4-Hydroxy-4-(2-nitrophenyl)butyl)isoindoline-1,3-dione (69) The title compound was 
synthesized from 2-iodonitrobenzene 36 (2.49 g, 10.00 mmol) and aldehyde 69i according to general 
method A. Purification by flash chromatography (petroleum ether/ethyl acetate 5:2) gave 69 (2.89 g, 
85 %) as a yellowish solid. 
1
H NMR (500 MHz, DMSO-d6) δ 1.56-1.61 (m, 1H), 1.63-1.72 (m, 2H), 
1.78-1.86 (m, 1H), 3.58-3.61 (m, 2H), 4.93-4.96 (m, 1H), 5.54 (d, J = 4.7, 1H), 7.46-7.49 (m, 1H), 
7.70 (td, J = 7.3, J = 1.3, 1H), 7.76 (dd, J = 7.9, J = 1.3, 1H), 7.82-7.87 (m, 5H). 
13
C NMR (125 MHz, 
DMSO-d6) δ 24.0, 35.7, 37.4, 67.3, 123.0, 123.6, 128.0, 131.6, 133.2, 134.3, 140.6, 147.5, 167.9. Rt = 
10.86 min; purity ≥ 99 % (UV). HRMS (ESI) m/z: (M+H)+ calculated 341.11320, found 341.11214. 
Mp: 169°C. 
 
2-(5-Hydroxy-5-(2-nitrophenyl)pentyl)isoindoline-1,3-dione (70) The title compound was 
synthesized from 2-iodonitrobenzene 36 (4.00 g, 16.06 mmol) and aldehyde 70i according to general 
method A. Purification by flash chromatography (petroleum ether/ethyl acetate 2:1) gave 70 (2.29 g, 
40 %) as a yellowish solid. 
1
H NMR (500 MHz, DMSO-d6) δ 1.33-1.42 (m, 1H), 1.44-1.50 (m, 1H), 
1.52-1.70 (m, 4H), 3.57 (t, J = 7.3, 1H), 4.93 (m, 1H), 5.49 (d, J = 4.7, 1H), 7.50-7.48 (m, 1H), 7.68-
7.71 (m, 1H), 7.77 (dd, J = 7.9, J = 1.3, 1H), 7.82-7.87 (m, 1H). 
13
C NMR (125 MHz, DMSO-d6) δ 
23.0, 27.6, 37.4, 38.0, 67.2, 123.0, 123.6, 127.9, 128.1, 131.6, 133.2, 134.3, 141.0, 147.7, 167.9. Rt = 
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11.63 min; purity ≥ 99 % (UV). HRMS (ESI) m/z: (M+H)+ calculated 355.12885, found 355.12828. 
Mp: 120-122°C. 
 
1-(5-Methyl-2-nitrophenyl)propan-1-ol (71) The title compound was synthesized from 3-iodo-4-
nitro-toluene 38 (500 mg, 1.90 mmol) and propionaldehyde according to general method A. 
Purification by column chromatography (hexane/ethyl acetate 8:1) gave 71 (244 mg, 55 %) as an 
orange solid.
 1
H NMR (300 MHz, acetone-d6) δ 1.01 (t, J = 7.3, 3H), 1.57-1.83 (m, 2H), 2.45 (s, 3H), 
4.47 (d, J = 4.5, 1H), 5.16-5.22 (m, 1H), 7.29 (dd, J = 5.7, J = 1.6, 1H), 7.70 (s, 1H), 7.80 (d, J = 8.2, 
1H). 
13
C NMR (75 MHz, acetone-d6) δ 10.9, 21.5, 32.7, 70.4, 124.9, 129.1, 129.4, 142.4, 145.0, 146.7. 
Rt = 11.06 min; purity ≥ 98 % (UV). HRMS (ESI) m/z: (M+H)
+
 calculated 196.09646, found 
196.09682. Mp: 72-74°C. 
 
(5-Methyl-2-nitrophenyl)(thiophen-2-yl)methanol (72) The title compound was synthesized from 
3-iodo-4-nitro-toluene 38 (500 mg, 1.90 mmol) and thiophen-2-carboxaldehyde according to general 
method A. Purification by column chromatography (hexane/ethyl acetate 8:1) gave 72 (54 mg, 11 %) 
as an orange solid.
 1
H NMR (500 MHz, acetone-d6) δ 2.47 (s, 3H), 5.45 (s, 1H), 6.72 (s, 1H), 6.85-6.87 
(m, 1H), 6.91 (dd, J = 5.09, J = 3.5, 1H), 7.34 (dd, J = 5.05, J = 1.2, 1H), 7.37 (dd, J = 8.1, J = 1.6, 
1H), 7.84 (m, 1H), 7.88 (d, J = 8.3, 1H). 
13
C NMR (125 MHz, acetone-d6) δ 21.6, 67.1, 125.3, 125.6, 
126.0, 127.2, 129.6, 129.8, 140.3, 145.5, 146.6, 148.6. Rt = 11.78 min; purity ≥ 95 % (UV). HRMS 
(ESI) m/z: (M-OH)
+
 calculated 232.04268, found 232.04251. Mp: 93-96°C. 
 
(5-Methyl-2-nitrophenyl)(thiophen-3-yl)methanol (73) The title compound was synthesized from 
3-iodo-4-nitro-toluene 38 (500 mg, 1.90 mmol) and thiophene-3-carboxaldehyde according to general 
method A. Purification by column chromatography (hexane/ethyl acetate 8:1) gave 73 (127 mg, 27 %) 
as a yellow oil. 
1
H NMR (500 MHz, acetone-d6) δ 2.45 (s, 3H), 5.13 (d, J = 4.7, 1H), 6.52 (d, J = 4.8, 
1H), 7.06 (dd, J = 5.1, J = 1.3, 1H), 7.21-7.22 (m, 1H), 7.33 (dd, J = 7.6, J = 1.3, 1H), 7.36 (dd, J = 5, 
J = 3, 1H), 7.78 (m, 1H), 7.83 (d, J = 8.2, 1H). 
13
C NMR (125 MHz, acetone-d6) δ 21.6, 67.5, 122.6, 
125.1, 126.5, 127.7, 129.5, 129.9, 142.5, 145.3, 145.8, 146.8. Rt = 12.26 min; purity ≥ 95 % (UV). 
HRMS (ESI) m/z: (M-OH)
+
 calculated 232.04268, found 232.04242. 
 
Furan-2-yl(5-methyl-2-nitrophenyl)methanol (74) The title compound was synthesized from 3-
iodo-4-nitro-toluene 38 (500 mg, 1.90 mmol) and furan-2-carboxaldehyde according to general 
method A. Purification by column chromatography (hexane/ethyl acetate 8:1) gave 74 (244 mg, 44 %) 
as a red-brown oil. 
1
H NMR (300 MHz, acetone-d6) δ 2.50 (s, 3H), 5.29 (s, 1H), 6.03 (d, J = 3.3, 1H), 
6.32 (dd, J = 3.3, J = 1.9, 1H), 6.53 (s, 1H), 7.39 (d, J = 8.4, 1H), 7.45 (dd, J = 1.9, J = 0.9, 1H), 7.87 
(s, 1H), 7.91 (d, J = 8.3, 1H). 
13
C NMR (75 MHz, acetone-d6) δ 21.6, 65.3, 107.7, 111.0, 125.3, 129.8, 
130.0, 138.0, 143.2, 145.4, 146.6, 156.8. Rt = 10.90 min; purity ≥ 96 % (UV). HRMS (ESI) m/z: (M-
OH)
+
 calculated 216.06522, found 216.06552. 
 
2-(3-Hydroxy-3-(5-methyl-2-nitrophenyl)propyl)isoindoline-1,3-dione (75) The title compound 
was synthesized from 3-iodo-4-nitro-toluene 38 (500 mg, 1.90 mmol) and aldehyde 68i according to 
general method A. Purification by semi-preparative HPLC gave 75 (100 mg, 15 %) as a yellow 
crystalline solid. 
1
H NMR (300 MHz, CDCl3) δ 1.82-1.93 (m, 1H), 2.19-2.30 (m, 1H), 2.44 (s, 3H), 
3.90-3.97 (m, 1H), 4.02-4.12 (m, 1H), 5.27 (dd, J = 9.7, J = 2.8, 1H), 7.17 (dd, J = 8.7, J = 1.9, 1H), 
7.67 (s, 1H), 7.73-7.77 (m, 2H), 7.85-7.89 (m, 3H). 
13
C NMR (75 MHz, CDCl3) δ 21.8, 35.0, 37.7, 
66.6, 123.6, 125.0, 128.4, 128.8, 132.2, 134.3, 140.0, 144.8, 145.4, 169.2. Rt = 11.91 min; purity ≥ 98 
% (UV). HRMS (ESI) m/z: (M+H)
+
 calculated 341.11320, found 341.11255. Mp: 130-132°C. 
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2-(4-Hydroxy-4-(5-methyl-2-nitrophenyl)butyl)isoindoline-1,3-dione (76) The title compound 
was synthesized from 3-iodo-4-nitro-toluene 38 (500 mg, 1.90 mmol) and aldehyde 69i according to 
general method A. Purification by semi-preparative HPLC gave 76 (168 mg, 25 %) as an orange oil. 
1
H NMR (300 MHz, CDCl3) δ 1.75-2.02 (m, 4H), 2.44 (s, 3H), 2.59 (s, 1H), 3.79 (t, J = 6.4, 2H), 5.32 
(dd, J = 7.6, J = 3.2, 1H), 7.19 (dd, J = 8.6, J = 2.0, 1H), 7.59 (d, J = 1.6, 1H), 7.68-7.74 (m, 2H), 
7.81-7.87 (m, 3H). 
13
C NMR (75 MHz, CDCl3) δ 21.8, 25.8, 35.2, 37.9, 69.4, 123.4, 125.0, 128.6, 
128.9, 132.6, 134.1, 140.2, 145.1, 145.6, 168.7. Rt = 12.40 min; purity ≥ 99 % (UV). HRMS (ESI) 
m/z: (M-OH)
+
 calculated 355.12848, found 355.12885. 
 
3-Amino-1-(2-nitrophenyl)propan-1-ol (77) The title product was prepared according to method E 
to yield 77 (89 %) as a brown oil. 
1
H NMR (500 MHz, MeOH-d4) δ 1.77-1.84 (m, 1H), 1.91-1.97 (m, 
1H), 2.81-2.91 (m, 2H), 5.26 (dd, J = 9.0, J = 3.2, 1H), 7.44-7.48 (m, 1H), 7.68-7.71 (m, 1H), 7.86-
7.80 (m, 2H). 
13
C NMR (125 MHz, MeOH-d4) δ 40.1, 42.3, 68.6, 125.0, 129.1, 129.2, 134.3, 142.1, 
149.1. Rt = 1.60 min; purity ≥ 97 % (UV).
§
 HRMS (ESI) m/z: (M-OH)
+
 calculated 197.09167, found 
197.09207. 
 
4-Amino-1-(2-nitrophenyl)butan-1-ol (78) The title product was prepared according to method E 
to yield 78 (62 %) as a brown oil. 
1
H NMR (500 MHz, MeOH-d4) δ 1.63-1.76 (m, 3H), 1.77-1.87 (m, 
1H), 2.67-2.77 (m, 2H), 5.17 (dd, J = 7.9, J = 3.5, 1H), 7.45 (m, 1H), 7.67-7.70 (m, 1H), 7.85 (dd, J = 
7.9, J = 1.6, 1H), 7.87 (dd, J = 8.2, J = 1.3, 1H). 
13
C NMR (125 MHz, MeOH-d4) δ 30.0, 37.3, 42.1, 
69.4, 125.0, 129.0, 129.1, 134.2, 142.1, 149.3. Rt = 5.24 min; purity ≥ 98 % (UV).
§
 HRMS (ESI) m/z: 
(M+H)
+
 calculated 211.10772, found 211.10738. 
 
5-Amino-1-(2-nitrophenyl)pentan-1-ol (79) The title product was prepared according to method E 
to yield 79 (86 %) as a brown oil. 
1
H NMR (500 MHz, MeOH-d4) δ 1.44-1.61 (m, 4H), 1.63-1.70 (m, 
1H), 1.73-1.80 (m, 1H), 2.60-2.68 (m, 2H), 5.16 (dd, J = 8.5, J = 3.5, 1H), 7.43-7.47 (m, 1H), 7.66-
7.70 (m, 1H), 7.83 (dd, J = 7.9, J = 1.6, 1H), 7.86 (dd, J = 8.2, J = 1.3, 1H). 
13
C NMR (125 MHz, 
MeOH-d4) δ 24.5, 33.4, 39.7, 42.4, 69.5, 124.9, 129.0, 129.1, 134.2, 142.2, 149.3. Rt = 7.04 min; 
purity ≥ 99 % (UV).§ HRMS (ESI) m/z: (M+H)+ calculated 225.12307, found 225.12337. 
 
5-(Dimethylamino)-N-(3-hydroxy-3-(2-nitrophenyl)propyl)naphthalene- 1-sulfonamide (80) To 
a solution of the amine 77 (150 mg, 0.765 mmol) in dry DCM (40 ml) a solution of dansyl chloride 
(200 mg, 0.803 mmol) in dry DCM and TEA (0.158 ml, 1.137 mmol) were added. After stirring for 24 
h at room temperature, the solution was washed with water and the aqueous phase was extracted twice 
with DCM. The combined organic layers were dried and the solvent was evaporated under reduced 
pressure. The crude product was purified by semi-preparative HPLC to yield 80 (147 mg, 45 %) as a 
yellow solid. 
1
H NMR (500 MHz, CDCl3) δ 1.69-1.74 (m, 1H), 1.92-1.98 (m, 1H), 2.60 (d, J = 3.8, 
1H), 2.89 (s, 6H), 3.02-3.09 (m, 1H), 3.19-3.26 (m, 1H), 5.25-5.27 (m, 1H), 5.46 (dd, J = 7.6, J = 3.5, 
1H), 7.19 (dd, J = 7.6, J = 0.6, 1H), 7.36-7.39 (m, 1H), 7.51-7.55 (m, 2H), 7.57-7.62 (m, 2H), 7.88 
(dd, J = 8.2, J = 1.3, 1H), 8.26 (dd, J = 7.3, J = 1.3, 1H), 8.32-8.34 (m, 1H), 8.53-8.55 (m, 1H). 
13
C 
NMR (125 MHz, CDCl3) δ 36.9, 41.3, 45.6, 68.4, 115.4, 118.9, 123.4, 124.6, 128.1, 128.4, 128.6, 
129.7, 130.0, 130.1, 130.6, 133.9, 134.6, 139.6, 147.3, 152.2. Rt = 8.77 min; purity ≥ 96 % (UV). 
HRMS (ESI) m/z: (M+H)
+
 calculated 430.14312, found 430.14242. Mp: 53-56°C. 
 
5-(Dimethylamino)-N-(4-hydroxy-4-(2-nitrophenyl)butyl)naphthalene-1-sulfonamide (81) 
Synthesis of 81 was carried out following the procedure described for 80 using 78 (85 mg, 0.404 
mmol), dansyl chloride (106 mg, 0.424 mmol) and TEA (0.10 ml, 0.687 mmol). 81 (52 mg, 29 %) was 
obtained as a yellow solid. 
1
H NMR (500 MHz, CDCl3) δ 1.57-1.73 (m, 4H), 2.58 (s, 1H), 2.87 (s, 
6H), 2.90-3.02 (m, 2H), 5.07-5.10 (m, 1H), 5.16 (t, J = 6.0, 1H), 7.15 (d, J = 7.6, 1H), 7.35-7.39 (m, 
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1H), 7.49-7.59 (m, 3H), 7.65 (dd, J = 7.9, J = 1.6, 1H), 7.86 (dd, J = 8.2, J = 1.3, 1H), 8.23 (dd, J = 
7.3, J = 1.3, 1H), 8.27-8.30 (m, 1H), 8.50-8.53 (m, 1H). 
13
C NMR (125 MHz, CDCl3) δ 26.5, 35.1, 
43.1, 45.5, 69.0, 115.3, 118.8, 123.3, 124.5, 128.0, 128.2, 128.5, 129.7, 129.8, 130.0, 130.5, 133.8, 
134.8, 140.2, 147.6, 152.1. Rt = 10.18 min; purity ≥ 98 % (UV). HRMS (ESI) m/z: (M+H)
+
 calculated 
444.15877, found 444.15416. Mp: 47-48°C. 
 
5-(Dimethylamino)-N-(5-hydroxy-5-(2-nitrophenyl)pentyl)naphthalene- 1-sulfonamide (82) 
Synthesis of 82 was carried out following the procedure described for 80 using 81 (150 mg, 0.669 
mmol), dansyl chloride (175 mg, 0.702 mmol) and TEA (0.158 ml, 1.137 mmol). 82 (126 mg, 41 %) 
was obtained as a as a yellow solid. 
1
H NMR (500 MHz, CDCl3) δ 1.31-1.50 (m, 4H), 1.52-1.60 (m, 
1H), 1.62-1.68 (s, 1H), 2.25 (d, J = 4.1, 1H), 2.88 (s, 6H), 2.90-2.94 (m, 2H), 4.70 (t, J = 6.3, 1H), 
5.06-5.09 (m, 1H), 7.18 (dd, J = 7.6, J = 0.9, 1H), 7.38-7.41 (m, 1H), 7.51-7.56 (m, 2H), 7.59-7.63 (m, 
1H), 7.72 (dd, J = 7.9, J = 1.3, 1H), 7.88 (dd, J = 8.2, J = 1.3, 1H), 8.25 (dd, J = 7.3, J = 1.3, 1H), 
8.28-8.30 (m, 1H), 8.52-8.54 (m, 1H). 
13
C NMR (125 MHz, CDCl3) δ 23.1, 29.2, 37.5, 43.2, 45.5, 
69.1, 115.3, 118.8, 123.4, 124.5, 128.1, 128.2, 128.6, 129.8, 129.9, 130.6, 133.7, 134.8, 140.2, 152.2. 
Rt = 9.51 min; purity ≥ 98 % (UV). HRMS (ESI) m/z: (M+H)
+
 calculated 458.17442, found 
458.17363. Mp: 50-51°C. 
 
4-((7-Nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)-1-(2-nitrophenyl)butan-1-ol (83) At 0°C, 4-
chlor-7-nitrobenzofurazan (100 mg, 0.499 mmol) and NaHCO3 (126 mg, 1.497 mmol) were added to a 
solution of 78 (105 mg, 0.499 mmol) in 8 ml of methanol. The mixture was stirred for 30 min at 0°C, 
followed by 90 min at room temperature and, finally, another 90 min at 50°C. After extraction with 
ethyl acetate (three times) the combined organic layers were dried and concentrated under reduced 
pressure. The crude product was purified by flash chromatography (petroleum ether/ethyl acetate 1:2) 
to give 83 (74 mg, 40 %) as a brown oil. 
1
H NMR (500 MHz, MeOH-d4) δ 1.76-1.83 (m, 1H), 1.91-
1.99 (m, 2H), 2.00-2.06 (m, 1H), 3.59 (s, 2H), 5.23 (dd, J = 8.5, J = 2.8, 1H), 6.33 (d, J = 8.8, 1H), 
7.43-7.47 (m, 1H), 7.66-7.70 (m, 1H), 7.51-7.87 (m, 2H), 8.49 (d, J = 7.9, 1H). 
13
C NMR (125 MHz, 
MeOH-d4) δ 14.4, 26.0, 37.0, 61.5, 69.4, 125.0, 129.1, 129.1, 134.4, 138.5, 142.0, 149.2. Rt = 10.82 
min; purity ≥ 96 % (UV). HRMS (ESI) m/z: (M+H)+ calculated 374.10951, found 574.10908. 
 
N-(4-Hydroxy-4-(2-nitrophenyl)butyl)-3-((7-nitrobenzo[c][1,2,5]oxadiazol-4-
yl)amino)propanamide (84) To a solution of 78 (200 mg, 0.951 mmol) in 12 ml of acetonitrile 84i 
(240 mg, 0.951 mmol), N-methylmorpholine (0.52 ml, 4.755 mmol), N-hydroxy-benzotriazole (HOBt) 
hydrate (231 mg, ~1.510 mmol) and N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (EDC) hydro-
chloride (328 mg, 1.712 mmol) were added. After stirring for 20 h at room temperature water was 
added and the mixture was extracted with ethyl acetate (three times). The combined organic layers 
were washed with brine, dried, and concentrated in vacuo. The crude product was purified by flash 
chromatography (100 % ethyl acetate) to give 84 (133 mg, 32 %) as a brown oil. 
1
H NMR (500 MHz, 
MeOH-d4) δ 1.56-1.64 (m, 2H), 1.71-1.76 (m, 2H), 2.65 (t, J = 6.9, 2H), 3.19-3.27 (m, 2H), 3.83 (s, 
2H), 5.09 (dd, J = 8.2, J = 2.7, 1H), 6.40 (d, J = 8.8, 1H), 6.41-6.45 (m, 1H), 7.64-7.67 (m, 1H), 7.77 
(dd J = 7.9, J = 1.3, 1H), 7.82 (dd, J = 8.2, J = 1.3, 1H), 8.50 (d, J = 8.8, 1H). 
13
C NMR (125 MHz, 
MeOH-d4) δ 27.0, 37.0, 40.2, 69.3, 77.3, 118.0, 124.9, 129.0, 129.0, 134.3, 142.0, 149.1, 173.1. Rt = 
9.22 min; purity ≥ 99 % (UV). HRMS (ESI) m/z: (M+H)+ calculated 445.14662, found 445.14667. 
 
N-(4-Hydroxy-4-(2-nitrophenyl)butyl)-6-((7-nitrobenzo[c][1,2,5]oxadiazol-4-
yl)amino)hexanamide (85) Synthesis of 85 was carried out following the procedure described for 84 
using 78 (130 mg, 0.618 mmol), 85i (182 mg, 0.618 mmol), N-methylmorpholine (0.340 ml, 3.092 
mmol), HOBt hydrate (150 mg, ~0.980 mmol) and EDC hydrochloride (213 mg, 1.113 mmol) in 6 ml 
of acetonitrile. The crude product was purified by preparative HPLC to yield 85 (117 mg, 46 %) as a 
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brown oil. 
1
H NMR (500 MHz, MeOH-d4) δ 1.43-1.50 (m, 2H), 1.62-1.71 (m, 4H), 1.43-1.82 (m, 4H), 
2.21 (t, J = 7.4, 2H), 3.20-3.23 (m, 2H), 3.51 (s, 2H), 5.13-5.15 (m, 1H), 6.33 (d, J = 8.8, 1H), 7.41-
7.45 (m, 1H), 7.66 (td, J = 7.6, J = 1.3, 1H), 7.81-7.85 (m, 2H), 8.50 (d, J = 8.5, 1H). 
13
C NMR (125 
MHz, MeOH-d4) δ 14.4, 26.6, 27.2, 27.5, 36.9, 37.2, 40.1, 69.4, 125.0, 129.0, 129.1, 134.3, 138.5, 
142.1, 149.2, 155.3, 176.0. Rt = 13.75 min; purity ≥ 96 % (UV). HRMS (ESI) m/z: (M+H)
+
 calculated 
487.19357, found 487.19290. 
 
1-(3',6'-dihydroxy-3-oxo-3H-spiro[isobenzofuran-1,9'-xanthen]-5-yl)-3-(4-hydroxy-4-(2-
nitrophenyl)butyl)thiourea (86) Fluorescein isothiocyanate (111 mg, 0.285 mmol) was added to a 
solution of 78 (60 mg, 0.285 mmol) and DIEA (0.348 ml, 1.998 mmol) in 5 ml of DMF and the 
mixture was stirred for 18 h at room temperature. The solvent was evaporated under reduced pressure 
and the crude product was purified by preparative HPLC to give 86 (61 mg, 36 %) as an orange solid. 
1
H NMR (500 MHz, MeOH-d4) δ 1.71-1.96 (m, 4H), 3.49 (s, 2H), 5.21 (dd, J = 8.5, J = 2.8, 1H), 6.53 
(dd, J = 8.8, J = 2.2, 2H), 6.67-6.68 (m, 4H), 7.14 (d, J = 8.2, 1H), 7.43-7.46 (m, 1H), 7.66-7.69 (m, 
1H), 7.74 (dd, J = 8.2, J = 1.6, 1H), 7.85-7.89 (m, 2H), 8.19 (d, J = 1.9, 1H). 
13
C NMR (125 MHz, 
MeOH-d4) δ 26.8, 37.1, 69.5, 103.5, 111.5, 113.7, 125.0, 129.1, 129.1, 130.3, 134.3, 142.1, 149.2, 
154.2, 171.2. Rt = 9.98 min; purity ≥ 97 % (UV). HRMS (ESI) m/z: (M+H)
+
 calculated 600.14351, 
found 600.14344. Mp: 168-174°C. 
 
 
 
6.4.2 Experiment procedure for HPLC, HRMS, and MS 
 
The retention time Rt and purity of every compound tested in the biological assays were determined 
using HPLC according to the following procedure: 
 
A SpectraSystems
®
 LC system consisting of a pump, an autosampler, and a PDA detector was 
employed. The system was operated by the standard software Xcalibur
®
. An RP-C18 NUCLEODUR
®
 
100-5 (125x3 mm) column (Macherey-Nagel GmbH, Düren, Germany) was used as stationary phase. 
All solvents were HPLC grade. 
In a gradient run, the percentage of acetonitrile (containing 0.1 % trifluoroacetic acid; TFA) in an 
aqueous solution of 0.1 % TFA was increased from an initial concentration of 0 % at 0 min to 100 % 
at 15 min and kept at 100 % for 5 min. RT values determined without the use of trifluoroacetic acid 
are marked by a paragraph (§). The injection volume was 10 µL and flow rate was set to 800 µL/min. 
Chromatograms were recorded at 254 nm for the UV trace. 
 
HRMS values were determined by the following procedure:  
 
Measurements were performed on a Dionex Ultimate 3000 RSLC system using a Waters BEH C18, 50 
x 2.1 mm, 1.7 µm dp column by injection of two µl methanolic sample. Separation was achieved by a 
linear gradient with (A) H2O + 0.1 % FA to (B) ACN + 0.1 % FA at a flow rate of 600 µL/min and 45 
°C. The gradient was initiated by a 0.33 min isocratic step at 5 % B, followed by an increase to 95 % 
B in 9 min to end up with a 1 min flush step at 95 % B before reequilibration under the initial 
conditions. UV and MS detection were performed simultaneously. Coupling the HPLC to the MS was 
supported by an Advion Triversa Nanomate nano-ESI system attached to a Thermo Scientific 
Orbitrap. Mass spectra were acquired in centroid mode ranging from 100 – 2000 m/z at a resolution of 
R = 30000. 
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In two cases (49 and 55), m/z values were generated by a DSQII electron ionization analyzer 
(ThermoFisher, Dreieich, Germany). These values are marked by an asterisk (*). 
 
For intermediates, m/z values were measured on an MSQ
®
 electro spray mass spectrometer 
(ThermoFisher, Dreieich, Germany). A spray voltage of 3800 V, a capillary temperature of 350°C, and 
a source CID of 10 V was applied. MS spectra were acquired in positive mode.  
 
 
 
6.4.3 Synthesis and analytical data of synthetic intermediates 
 
a) Synthesis and Analytical Data of Intermediates 68i and 70i
S16
 
 
 
 
2-(3-Hydroxypropyl)isoindoline-1,3-dione (68ii) Phthalic anhydride (9.9 g, 67 mmol) was added 
to a solution of 3-aminopropan-1-ol (5.0 g, 67 mmol) and TEA (9.3 ml, 67 mmol) in 100 ml of 
toluene. The mixture was stirred for 3 h at 125°C and water was removed using a Dean-Stark 
apparatus. After cooling to room temperature the solvent was evaporated under reduced pressure to 
yield the desired product 68ii (13.5 g, 99 %), which was used in the next step without further 
purification. 
1
H NMR (500 MHz, DMSO-d6) δ 1.71-1.76 (m, 2H), 3.43-3.46 (m, 2H), 3.63 (t, J = 7.3, 
2H), 4.49 (s, 1H), 7.81-7.86 (m, 4H). 
13
C NMR (125 MHz, DMSO-d6) δ 31.2, 35.2, 58.5, 122.9, 131.7, 
134.3, 167.9. MS (ESI) m/z: 206.3 (M+H)
+
. 
 
2-(5-Hydroxypentyl)isoindoline-1,3-dione (70ii) Following the procedure described for 68ii using 
phthalic anhydride (16.1 g, 109 mmol), 5-aminopentan-1-ol (11.2 g, 109 mmol) and TEA (15.2 ml, 
109 mmol) in 140 ml of toluene, the desired product 70ii (25.1 g, 99 %) was obtained, which was used 
in the next step without further purification. 
1
H NMR (500 MHz, DMSO-d6) δ 1.25-1.32 (m, 2H), 
1.40-1.46 (m, 2H), 1.56-1.62 (m, 2H), 3.34-3.38 (m, 2H), 3.56 (t, J = 7.1, 2H), 4.33 (s, 1H), 7.82-7.87 
(m, 4H). 
13
C NMR (125 MHz, DMSO-d6) δ 22.8, 27.8, 32.0, 37.4, 60.4, 122.9, 131.6, 134.3, 167.9. 
MS (ESI) m/z: 234.2 (M+H)
+
. 
 
3-(1,3-Dioxoisoindolin-2-yl)propanal (68i) Oxalyl chloride (8.4 ml, 99 mmol) was added to 30 ml of 
dry DCM and the mixture was cooled to -78°C. Dry DMSO (21.1 ml, 297 mmol) was added drop-wise 
and the solution was stirred for 30 min. A solution of 68ii (13.5 g, 66 mmol) in 25 ml of dry DCM was 
added drop-wise and the solution was stirred for 30 min. DIPEA (56.1 ml, 330 mmol) was added and 
the mixture was stirred for another 30 min at -78°C. The mixture was warmed to room temperature 
and a solution of NaH2PO4 (11.9 g, 99 mmol) in 20 ml of water was added. The aqueous layer was 
extracted three times with DCM and the combined organic layers were washed with 1 M HCl, 
saturated NaHCO3 and brine. The solvent was removed under reduced pressure to yield 68i (13.4 g, 
100 %), which was sufficient pure for use in the next step. 
1
H NMR (500 MHz, DMSO-d6) δ 2.81 (td, 
J = 6.8, J = 1.6, 2H), 3.86 (t, J = 3.9, 2H), 7.82-7.87 (m, 4H), 9.67 (t, J = 1.6, 1H). 
13
C NMR (125 
MHz, DMSO-d6) δ 31.4, 41.5, 123.0, 131.6, 134.3, 167.7.   
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5-(1,3-Dioxoisoindolin-2-yl)pentanal (70i) Following the procedure described for 68i using oxalyl 
chloride (13.7 ml, 162 mmol) in 30 ml of DCM, DMSO (34.5 ml, 486 mmol), 70ii (25.1 g, 108 mmol) 
in 20 ml of DCM, DIPEA (91.8 ml, 540 mmol) and a solution of NaH2PO4 (19.4 g, 162 mmol) in 30 
ml of water, the desired product 70i (20.1 g, 80 %) was obtained in sufficient purity for use in the next 
step without further purification. 
1
H NMR (500 MHz, DMSO-d6) δ 1.49-1.54 (m, 2H), 1.56-1.62 (m, 
2H), 2.46 (td, J = 7.3, J = 1.6, 2H), 3.57 (t, J = 6.6, 2H), 7.78-7.87 (m, 4H), 9.64 (t, J = 1.4, 1H). 
13
C 
NMR (125 MHz, DMSO-d6) δ 18.8, 27.4, 37.1, 42.4, 122.9, 131.6, 134.3, 167.9. MS (ESI) m/z: 232.3 
(M+H)
+
. 
 
 
 
b) Synthesis and Analytical Data of Intermediate 69i
S17 
 
 
 
2-(4,4-Diethoxybutyl)isoindoline-1,3-dione (69ii) N-Carbethoxyphthalimide (13.0 g, 59 mmol) 
and 4-aminobutyraldehyde diethyl acetal (10.3 g, 59 mmol) were dissolved in THF (90 ml) and TEA 
(8.4 ml, 59 mmol) was added. After stirring for 20 h at room temperature the solvent was evaporated 
under reduced pressure and the remaining oil was purified by flash chromatography (n-hexane/ethyl 
acetate 8:1) to yield the title compound 69i (15.4 g, 88 %) as a colorless oil. 
1
H NMR (500 MHz, 
CDCl3) δ 1.17 (t, J = 7.0, 6H), 1.62-1.67 (m, 2H), 1.72-1.78 (m, 2H), 3.44-3.50 (m, 2H), 3.58-3.64 (m, 
2H), 3.70 (t, J = 7.3, 2H), 4.49 (t, J = 5.5, 1H), 7.69 (dd, J = 5.5, J = 3.0, 2H), 7.82 (dd, J = 5.5, J = 
3.0, 2H). 
13
C NMR (125 MHz, CDCl3) δ 15.4, 24.1, 31.1, 37.9, 61.4, 102.5, 123.3, 132.3, 134.0, 168.5. 
MS (ESI) m/z: 246.2 (M-OEt)
+
. 
 
4-(1,3-Dioxoindolin-2-yl)butanal (69i) A mixture of 2-(4,4-diethoxybutyl)isoindoline-1,3-dione 
69ii (15.4 g, 53 mmol) and 1 M aqueous HCl (101 ml) in acetone (108 ml) was heated under reflux for 
2 h. The solvent was removed in vacuo and the residue was extracted with ether (three times). The 
combined organic extracts were washed with water, dried, filtered, and concentrated in vacuo to yield 
the title compound 69i (11.1 g, 97 %) as a white solid, which was used in the next step without further 
purification. 
1
H NMR (500 MHz, CDCl3) δ 2.02 (m, 2H), 2.53 (td, J = 7.3, J = 0.9, 2H), 3.74 (t, J = 
6.7, 2H), 7.72 (dd, J = 5.5, J = 3.0, 2H), 7.84 (dd, J = 5.5, J = 3.0, 2H), 9.77 (s, 1H). 
13
C NMR (125 
MHz, CDCl3) δ 21.3, 37.3, 41.2, 123.4, 132.2, 134.2, 168.5, 200.9. MS (ESI) m/z: 218.1 (M+H)
+
. 
 
  
6  SUPPORTING INFORMATION  119 
 
c) Synthesis and Analytical Data of Intermediate 84i
S6
 
 
 
 
3-((7-Nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)propanoic acid (84i) At 0°C, 4-chlor-7-
nitrobenzofurazan (300 mg, 1.503 mmol) and NaHCO3 (379 mg, 4.509 mmol) were added to a 
solution of 3-aminopropanoic acid (134 mg, 1.503 mmol) in 30 ml of methanol. The mixture was 
stirred for 30 min at 0°C, followed by 90 min at room temperature and another 90 min at 50°C. The 
pH was adjusted to 2-3 by addition of 0.1 M aqueous HCl. After extraction with ethyl acetate (three 
times) the combined organic layers were dried and concentrated under reduced pressure. The crude 
product was purified by flash chromatography (8 % methanol/DCM) to give the title compound 84i 
(211 mg). The identity of 84i (211 mg) was proven by LC/MS (ESI) m/z: 253.22 (M+H)
+
, indicating 
72 % purity (UV). The product was used in the next step without further purification. 
 
6-((7-Nitrobenzo[c][1,2,5]oxadiazol-4-yl)amino)hexanoic acid (85i)
S18
 Following the procedure 
described for 84i using 3-aminopropanoic acid (198 mg, 1.503 mmol), 4-chlor-7-nitrobenzofurazan 
(300 mg, 1.503 mmol) and NaHCO3 (379 mg, 4.509 mmol) in 20 ml of methanol, the crude product 
was recrystallized from methanol to give 383 mg of the title compound 85i (87 %). 
1
H NMR (500 
MHz, DMSO-d6) δ 1.35-1.41 (m, 2H), 1.52-1.58 (m, 2H), 1.65-1.71 (m, 2H), 2.22 (t, J = 7.3, 2H), 
3.43-3.48 (m, 2H), 6.40 (d, J = 8.8, 1H) 8.49 (d, J = 8.7, 1H), 9.52 (s, 1H), 11.98 (s, 1H). 
13
C NMR 
(125 MHz, DMSO-d6) δ 24.1, 25.9, 27.3, 43.2, 48.6, 99.1, 120.5, 137.9, 144.2, 144.4, 145.2, 174.4. 
MS (ESI) m/z: 295.01 (M+H)
+
. 
 
 
 
6.4.4 Synthesis of substrates used in the enzyme inhibition assay 
 
Synthesis of anthraniloyl-S-CoA thioester
S19
 
Anthraniloyl-CoA (ACoA) was synthesized from isatoic anhydride and coenzyme A (CoA) using a 
previously described method. ACoA was purified by HPLC (Agilent 1200 series consisting of a 
quaternary pump, a fraction collector and an MWD; Agilent Technologies, USA) after freeze drying 
of the aqueous reaction mixture (25 mL) and resuspending of the dried residue in 3 mL of a mixture of 
50 % methanol and water. A 10 µm RP C18 150-30 column (30 x 100 mm, Agilent) was used along 
with a mobile phase consisting of water containing 1‰ TFA (A) and acetonitrile containing 1‰ TFA 
(B) with a flow rate of 5 mL/min. The following gradient was used: 0-35 min, linear gradient 10 % - 
100 % B; 35-42 min, 100 % B; 42-43 min, 10 % B (initial conditions). ACoA containing fractions 
were pooled and freeze dried. 
 
Synthesis of β-ketodecanoic acidS20 
Ethyl 3-oxodecanoate (300 mg, 1.4 mmol, 1.0 eq) was stirred with NaOH (56 mg, 1.4 mmol, 1.0 eq) in 
water (2 ml) overnight. Any remaining ester was removed by washing with Et2O (10 ml). The aqueous 
layer was cooled and acidified with 32 % HC1 to pH = 6. After filtration the 3-oxodecanoic acid was 
dried in vacuo and obtained as white solid (100 mg, 0.54 mmol, 38 %). 
1
H NMR (500 MHz, CDCl3) δ 
0.86 (t, J = 7.0, 3H), 1.25-1.29 (m, 8H), 1.58 (quintet, J = 7.0, 2H), 2.54 (t, J = 7.5, 2H), 3.49 (s, 2H). 
LC/MS (ESI) no ionization, 99 % (UV).  
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Synthesis of ethyl 3-oxodecanoate
S21 
To a THF solution of 2M LDA (20 ml, 40 mmol 2.4 eq) was added ethyl acetoacetate (2.16 g, 16.6 
mmol, 1.0 eq) at 0°C. The deep yellow clear solution was stirred at 0°C for 1 h. To this solution the 1-
iodohexane was added (4.20 g, 19.81 mmol, 1.2 eq) at -78°C. The temperature was allowed to reach 
an ambient temperature over 14 h and the solution was stirred at room temperature for 2 h. To the 
solution was added 10 % HCl (200 ml) and the mixture was extracted with Et2O (4 × 250 ml). The 
combined organic layers were dried over Na2SO4, filtered, and the filtrate was concentrated in vacuo. 
The residue was purified by column chromatography (n-hexane/ethyl acetate, 30/1) to give ethyl 3-
oxodecanoate as a yellow oil (1.98 g, 9.24 mmol, 55 %). 
1
H NMR (500 MHz, CDCl3) δ 0.84 (t, J = 
7.0, 3H), 1.23-1.28 (m, 11H), 1.54 (quintet, J = 7.0, 2H), 2.49 (t, J = 7.0, 2H), 3.39 (s, 2H), 4.16 (m, 
2H). 
 
 
 
6.4.5 Mutagenicity assay 
 
The S. typhimurium derivatives TA100, TA1535 and TA102 were used as bacterial strains. These 
were provided by B. N. Ames (University of California, Berkeley, USA) or Trinova Biochem (Gießen, 
Germany). 
The standard S. typhimurium plate incorporation assay was carried out.
S22
 All mutagenicity assays 
were performed with and without S9 mix. S9, prepared from livers of male rats pre-treated with 
Aroclor 1254 (500 mg/kg), was provided by Trinova Biochem GmbH (Gießen, Germany). The 
concentrations of cofactors in the S9 mix (before adding them to the overlay) were 33 mM KCl, 8 mM 
MgCl2, 5 mM glucose-6-phosphate, 4 mM NADP, 100 mM phosphate buffer (pH=7.4), and 5 % S9.  
In absence of S9 mix sodium azide was used as positive control in TA100 (1 µg/plate) and TA1535 (2 
µg/plate), whereas Mitomycin D (0.3 µg/plate) was used for TA102. When the assay was carried out 
with S9 mix, 2-aminoanthracen (1.5 µg/plate for TA100 and TA1535, respectively, and 8.0 µg/plate 
for TAS102) were added as positive control. The compound and positive controls were dissolved in 
DMSO was used as negative control. Doses of compound 3 for each strain with and without S9 mix 
were 5, 16, 50, 160, 500, 1600, and 5000 µg/plate (3 plates per dose level).  
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6.4.6 Effects on P. aeruginosa wild-type 
 
Cultivation of P. aeruginosa PA14 wild-type 
For determination of extracellular HHQ and PQS levels, cultivation was performed in the following 
way: cultures of P. aeruginosa PA14 wild-type cells (initial OD600 = 0.02) were incubated with or 
without inhibitor (final DMSO concentration 1 %, v/v) at 37°C, 200 rpm and a humidity of 75 % for 
16 h in 24-well Greiner Bio-One Cellstar plates (Frickenhausen, Germany) containing 1.5 ml medium 
per well. Cultures were generally grown in PPGAS medium (20 mM NH4Cl, 20 mM KCl, 120 mM 
Tris-HCl, 1.6 mM MgSO4, 0.5 % (w/v) glucose, 1 % (w/v) BactoTM Tryptone). Exceptionally, LB 
medium (86 mM NaCl, 0.5 % (w/v) yeast extract; 1 % (w/v) peptone from casein) was used for PQS 
quantification. For each sample, cultivation and sample work-up were performed in triplicates. 
 
Determination of extracellular HHQ and PQS levels 
Extracellular levels of HHQ were determined according to the method of Lépine et al. with the 
following modifications.
S23
 An aliquot of 500 µl of bacterial cultures were supplemented with 50 µl of 
a 10 µM methanolic solution of the internal standard (IS) 5,6,7,8-tetradeutero-2-heptyl-4(1H)-
quinolone (HHQ-d4) and extracted with 1 ml of ethyl acetate by vigorous shaking. After 
centrifugation, 400 µl of the organic phase were evaporated to dryness in LC glass vials. The residue 
was re-dissolved in methanol. UHPLC-MS/MS analysis was performed as described in detail 
recently.
S24
 The following ions were monitored (mother ion [m/z], product ion [m/z], scan time [s], 
scan width [m/z], collision energy [V], tube lens offset [V]): HHQ: 244, 159, 0.5, 0.01, 30, 106; HHQ-
d4 (IS): 248, 163, 0.1, 0.01, 32, 113. Xcalibur software was used for data acquisition and 
quantification with the use of a calibration curve relative to the area of the IS. Quantification of PQS 
produced by P. aeruginosa PA14 was performed as described by Maurer and colleagues.
S25
 
 
Results: Effects on P. aeruginosa wild-type.  
We selected three structurally divers compounds with good inhibitory potency in the pqsH
-
 mutant to 
examine their effects on P. aeruginosa PA14 wild-type. Since HHQ is not fully converted into PQS, 
both signal molecules had to be quantified to gain a full insight into inhibition of signal molecule 
production. All three compounds 3, 48 and 62 were potent inhibitors of both signal molecules, 
whereas the most pronounced effects were exerted by 62 (Table S2). This is in accordance to the data 
observed in the pqsH
-
 mutant, which validates the latter as appropriate simplified test system to 
measure PqsD inhibition by quantification of only a singular reporter molecule. 
 
Table S2. Effects of PqsD inhibitors on HHQ and PQS production in P. aeruginosa PA14 wild-type. 
Compound % HHQ inhibition
a
 % PQS inhibition
a
 
3 38 ± 6
b 
37 ± 6
b
 
48 33 ± 6 60 ± 11 
62 49 ± 1 68 ± 1 
a
Planctonic P. aeruginosa PA14. Inhibitor concentration 250 µM. Percentage of inhibition was 
normalized regarding OD600.  
b
Values differ from ref. S24 due to improvements of the assay procedures.  
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